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1. Endothelial dysfunction in renal disease
1.1 General introduction
Endothelial cells (ECs) line the lumina of all blood vessels and form the interface between the 
blood and tissue (1). A well-functioning endothelium is critical for the delivery of oxygen and 
nutrients (2). The endothelium forms an important physical barrier and regulates vasomotor 
tone and the control of tissue inflammation and of thrombosis (3). This process is tightly 
regulated by both autocrine and paracrine factors that influence the microvascular integrity 
in the kidney and other organs (4;5). As a consequence of chemical and mechanical injuries, 
the endothelium is constantly undergoing injury and repair. Upon EC injury there is a switch 
from a quiescent phenotype toward responsive activated endothelium. Most cardiovascular 
risk factors, including diabetes mellitus (DM) and chronic kidney disease (CKD) activate 
the endothelial layer that consequently results in upregulation of chemokines, cytokines, 
and adhesion molecules designed to prevent further damage (2;6). Repetitive exposure to 
injury/activation of the endothelium can ultimately exhaust these protective anti-inflammatory 
mechanisms within ECs (6). As a consequence, the microvascular endothelium loses integrity 
and its ability to maintain homeostasis, which results in disturbed capillary blood flow and 
detachment of ECs into the circulation (6;7). Eventually, if damaged endothelium is not repaired 
by replication of adjacent mature ECs or circulating endothelial progenitor cells (EPCs), ECs 










































































Figure 1: In healthy kidneys, there is a tightly controlled equilibrium between factors favoring  (e.g. 
Angiopoietin-1 (Ang-1), Vascular Endothelial Growth Factors (VEGF) , Platelet Derived Growth 
Factor (PDGF)) and inhibiting ( e.g. Angiopoietin-2 (Ang-2), Thrombospondin-1 (TSP-1), Endostatin) 
EC proliferation and survival. When ECs become activated upon injury, a dysbalance in proangiogenic 
and antiangiogenic growth factors favors loss of renal microvascular ECs and loosening interaction 
with pericytes. EC: endothelial cells; PC: pericytes; WPB: Weibel Palade bodies. 
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1.2 Angiogenic factors play a central role in microvascular stability
The molecular mechanisms that lead to microvascular injury in organ failure are largely 
unknown. It has been suggested that several angioregulatory growth factors play a central 
role in the loss of vascular integrity (5;8). Under homeostatic conditions, there is a tightly 
controlled equilibrium between factors favoring (e.g. Angiopoietin-1 (Ang-1), Vascular 
endothelial growth factors (VEGF), Platelet derived growth factor (PDGF)) and inhibiting ( e.g. 
Angiopoietin-2 (Ang-2), Hepatocyte Growth Factor (HGF), Endostatin) EC proliferation and 
survival in the kidney (5). A dysbalance in proangiogenic and antiangiogenic growth factors 
favors loss of renal microvascular ECs (Figure 1) (2;5). Recently, the angiopoietin/Tie2 system 
has been identified as playing a critical role in angiogenesis and inflammation of the renal 
microvasculature in progressive renal disease (5;9-12). Ang-1 and Ang-2 are growth factors 
that regulate endothelial function during angiogenesis and inflammation and are competitive 
ligands for the Tie-2 receptor. Ang-1 is produced by pericytes and has vasculoprotective effects 
by suppressing vessel leakage, inhibiting vascular inflammation, and preventing endothelial 
death. In addition, Ang-1 has a critical role in the crosstalk between ECs and perivascular 
stromal cells. In contrast, Ang-2 is released by ECs from Weibel Palade bodies (WPB) at 
sites of vascular remodeling and inflammation. Ang-2 has antagonistic effects and acts as 
a competitive inhibitor for Ang-1, with consequently vessel destabilization, inflammation and 
induction of the angiogenic response, with formation of abnormal tortuous capillary networks 
that lead to an abnormal blood flow and results in chronic hypoxia (8;12-15). Under pathological 
conditions, Ang-2 acts in concert with VEGF to induce inflammatory angiogenesis (16;17). By 
promoting pericyte dropout, Ang-2 will lead to loosening contacts between ECs and pericytes. 
In the presence of VEGF, Ang-2 can eventually lead to an active, sprouting state of ECs. 
Otherwise, when VEGF is absent, Ang-2 facilitates capillary regression (18). 
1.3 Pericytes are the link between endothelial damage and renal fibrosis
Pericytes are contractile cells that wrap around ECs and have important roles in supporting the 
growth and maintenance of capillaries (19). In the microvasculature, communication between 
ECs and pericytes has been shown to stabilize capillaries and protect them from regression 
and rarefaction (20;21). Pericytes signal to the endothelium through secreted factors such 
as PDGF- β, TGF-β and Ang-1, as well as by direct endothelial/pericyte crosstalk which 
involves notch-3 signaling (22). Similarly, the endothelium signals to surrounding stromal cells 
using similar growth factors such as Ang-2 and VEGF as well as the notch ligand jagged-1. 
Bidirectional signaling between pericytes and ECs in disease states may result in pericyte 
detachment from capillary ECs, resulting in an angiogenic response and formation of unstable 
tortuous ECs, capillary rarefaction and exacerbation of tissue hypoxia and fibrosis (Figure 2) 
(8;12-15;23-25). The group of Duffield et al showed migration of pericytes from capillaries 
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After loosening contact from the capillaries, pericytes became activated and proliferated into 
collagen producing myofibroblasts contributing to fibrosis (20;23;24). Using a transgenic 
mouse model of UUO, expressing green fluorescent protein in cells producing the collagen type 
I, the same group confirmed that pericytes are the main source for interstitial myofibroblasts 
during renal fibrosis (23). Transformation of pericytes into myofibroblasts also induced a 
switch in VEGF isomers from proangiogenic to antangiogenic isoforms, which counted for 
ECs loss (25). The process of pericyte detachment has been suggested to be reversible. For 
example, blockade of PDGFR-β on pericytes attenuated recruitment of inflammatory cells and 
detachment of pericytes from ECs in mice subjected to renal I/R injury and unilateral ureter 
model. Conversely, inhibition of VEGF on ECs abolished pericyte detachment and attenuated 
both EC loss and development of fibrosis during kidney injury induced by UUO or renal I/R 
injury (20). These data suggest that targeting interaction between ECs and pericytes may 
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Figure 2: Angiopoietin-1 (Ang-1) produced by pericytes regulates vascular assembly and endothelial 
quiescence. Endothelial injury induced by different insults (e.g. diabetes mellitus, renal ischemia 
reperfusion (I/R) injury) leads to activation of endothelial cells (ECs) and release of Ang-2. 
Consequently, pericytes will detach from the capillary wall which results in vessel destabilization and 
induction of angiogenesis, partly in concert with other cytokines such as VEGF.  When inflammation is 
sustained, formation of unstable tortuous capillaries occurs and finally microvascular rarefaction. This 
exacerbates tissue hypoxia and leads to transformation of pericytes into collagen producing 
myofibroblasts and ultimately scar formation with loss of renal function. sTM: soluble thrombomodulin; 
VEGF: Vascular Endothelial Growth Factor; CECs: Circulating Endothelial Cells. 
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2 Assessment of endothelial function
2.1 Circulating markers of endothelial function
The endothelium is relatively inaccessible to direct examination; therefore investigators 
have concentrated on various surrogate markers of endothelial function which include 
the measurement of specific plasma markers including the angiopoietins and sTM and 
measurement of circulating ECs and EPC’s in peripheral blood (9;11;26-30). Elevated 
circulating levels of Ang-2 are reported to be associated with progression of renal disease and 
with systemic markers of micro-inflammation in chronic kidney disease (CKD) patients (9;26). 
Furthermore, elevated Ang-2 levels are shown to be strong predictors of long term mortality 
in CKD patients, independent of vascular stiffness and calcifications (31). Accordingly, renal 
angiopoietin dysbalance, in favor of Ang-2, has been found in different animal and human 
models of renal disease (both diabetic and non-diabetic) (13;32;33). In line, trombomodulin 
levels are studied in detail in different vascular disease including CKD (29;34). Indeed, 
increased levels of sTM are demonstrated in CKD patients with and without diabetes and 
normalization after KTx is reported (29). In patients undergoing long-term hemodialysis 
treatment increased number of circulating ECs, as marker for systemic endothelial dysfunction, 
were found compared to healthy controls. EPCs in renal disease have been suggested to be 
useful for regenerating and maintaining the integrity of vascular structures. In patients with 
chronic renal disease, EPC numbers and function were decreased compared with healthy 
subjects, which may prevent physiological vascular repair and contribute to the increased risk 
for cardiovascular diseases observed in CKD patients (30;35;36). 
2.2 Noninvasive visualization of human microcirculation
An additional method for the assessment of endothelial function in CKD includes the non-
invasive monitoring of the microvasculature. Capillary nailfold videomicroscopy in advanced 
CKD patients showed an impaired functional and structural capillary density in the skin (37). 
These abnormalities may represent manifestations of ongoing systemic microvascular damage 
and underlie much of the organ dysfunction associated with cardiovascular disease in CKD 
patients (38). Another study has found a significant association between retinal microvascular 
abnormalities, using retinal fundus photographs, and renal function deterioration (39).
Recently, sidestream dark field (SDF) imaging has been used to visualize the human 
microcirculation. Compared to conventional capillaroscopy, this method has been used to 
assess the microvasculature in vivo without injecting fluorescent dyes (40;41). The SDF 
imaging has opened a way to study the human microcirculation in more detail than previously. 
In this technique, the tissue is illuminated by light with a wavelength corresponding to the 
hemoglobin spectrum. Part of the light will be absorbed by the hemoglobin and the rest will 
be reflected from the background. Specific optical filtration allows the elimination of the light 
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microcirculation. Hence, red blood cells will appear dark and white blood cells and platelets 
may be visible as refrinent bodies. Vessel walls are not visible and therefore, vessels will be 
visible only if they contain red blood cells (Figure 3). The SDF imaging device is particularly 
convenient for studying tissues protected by a thin epithelial layer such as mucosal 
surfaces (40). By using SDF imaging, capillary tortuosity and density can be measured to 
assess microvascular damage. In addition, this technique also enables measurement of the 
Endothelial Surface Layer (ESL) dimensions, calculated as the difference in Red Blood Cell 
(RBC) column width before (functionally perfused capillary diameter) and after (anatomical 
capillary diameter) leukocyte passage (42;43).
We previously used this validated technique to compare the labial mucosal tortuosity, as 
markers for microvascular damage, in DM patients and controls. We found increased capillary 
tortuosity in DM patients compared with healthy controls (41). However, there are no studies 
which have used SDF imaging for assessment of systemic microvascular alterations in CKD 





 We previously used this validated technique to compare the labial mucosal tortuosity, as 
markers for microvascular damage, in DM patients and controls.  We found increased 
capillary tortuosity in DM patients compared with healthy controls (41). However, there are 
no studies which have u ed SDF imaging for assessment of systemic mic ovascular 
alterations in CKD  patients (includ ng pa ients with diabetic n phropathy) befor  and after 











Figure 3: Visualization of the microcirculation using SDF imaging. The tissue is 
illuminated by light with a wavelength corresponding to the haemoglobin spectrum 
(548nm).  Part of the light will be absorbed by the haemoglobin containing red blood cells 
and the rest will be reflected from the background.  Specific optical filtration allows the 
elimination of the light reflected at the surface of the tissue to produce high-contrast 
reflected light images of the microcirculation.  Vessels will be visible only if they contain 
red blood cells. Adapted from Goedhart et al 2007. 
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3. The microvasculature in disease
3.1 Endothelial injury in renal disease
Injury of microvascular ECs contributes to the impairment of renal perfusion and continued 
renal hypoxia/ischemia (44). Chronic hypoxia is an important trigger for profibrotic and 
inflammatory changes, from the early stages of chronic kidney disease (CKD), and finally 
scar formation and progression to end stage renal disease (5). A dysfunctional endothelium 
loses its ability to protect the microvasculature by reducing its anti-inflammatory and anti-
coagulation effects (45). With decreasing renal function, the endothelium is exposed to 
pro-inflammatory cytokines which lead to upregulation of cell-surface adhesion molecules 
and impairs endothelium-dependent vascular relaxation, with further loss of ECs and 
development of fibrosis (5). In both experimental animal models and in humans, it has been 
shown that there is significant loss of peritubular capillaries and reduction in the capacity 
of EC proliferation as well as defective capillary repair in association with the development 
of renal interstitial fibrosis (2). Interestingly, there is intriguing evidence that stimulation of 
capillary repair may stabilize renal function and slow progression and that this benefit occurs 
independently of effects on blood pressure or proteinuria (4;5). Indeed, in patients with chronic 
renal failure, autopsy material revealed not only diffuse media calcifications and thickening of 
the arteries, but above all changes in the myocardial microcirculation including rarefaction of 
the intramyocardial capillaries (46).
3.2 Microvascular disease in diabetes mellitus 
Diabetes mellitus is strongly associated with the development of macrovascular and 
microvascular disease, including retinopathy, neuropathy and nephropathy (DN), which is the 
leading cause of CKD (47;48). The development of these complications have been correlated 
with glucose mediated endothelial damage, oxidative stress due to accumulation of toxic 
intracellular products such as sorbitol or advanced glycation end products (AGEs) (49). As 
a response to hyperglycemia, microvascular ECs undergo several metabolic derangements, 
which cause activation of ECs, increased expression of different growth factors, altered blood 
flow and permeability of the endothelium and coagulation resulting in structural and functional 
alterations in microvascular integrity (50;51). Endothelial dysfunction and increased oxidative 
stress are reported in patients with prediabetes and in the early course of DM as well, 
indicating a prominent role of microvascular EC damage in the onset of early microangiopathy 
(52). Different angiogenic growth factors have been shown to be increased in DM including 
VEGF and Ang-2 (53). Several studies suggest that Ang-2 and VEGF act together inducing 
sprouting angiogenesis and ultimately leading to vascular destabilization and dysfunction 
(17). In diabetic retinopathy, loss of pericytes is reported to be one of the first morphological 
changes that occurs in the capillaries with concomitant endothelial alterations, such as ECs 
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3.3 Transplantation and microvasculature
Kidney transplantation has improved survival and quality of life for patients with end-stage 
renal failure. Despite dramatic improvements in short-term survival, long-term survival of renal 
allografts has changed little during the past decade (55). Most late renal allograft loss has been 
attributed to progressive renal dysfunction, histological characterized by interstitial fibrosis 
and renal atrophy (IFTA) (56). The fibrosis in the transplanted kidney represents cumulative 
and incremental damage to nephrons from various immunological (antibody-mediated and T 
cell-mediated rejection, sensitization, HLA mismatch) and non-immunological (nephrotoxicity 
of calcineurin inhibitors, ischemia-reperfusion (I/R) injury, donor age, hypertension, infections) 
insults (57). Among these factors, acute rejection and I/R injury primarily target the endothelium 
and disrupt microvascular homeostasis. Activation of pro-inflammatory and pro-coagulant 
pathways lead to irreversible injury of the endothelium with ensuing renal fibrosis and loss of 
allograft function (2;58). 
3.3.1 Ischemia-reperfusion injury
Renal I/R injury is an inevitable consequence of organ transplantation, and a major 
determinant of patient and graft survival (59). The pathophysiology of I/R injury is complex and 
incompletely understood (60). Although the role of tubular cell injury in post-transplantation graft 
dysfunction is widely acknowledged, damage to microvascular endothelial cells is emerging 
as increasingly important (61). Inflammation after reperfusion is considered to be the most 
crucial initiator of EC injury in kidneys subjected to I/R. This will lead to production and release 
of pro-inflammatory and pro-angiogenic factors by ECs (e.g. tumor necrosis factor, VEGF, 
Ang-2) and upregulation of different adhesion molecules, that facilitate leukocyte-endothelial 
cell interactions with consequently ECs dysfunction and peritubular capillary loss (62;63). If 
early capacity of EC repair and protection is limited, ongoing local ischemic injury will result in 
persistent cell death and chronic allograft injury (2). Indeed, it is demonstrated that early loss 
of peritubular capillaries predicts the development of tubulointerstitial fibrosis and rejection 
after transplantation and can be predictive of long-term graft survival (64). Therapeutic 
interventions aiming at enhancement of the microvasculature and promoting repair early after 
transplantation may be beneficial for graft health and prevent chronic injury and rejection.
3.3.2 Allograft rejection
In the pathogenesis of rejection, ECs respond to cytokines and growth factors produced in 
association with alloimmune responses (64;65). Activated microvascular ECs express adhesion 
molecules, cytokines, chemokines and growth factors that mediate the recruitment of recipient 
leukocytes (2;64;65). In addition, activated ECs express MHC class I and II molecules which 
are critical for the presentation of alloantigen to infiltrating lymphocytes (64). It is proposed that 










































may result in impaired delivery of oxygen and nutrients to renal tubular epithelial cells, chronic 
ischemia and cell death (58). In vascularized solid organ allografts, such as the kidney, the 
degree of injury and microvascular EC loss has been reported to predict the development 
of IFTA and later chronic rejection and strategies which can protect the endothelium have 
potential to improve long-term graft survival (58;66;67).
4. Restoration of the renal microvasculature 
The concept that injury to the endothelium may precede renal fibrosis strongly suggests 
that interventions to maintain vascular integrity are of major importance in the treatment of 
renal disease (5). On the beneficial effects of preservation of the microvasculature in renal 
disease several studies have been reported using different therapeutic strategies. Promising 
results about the administration of different growth factors have been shown in experimental 
animal models to enhance angiogenic sprouting and subsequently repair the injured kidney 
microvasculature. The use of recombinant COMP-Ang-1 (a soluble, stable and more potent 
form of Ang-1) and VEGF-A in kidney models of progressive renal failure, improved renal 
function, preserved renal microvasculature and decreased inflammation and fibrosis. Another 
important factor for angiogenic therapy to be successful is the stage of disease. Indeed, 
initial stages of DN are associated with upregulation of VEGF and increased number of 
vessels, implicating that at this stage antiangioneic therapy may be beneficial. In contrast, 
advanced stage of DN is associated with loss of peritubular capillaries, and proangiogenic 
therapies have shown promising results at this stage (5;10;68;69). An alternative strategy 
is the use of EPCs. In different animal models of CKD, transplantation of EPCs resulted 
in preservation of peritubular capillaries, improvement in renal function and reduction 
glomerulosclerosis and development of fibrosis, by homing to areas of injury and inflammation 
in the kidney. Furthermore, there is also evidence that resident stem/progenitor cells in the 
kidney might contribute to the maintenance and repair of renal endothelium and interstitium 
(2;5;35;36;70). Finally, mesenchymal stromal cells (MSCs) have been reported to have potent 
immunomodulatory and reparative effects. In different experimental animal models of renal 
disease, infusion of MSCs decreased fibrosis and promoted angiogenesis. For example, in 
renal ischemia, the process of microvascular loss was hampered in postischemic kidneys 
after injection of MSCs (71;72). 
5. Aims and outline of this thesis
The growing literature indicates that endothelial injury and repair are most important concepts 
for our understanding of renal disease and that manipulation of the response might have 
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microavascular damage and the measurement of endothelial dysfunction markers may be 
useful diagnostic tool for monitoring the microvasculature before and after transplantation. 
This could ultimately lead to a better understanding of the pathogenesis, earlier diagnosis 
and effective treatment of microvascular damage in CKD and renal (pancreas) transplant 
recipients. This thesis focuses on the mechanisms involved in the process of endothelial 
damage and repair in CKD, (early) DM, renal I/R injury and after transplantation 
The aims of this thesis are:
1. Study in detail the effect of renal I/R injury on angiopoietin expression and its association 
with pericytes and fibrosis development, using a rat I/R injury model (chapter 2).
2. Study damage to the microvasculature and the role of angiopoietins in human renal I/R 
injury and compare living-donor (LD) and deceased-donor (DD) kidney transplantation 
 (chapter 3).
3. Investigate the early effects of atherogenic diabetes on systemic microvasculature and 
its association with renal damage using a streptozotocin -induced model of diabetes and 
atherogenesis in pigs (chapter 4).
4. Assess effect of simultaneous pancreas kidney transplantation in DN patients on 
microvascular alterations using SDF imaging and endothelial dysfunction markers 
(chapter 5).
5. Investigate systemic microvascular alterations in CKD patients before and after 
living kidney transplantation, using SDF imaging and endothelial dysfunction markers 
(chapter 6).
6. Investigate whether acute rejection after kidney transplantation is associated with systemic 
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Introduction: Endothelial cells (ECs) are highly susceptible to hypoxia and easily affected 
upon ischemia/reperfusion (I/R) during renal transplantation. Pericytes and angiopoeitins 
play important role in modulating EC function. In the present study, we investigate the effect 
of renal I/R on dynamics of angiopoietin expression and its association with pericytes and 
fibrosis development.
Methods: Male Lewis rats were subjected to unilateral renal ischemia for 45 minutes followed 
by removal of the contralateral kidney. Rats were sacrificed at different time points after 
reperfusion. Endothelial integrity (RECA-1), pericytes (PDGFRβ), Angiopoietin-2 (Ang-2)/
Angiopoietin-1 (Ang-1) expression and interstitial collagen deposition (Sirius Red and α-SMA) 
were assessed using immunohistochemistry and RT-PCR. 
Results: Our study shows an increase in protein expression of Ang-2 starting at 5 hours and 
remaining elevated up to 72 hours, with consequently higher Ang-2/Ang-1 ratio after renal 
I/R (p<0.05 at 48 hours). This was accompanied by an increase in protein expression of the 
pericytic marker PDGFRβ and a loss of ECs (both at 72 hours after I/R, p<0.05). Nine weeks 
after I/R, when renal function was restored, we observed normalization of the Ang-2/Ang-
1 ratio and PDGFRβ expression and increase in cortical ECs, which was accompanied by 
fibrosis.
Conclusions: Renal I/R induces a dysbalance of Ang-2/Ang-1 accompanied by proliferation 
of pericytes, EC loss and development of fibrosis. The Ang-2/Ang-1 balance was reversed 
to baseline at 9 weeks after renal I/R, which coincided with restoration of cortical ECs and 
pericytes. Our findings suggest that angiopoietins and pericytes play an important role in renal 













































Renal I/R is an inevitable consequence of renal transplantation causing significant graft injury 
(5;16;29). Renal I/R impairs the integrity of ECs and leads to loss of peritubular capillaries 
(6;9;17;19;25;32;36). Loss of integrity and function of the endothelial monolayer lead to renal 
hypoxia, which is suggested to be a major initiator of profibrotic changes and interstitial scar 
formation in the kidney (2;24). These microvascular changes and renal scarring eventually 
lead to a deteriorating of renal function and graft loss (26).
Pericytes play a critical role in the stabilization and proliferation of peritubular capillaries via 
interaction with ECs (1;20;30). This process is mediated by several angioregulatory factors, 
including Ang-1, produced by pericytes and Ang-2 produced by activated ECs (7;30;35). 
Angiopoietins are a group of vascular regulatory molecules that bind to the receptor tyrosine 
kinase Tie-2, which is predominantly expressed by vascular ECs. Ang-1 is a strong vascular 
protective agonist of the Tie-2 receptor responsible for suppressing vascular leakage, 
maintaining EC survival and inhibiting vascular inflammation. Ang-2 acts as an antagonist 
of Ang-1 and promotes, in a dose dependent manner, destabilization, vessel leakage 
and inflammation. By promoting pericyte dropout, Ang-2 will lead to loosening contacts 
between ECs and perivascular cells, with subsequent vessel destabilization and abnormal 
microvascular remodeling (7;14;15;35). Recent studies have shown that pericytes detach 
from the endothelium and migrate to the interstitium to become activated and differentiate 
into myofibroblasts contributing to renal fibrosis (10;12). Interestingly, treatment with cartilage 
oligomeric matrix protein (COMP)-Ang-1 in a mice model of renal I/R injury resulted in 
protection against peritubular capillary damage and decrease in inflammatory cells and renal 
interstitial fibrosis (19). 
However, dynamics and the time course of angiopoietin expression, its relation with EC and 
pericyte expression and development of fibrosis in the repair phase after renal I/R injury are 
unknown. Using an established rat model of renal I/R injury, we assessed the impact of I/R on 
Ang-2/Ang-1 balance and its effect on microvascular remodeling, pericytes and the formation 
of fibrosis up to 9 weeks after renal I/R injury. We hypothesize that I/R injury leads to activation 
of ECs with consequent elevation of Ang-2 levels, which may lead to proliferation of pericytes 
and loss of ECs, but may also induce fibrosis in the long term.
Materials and Methods
Rat model of renal I/R injury
Renal I/R injury was induced as previously described (34). The Animal Care and Use 










































old male Lewis rats (200–250 g) purchased from Harlan (Horst, The Netherlands) were 
housed in standard laboratory cages and allowed free access to food and water throughout 
the experiments. Unilateral ischemia was induced by clamping of the left renal pedicle for 
45 min using a bulldog clamp (Fine Science Tools, Heidelberg, Germany). During clamping 
the contra- lateral kidney was removed. Sham-treated rats had identical surgical procedures 
except for clamping of the left kidney. Tail blood samples were taken before and at indicated 
time points after reperfusion and were kept on ice. Rats were sacrificed at 2, 5, 24, 48 or 
72 hours (hr) and 1, 6 and 9 weeks (wk) after reperfusion and kidneys were harvested for 
histological examination and immunohistochemical staining. Renal function was assessed 
by measuring creatinine and urea (BUN) in serum samples using standard auto analyzer 
methods by our hospital research services.
Immunohistochemistry and immunofluorescent staining
Rat kidney sections (4 µm) of snap-frozen kidneys were air dried and acetone fixed. Slides 
were incubated overnight with goat polyclonal IgG against Ang-1 (N18) or Ang-2 (F18; both 
Santa Cruz Biotechnology), mouse monoclonal IgG against endothelial cells (RECA-1; Hycult 
Biotechnology, Uden Netherlands and CD31; Abcam, Cambridge, England), myofibroblasts 
(α-SMA, Progen, Heidelberg, Germany), inflammatory cells (OX42+ for monocytes, dendritic 
cells and granulocytes (kindly provided by Dr. P. Kuppen, LUMC Leiden, the Netherlands)) 
and CD45 for leukocytes (BD Pharminghen, Breda Netherlands) or rabbit polyclonal IgG 
against pericytes (PDGFRβ; Abcam, Cambridge, England). Antibody binding was detected 
with horseradish peroxidase (HRP)-labeled rabbit anti-goat IgG (DAKO, Glostrum, Germany), 
goat anti-mouse IgG (Jackson, Suffolk, England) or goat anti-rabbit IgG (DAKO), respectively. 
After washing, sections were incubated with tyramide-fluorescein isothiocyanate in tyramide 
buffer (NENTM Life Science Products, Boston, MA, USA), washed and incubated with HRP-
labeled rabbit anti-fluorescein isothiocyanate (DAKO, Glostrum, Germany) and developed 
with 3,3’-Diaminobenzidine (DAB) (Sigma, St Louis, MO, USA). Sections were counterstained 
with haematoxylin (Merck, Darmstadt, Germany) and mounted with imsol (Klinipath, Duiven, 
the Netherlands). Quantification of immunohistochemistry was performed in a blinded manner 
by assessing consecutive high power fields (magnification, ×100) on each section from the 
cortex, outer and inner medulla. Using Image J software, the percentage of positivity per 
specific region of the kidney was determined, with exception of Ang-1 and Ang-2, which was 
only analyzed for the cortex. For cortical RECA-1 expression, the ratio of mean percentage 
of positivity of I/R injured and sham operated rats was calculated. Glomeruli were excluded 
from all analyses of the cortex. Since the Ang-2/Ang-1 ratio, rather than the absolute 
expression of either angiopoietin is generally used to determine the functional status of the 
microvasculature (26), this ratio was calculated using the Ang-2 and Ang-1 quantification. 








































Effect of renal I/R injury on Ang-2/Ang-1 balance and pericytes
29
2
polyclonal rabbit IgG (Abcam, Cambridge, England) and RECA-1 and Ang-2/RECA-1. Due 
to technical reasons double stainings with Ang-1/ PDGFRβ and RECA-1/ PDGFRβ could not 
be performed, therefore the pericyte marker NG2 (rabbit polyclonal IgG; BD Pharmingen, 
Breda, Netherlands) was used for these double stainings. Antibody binding was visualized 
using Alexa™ 488-labeled goat anti-rabbit IgG, Alexa™ 568-labeled goat anti-mouse IgG 
(both Life science) and donkey anti-goat IgG (Jackson, Suffolk, England). Nuclei were stained 
using Hoechst (Molecular Probes, Leiden, the Netherlands). Micrographs were made using a 
fluorescence microscope (Leica, DMI6000, Rijswijk, the Netherlands).
Histologic evaluation
Renal fibrosis was evaluated histologically by Sirius Red staining as described previously (27) 
on 4 µm paraffin slides of renal rat tissue. From each part of the kidney (cortex, outer and inner 
medulla) five random images were obtained. Image analyses was performed using Image J 
software. The amount of collagen deposition was measured and expressed as percentage of 
positivity per region of the kidney. In addition, all tissue specimens were scored for severity of 
fibrosis on a semi-quantitative scale (0-3) in a blinded manner by an experiences pathologist.
RNA isolation and Real-Time PCR
RT-PCR was performed as described previously (34). Total RNA was extracted from snap 
frozen cross-section kidney slices using the RNeasy Mini isolation Kit according to the 
manufacturer’s instructions (QIAGEN, Hilden, Germany). cDNA was synthesized from 1 µg 
total RNA, using an oligo dT primer, RNase-OUT, M-MLV reverse transcriptase, 0.1 M-DTT 
and buffers in a volume of 20 µL (all purchased from Invitrogen, Breda, The Netherlands). 
Quantitative real-time PCR was performed in duplicate by using iQ SYBR Green Supermix on 
iCycler Real-Time Detection System (BioRad). The amplification reaction volume was 20 µL, 
consisting of 10 µL iQ SYBR Green PCR mastermix, 1 µL primers, 1 µL cDNA, and 8 µL water. 
Data were analyzed using Gene Expression Analysis for iCycler Real-Time PCR Detection 
System (Biorad). Expression of each gene was normalized against mRNA expression of the 
housekeeping gene Rsp-15. RT PCRs were performed in duplicate. The primer sequences 
are shown in Table 1.
Table 1: Primer sequences used for quantitative real-time polymerase chain reaction
Gene Forward primer 5’->3’ Reverse primer 5’->3’ Supplier
RSP-15 CGTCACCCGTAATCCACC CAGCTTCGCGTATGCCAC Biolegio
ANG-1 TCTCTTCCCAGAAACTTCA TTTGATTTAGTACCTGGGTCTC Biolegio
ANG-2 TGCATCTGCAAGTGTTCCC GCCTTGAGCGAGTAACCG Biolegio











































Data are reported as mean ± standard error of the mean (SEM). Statistical comparisons 
were performed using one-way ANOVA or Mann–Whitney test with GraphPad Prism software 
(GraphPad Software Inc., San Diego, CA, U.S.A.). A value of p < 0.05 was considered 
statistically significant. 
Results
Renal I/R induces transient deterioration of renal function, influx of inflammatory cells 
and interstitial fibrosis
In the current study we used a rat model of renal I/R resulting in extensive renal dysfunction, 
as shown by increased serum creatinine and BUN levels, but characterized by normalized 
renal function after 1 week following I/R (p<0.05, compared to 72 hr) (Fig. 1A, B). Renal 
dysfunction was accompanied by significant infiltration of OX42+ inflammatory cells in the 
cortex, outer and inner medulla at 72 hr (p<0.05), which peaked at 1 week compared to sham-
operated rats (Fig. 1E, F, G). A decrease in OX42+ inflammatory cells was observed at 6 and 
9 weeks in the different parts of the kidney compared to 1 week following I/R (p<0.05). In the 
outer and inner medulla, the influx of OX42+ cells remained significantly increased up to 6 and 
9 weeks (p<0.05), respectively, after renal I/R injury compared with sham-operated rats (Fig. 






































































 Figure 1. Renal I/R induces deterioration of renal function and influx of inflammatory cells
Serum creatinine levels (A) and BUN (B) were measured at consecutive time points after reperfusion. 
CD45 positive leukocyte infiltrate was quantified using digital image analysis (C). Representative 
photomicrographs of kidney sections stained with CD45 (D) from a sham-operated rat and a rat subjected 
to I/R and sacrificed at 72 hr after reperfusion. An overview of the division of the different regions 
(cortex, outer medulla and inner medulla) in a kidney section stained with OX42 (E). Representative 
photomicrographs of kidney sections stained with OX42+ from a sham-operated rat and rats subjected to 
I/R and sacrificed at 72 hr or 9 weeks after reperfusion (F). OX42+ infiltrate of sham-operated rats and rats 
subjected to I/R was quantified in the different areas using digital image analysis (G) and demonstrated 
as % of the depicted area. Data are shown as mean ± SEM (n= 5 rats per group). *P<0.05 compared to 
corresponding sham controls. #P<0.05 compared to 72 hr or 1 wk rats. Original magnification of D, E and 










































One week after reperfusion, significant diffuse interstitial collagen deposition was observed 
in the cortex, outer and inner medulla compared to sham-operated rats (p<0.05) (Fig. 2A, 
B). After 9 weeks collagen deposition was significantly decreased in different regions of the 
kidney compared to 1 week following renal I/R injury (p<0.05), although kidneys were still 
characterized by focal areas of intense Sirius Red staining. The semi-quantitative analyses 
showed that fibrosis scores at 9 weeks were not statistically different from 1 week after I/R 
(data not shown), which is probably due to the focal areas of fibrosis. Consistently, the α-SMA 
immunohistochemical staining revealed a significant increase of fibrosis in cortex and outer 
medulla at 72 hr (p<0.05) and at all parts of the kidney at 1 week (p<0.05) following I/R injury 
compared with sham-operated rats (Fig. 2C, D). At 9 weeks, α-SMA staining was significantly 
decreased in the cortex, outer and inner medulla compared with 1 week after I/R injury (Fig. 
2C).
Restoration of peritubular capillaries in the cortex 9 weeks after renal I/R
Since endothelial damage is an important hallmark of I/R injury, we assessed peritubular 
capillaries over time by staining for RECA-1. A significant reduction in RECA-1 expression 
was observed at 72 hr post I/R (p<0.05) in the cortex and outer medulla and at 1 week in 
the inner medulla (p<0.05) compared with sham-operated rats (Fig. 3A-C). Interestingly, we 
found a significant increase of RECA-1 staining at 6 and 9 weeks in the cortex (p<0.05) 
following I/R compared to rats that were sacrificed at 72 hr (Fig. 3B). Calculation of the ratio 
IR injured/sham operated rats for RECA-1 expression confirmed the observed increase at 6 
and 9 weeks after injury (Fig. 3B). RECA-1 staining co localized with the proliferation marker 
Ki-67, suggesting EC proliferation in peritubular capillaries within the renal cortex at 9 weeks 
after I/R (Fig. 3D, E). No proliferation of ECs was found in the glomeruli following renal I/R. 
In the outer and inner medulla a different pattern was found. Here a significant reduction in 
RECA-1 expression was observed at 72 hr post I/R in the outer medulla (p<0.05) and at 1 
week in the inner medulla (p<0.05) compared with sham-operated rats (Fig. 3C). In contrast 
to the cortex, RECA-1 staining in these areas showed a further decrease up to 9 weeks after 
ischemic injury (p<0.05) (Fig. 3C). CD31 staining demonstrated a pattern comparable to the 






































































Figure 2. Renal I/R induces interstitial fibrosis
Representative photomicrographs of Sirius Red stained kidney sections (A) of the cortex, outer medulla 
and inner medulla obtained from a sham-operated rat (sacrificed at 1 week), and rats subjected to I/R and 
sacrificed at 1 or 9 weeks after reperfusion as indicated. Quantitative analysis of Sirius Red staining (B) 
and α-SMA staining (C) at different time points after reperfusion in sham-operated rats and rats subjected 
to I/R in the different regions as indicated. Quantification was performed by digital image analysis and is 
demonstrated as % of the depicted area. Representative images of whole kidney sections stained with 
α-SMA (D) of sham operated rat (sacrificed at 1 week) and rat subjected to 1 week I/R injury with insert 
showing α-SMA staining in the outer medulla. Data are shown as mean ± SEM (n= 5 rats per group). 
*P<0.05 compared to corresponding sham controls. #P<0.05 compared to 72 hr or 1 wk rats. Original 




































































 Figure 3. Restoration of I/R-induced peritubular capillary loss in the cortex late after reperfusion
Representative images of kidney sections of the cortex, outer medulla and inner medulla stained for 
RECA-1 (A) obtained from a sham-operated rat and rats subjected to I/R and sacrificed at 72 hr and 
9 weeks after reperfusion. Quantitative analysis of cortical (B), outer medullary and inner medullary 
(C) RECA-1 expression. Immunofluorescent double staining for RECA-1 (red) and Ki-67 (green) of 
representative kidney sections of a sham-operated rat and rats sacrificed at 72 hr (D) or 9 weeks (E) 
after reperfusion. Insert is showing double positivity of RECA-1 and Ki-67 staining in yellow in kidney 
sections at 9 weeks after reperfusion. Representative images of kidney sections of the cortex stained for 
CD31 (F) obtained from a sham-operated rat and rats subjected to I/R and sacrificed at 72 hr or 9 weeks 
after reperfusion. Data are shown as mean ± SEM (n= 5 rats in grouper group). *P<0.05 compared to 
corresponding sham controls. #P<0.05 compared to 72hr. Original magnification of A, D, E and F, x200; 
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Renal I/R induces a dysbalance in Ang-2/Ang-1 ratio at early time points and return to 
baseline after 6 weeks
In control kidneys of sham-operated rats, Ang-1 staining was observed in the glomeruli 
and in a capillary like pattern between the tubuli (Fig. 4A). Double staining of Ang-1 and 
the pericyte marker NG2 revealed co localization, suggesting that Ang-1 is expressed by 
pericytes (Fig. 4C). Starting at 24 hr after renal I/R, a significant decrease in Ang-1 expression 
was observed (data not shown), reaching a maximal decrease at 72 hr (p< 0.05) (Fig. 4A, F). 
Ang-1 expression increased significantly at 9 weeks after renal I/R compared to 72 hr (p<0.05) 
(Fig. 4A, F). Additionally, RT-PCR analyses revealed a decrease in Ang-1 mRNA levels which 
reached significance at 1 week compared the sham-operated rats (p<0.05; Fig. 4I). 
In control rats, low levels of Ang-2 protein were observed in glomeruli, interstitial vessels and 
on brushborders of tubuli (Fig. 4B, G). Due to the apical and brush border expression on 
tubuli of Ang-2 in the medulla, it was technically not possible to distinguish between interstitial 
and tubular presence of Ang-2 (Fig. 4E). Therefore quantification of angiopoietins was only 
performed in the cortex. Additional double staining of Ang-2 and RECA-1 confirmed the 
expression of Ang-2 by ECs (Fig. 4D). Compared to sham-operated rats, Ang-2 expression 
increased at 5 hr (data not shown) and remained elevated up to 72 hr (p< 0.05) after I/R (Fig. 
4G). Consequently higher Ang-2/Ang-1 ratios were observed after 48 hr and 72 hr (p<0.05) 
(Fig 4H). After 1 week, Ang-2 levels and Ang-2/Ang-1 ratio started to decrease, reaching 
significance at 6 and 9 weeks compared to 72 hr after renal I/R (Fig. 4B, G and H). Ang-2 
mRNA levels did not confirm the observed changes at protein levels (Fig. 4J). Tie-2 mRNA 
expression showed a significant decrease at 1 week compared with sham-operated group 
and reversal to baseline levels at 9 weeks after I/R (Fig. 4K). 
Renal I/R leads to proliferation of pericytes
Immunohistochemical staining revealed the presence of PDGFRβ positive cells in the 
mesangium, Bowman’s capsule, large vessels and peritubular capillaries (Fig. 5A). A significant 
increase of pericytes was observed at 48 hr upon I/R in all parts of the kidney compared with 
sham-operated rats, which persisted up to 72 hr in the cortex and up to 9 weeks in both the 
outer and inner medulla (p< 0.05) (Fig. 5A, B). PDGFRβ expression showed normalization at 
the protein level in all regions of the kidney (p<0.05) at 9 weeks after renal I/R injury (Fig. 5A, 
B). To investigate the anatomical relation of ECs and pericytes double staining with RECA-1 
and the pericyte marker NG2 were performed, which revealed expression of both markers in 




































































 Figure 4. Renal I/R induces a dysbalance in the Ang-2/Ang-1 ratio early after reperfusion
Representative cortical photomicrographs of kidney sections stained with Ang-1 (A) or Ang-2 (B) 
in a sham-operated rat and rats subjected to I/R and sacrificed at 72 hr or 9 weeks after reperfusion. 
Immunofluorescent double staining for Ang-1/NG2 (C), RECA-1/Ang-2 (D) and Ang-2/RECA-1 (E) of 
representative kidney sections in a sham-operated rat. Arrows indicate double staining in yellow (C,D) 
and apical expression of Ang-2 (E). Quantitative analysis of cortical protein expression of Ang-1 (F), 
Ang-2 (G), and Ang-2/Ang-1 ratio (H) at consecutive time points after reperfusion. Quantitative analysis 
of RNA expression of Ang-1 (I), Ang-2 (J) and Tie-2 (K) at consecutive time points after reperfusion. Data 
are shown as mean ± SEM (n= 5 rats per group). *P<0.05 compared to corresponding sham controls. 















































Figure 5. Renal I/R induces proliferation of pericytes 
Representative photomicrographs of whole kidney sections stained for PDGFRβ (A) in a sham-operated 
rat and rats subjected to I/R and sacrificed at 72 hr or 9 weeks after reperfusion. Insert is showing 
peritubular and glomerular expression of PDGFRβ in sham-operated rats. Quantitative analysis of 
PDGFRβ protein expression (B) at consecutive time points after reperfusion. Immunofluorescent double 
staining for RECA-1 (red) and NG2 (green) of representative kidney sections (C) in a sham-operated rat 
and rat subjected to I/R and sacrificed at 9 weeks after reperfusion. Data are shown as mean ± SEM (n= 5 
rats per group). *P<0.05 compared to corresponding sham controls. #P<0.05 compared to 72hr. Original 
magnification of A, x100; insert at 72hr and C, x200.
Discussion
We performed a detailed kinetic analysis of angiopoietin and pericyte expression after renal 
I/R injury. We demonstrate that renal I/R induces a dysbalance in Ang-2/Ang-1 which is 
accompanied by a loss of ECs, proliferation of pericytes and development of fibrosis. At 9 










































normalization of PDGFRβ expression in the cortex. Whereas renal function is fully restored at 
this time point, the renal tissue does still show signs of fibrosis.
It is postulated that loss of ECs is a central common pathway involved in organ failure that 
precedes and drives the profibrotic changes of the kidney parenchyma (2;3;24). Different reports 
using animal models have been published which demonstrate chronic deleterious effects of 
ischemic injury on long-term renal function and microvascular structure (2;6;16;17;29;36). 
Basile et al have shown that renal I/R in a rat model results in permanent damage to peritubular 
capillaries with development of tubulointerstitial fibrosis and decline in long-term renal function 
(2). In the present study, we also observed loss of peritubular capillaries and development 
of tubulointerstitial fibrosis following renal I/R, which were more severe and extensive in the 
outer and inner medulla than the cortex. The observed fibrosis at early time points after renal 
I/R injury in our study coincided with the influx of inflammatory cells. At later time points, we 
observed a different pattern of fibrosis, which was more dense and unrelated to the areas of 
inflammation. This ‘inflammatory fibrosis’ observed at early times has been reported to be 
important for restoration of the original tissue morphology and function (13). It is, however, 
also suggested that if repair is not efficient at early times, fibrosis at the repair phase cannot 
be prevented (9). In our study, at 9 weeks after reperfusion, restoration and proliferation of 
ECs was found in the cortex, but not in the outer and inner medulla. This could be caused 
by the anatomical relationship of capillaries and tubules in the outer and inner medulla, with 
consequently a greater impact of hypoxia- and leucocyte-induced EC damage than in the 
cortical peritubular capillaries (5). 
In contrast to the study of Basile et al, we found restoration and proliferation of ECs in the 
cortex in the repair phase (9 weeks after I/R). Possible explanations for this discrepancy 
between our study and the studies of Basile could be differences in clamping time (45 versus 
60 minutes, respectively) and the removal of the healthy contralateral kidney in our study. In 
the study of Basile, additional experiments in which rats were subjected to 30 and 45 minutes 
of bilateral ischemia were performed, to assess whether the duration of ischemic injury affects 
damage to the renal microvasculature and function. Both renal function and capillary density 
were more disturbed in the 45 minutes group compared to the 30 minutes rats, which might 
implicate a “critical ischemia time” for endothelial repair (2).
The molecular mechanisms that lead to microvascular injury in organ failure are largely 
unknown. It has been suggested that several angioregulatory growth factors, including the 
angiopoeitins, play a central role in the loss of vascular integrity (18;36). In this regard, a 
study has shown that treatment with COMP-Ang-1 (soluble, stable and potent form of Ang-
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decrease in interstitial inflammatory cells and renal interstitial fibrosis (5). Other investigators 
have demonstrated stabilization of peritubular capillaries along with increased fibrosis 
and inflammation after adenoviral Ang-1 treatment in a mouse model of folic acid-induced 
nephrotoxicity (37). These studies suggest that differences in efficacy of Ang-1 in the kidney 
may be due to variation in potency of Ang-1 and COMP-Ang-1 or difference in kidney disease 
models (5;12;37). Ang-2 acts as an antagonist of Ang-1 and increases vessel leakage, 
inflammation and destabilization by promoting pericyte loss, therefore loosening contacts 
between ECs and pericytes (18;36).
An interesting observation in this study is that we found a relation in time between Ang-2/Ang-
1 balance and microvascular integrity and pericytes in the cortex after I/R. Activation of ECs, 
reflected by increase in Ang-2 expression and consequently higher Ang-2/Ang-1 ratio, was 
accompanied by proliferation of pericytes, EC loss and development of fibrosis. This relation 
between EC loss and dysbalance in angiopoietins has also been demonstrated in a mouse 
model of anti-glomerular basement membrane glomerulonephritis, where glomerular capillary 
loss was associated with reduced Ang-1 and increased Ang-2 expression (38). In addition, 
in an animal model of diabetic retinopathy, Ang-1 was shown to have a profound effect in 
repairing integrity of the retinal EC permeability barrier (39). Moreover, injection of Ang-2 
into the eyes of normal rats has been shown to induce a dose-dependent pericyte loss (28). 
These findings suggest an important role for the angiopoeitins in generating a proangiogenic 
environment that is necessary for capillary repair.
Several studies have pointed at the critical importance of the interaction between pericytes 
and ECs in maintenance of the capillary network (1;30). Surprisingly, hardly any data are 
available on the relation between pericytes and loss of ECs in renal I/R. Only one study has 
shown an association between damage to peritubular capillaries and decreased number of 
pericytes in cadaveric renal allografts after I/R (21). Peritubular capillary integrity was better 
preserved and pericytes were more pronounced in patients who had a better recovery of 
their graft function compared to patients with sustained postischemic acute kidney injury (21). 
However, this study investigated the expression of pericytes at only one time-point early after 
renal I/R and did not investigate the relation to angiopoietins and development of fibrosis in a 
time course.
To investigate the role of pericytes in renal I/R injury, we used PDGFRβ as pericyte marker. 
PDGFRβ is a single-spanning transmembrane glycoprotein that binds to its dimeric ligand 
PDGF and a crucial receptor for recruitment and survival of pericytes by paracrine secretion 
of PDGFB by ECs (4;23;33). PDGFRβ has been shown in studies of obstructive and post-










































other pericyte markers, PDGFRβ continued to be expressed after proliferation of pericytes and 
after transformation into myofibroblasts upon injury. Recently, Duffield et al provided evidence 
for the contribution of pericytes to the development of renal fibrosis (11;18;23;30). Using a 
transgenic mouse model of unilateral ureter obstruction (UUO), expressing green fluorescent 
protein in cells producing the collagen type I, they demonstrated that pericytes are the main 
source for interstitial myofibroblasts during renal fibrosis (23). The same investigators showed 
migration of perivascular stromal cells from capillaries into the renal interstitium, within 9 hr 
after induction of ureter obstruction. After loosening contact from the capillaries, pericytes 
became activated and proliferated into collagen producing myofibroblasts contributing to 
fibrosis (23). PDGFRβ signaling has been reported to play an important role in the development 
of fibrosis. Blockade of PDGFRβ attenuated recruitment of inflammatory cells, loss of ECs and 
fibrosis in mice subjected to renal I/R injury and UUO (22). Also in our study we demonstrated 
proliferation of pericytes and loss of ECs which was accompanied by development of fibrosis. 
The pericytes may have responded to injury by detaching from the capillaries and becoming 
pathologic matrix depositing cells, that contribute to the population of α-SMA–positive cells in 
the fibrotic interstitial space observed in this study (8;31). The process of pericyte detachment 
has been suggested to be reversible, which could explain the observed decrease in PDGFRβ 
expression and the restoration of ECs in the cortex (22). However, in both the inner and 
outer medulla an increase of PDGFRb cells was observed up to 9 weeks after renal I/R. 
Interestingly, these areas had no increase in EC staining and demonstrated a more profound 
fibrosis reaction compared to the less damaged cortex area. 
An important discussion point remains whether the decrease in RECA-1 in the cortex observed 
in our study is explained by EC loss or by interstitial edema and compression of peritubular 
capillaries. However, previous studies utilizing microfilm analyses and EC staining with CD31 
confirmed the loss of ECs after I/R (2;3;17;19;32). Additional CD31 staining in this study, 
revealed a similar pattern as observed with RECA-1. Although, our study clearly suggests that 
angiopoietins are essential in renal microvascular remodeling in the cortex, we were not able 
to analyze the outer and inner medulla of Ang-2 staining. Ang-2 showed brush border and 
apical expression on tubules in the medulla, making it difficult to distinguish between interstitial 
and tubular presence of Ang-2. Therefore, we focused only on the cortex for angiopoietins 
staining. Furthermore, we observed a discrepancy in Ang-2 protein and mRNA expression, 
which could be explained by the use of whole kidney RNA extractions instead of a specific 
region as for immunohistochemistry or contribution of earlier produced Ang-2 by infiltrating 
cells, while lacking the detectable transcript (28). A therapeutic intervention would be required 
to prove a causal relationship between the functions of angiopoietins and pericytes and its role 
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In conclusion, our study demonstrates that renal I/R induces a dysbalance in angiopoietins, 
accompanied by proliferation of pericytes and development of fibrosis. These findings support 
the hypothesis that angiopoietins and pericytes play an important role in renal microvascular 
remodeling. Since angiopoietins and pericytes are considered as important hallmarks of 
microvascular integrity, strategies to counteract microvascular destabilization after I/R may 
well improve long term graft function.
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Background: Recent insights suggest that endothelial cell (EC) activation plays a major 
role in renal ischemia/reperfusion (I/R) injury. Interactions between ECs and pericytes via 
signaling molecules, including angiopoietins, are involved in maintenance of the vascular 
integrity. Experimental data have shown that enhancement of Angiopoietin (Ang)-1 signaling 
might be beneficial in renal I/R injury. However, little is known about the role of angiopoietins 
in human renal I/R injury.
Methods: In this study, EC activation and changes in angiopoeitins are assessed in human 
living and deceased donor kidney transplantation. Local release of angiopoietins was 
measured by unique, dynamic arteriovenous measurements over the reperfused kidney.
Results: Renal I/R is associated with acute EC activation shown by a vast Ang-2 release 
from both living and deceased donors shortly after reperfusion. Its counterpart Ang-1 was not 
released. Histological analysis of kidney biopsies showed EC loss after reperfusion. Baseline 
protein and mRNA Ang-1 expression was significantly reduced in deceased compared to 
living donors and declined further after reperfusion.
Conclusions: Human renal I/R injury induces EC activation after reperfusion reflected by 
Ang-2 release from the kidney. Interventions aimed at maintenance of vascular integrity by 












































Ischemia reperfusion (I/R) injury is an inevitable consequence of organ transplantation and 
a major determinant of patient and graft survival (1,2). The pathophysiology of renal I/R 
injury is complex and incompletely understood. Although the role of tubular cell injury in post-
transplantation graft dysfunction is widely acknowledged, microvascular endothelial cell (EC) 
damage is considered increasingly important (3). ECs line the lumen of all blood vessels 
within the kidney graft and in this unique position they form the interface between the recipient 
blood and the allograft tissue. ECs are very susceptible to damage, including I/R injury (4). 
The repetitive insults during transplantation may induce loss of the microvasculature, on the 
long term resulting in impaired delivery of oxygen and nutrients to renal tubular epithelial cells, 
chronic ischemia and cell death (4-8). 
  
The molecular mechanisms that lead to microvascular graft injury are largely unknown. 
Endothelial homeostasis is regulated by the angiopoietin system and pericytes (9). Pericytes 
are the basic supportive cells of the endothelium, connected to the vessel’s basement 
membrane (10). Angiopoietin-1 (Ang-1) and -2 (Ang-2) are both ligands for the Tie2 receptor, 
but have opposite effects. Ang-1 is produced by pericytes and is responsible for suppressing 
vascular leakage, maintaining EC survival and inhibiting vascular inflammation. Ang-
2 acts as an antagonist of Ang-1 and thereby destabilizes quiescent endothelium (11-14). 
Ang-2 promotes pericyte loss, leading to loosening contacts between ECs and pericytes, 
subsequent vessel destabilization and abnormal microvascular remodeling (15-18). ECs store 
Ang-2 in Weibel–Palade bodies from where it can be released quickly following stimulation, 
and Ang-2 expression can be upregulated manifold following endothelial activation (19). A 
few experimental studies have focused on the functional role of angiopoietins in endothelial 
damage in the kidney. The relation between a disbalance in angiopoietins and EC loss was 
demonstrated in a mouse model of anti-glomerular basement membrane glomerulonephritis, 
where glomerular capillary loss was associated with reduced Ang-1 and increased Ang-2 
expression (20). Similarly, Ang-1 expression decreased after renal I/R injury in mice (21). 
Moreover, Ang-1 overexpression even significantly improved renal function and renal tissue 
blood flow after renal I/R in mice and decreases inflammatory cells and renal interstitial fibrosis 
(22). 
Although these experimental data suggest a functional role of angiopoietins in renal I/R injury, 
their involvement in human renal I/R injury had not been investigated yet. In addition, their 
involvement in living and deceased donor kidney transplantation had not been compared. 
In our recent studies on renal I/R, we exploited selective arteriovenous measurements over 
the kidney as a reliable method to study inflammatory processes after reperfusion (23,24). In 
this study, local renal angiopoietin expression and release during renal I/R is systematically 











































Integrity of the renal microvasculature is disturbed after reperfusion
To assess endothelial structure and viability, staining for ECs was quantified in both living and 
deceased donor kidney tissue. Both CD34 and vWf staining showed a characteristic positive 
pattern of peritubular and glomerular ECs. Pre-reperfusion biopsies did not show a difference 
between living and deceased donor kidneys in either CD34 (p=0.76) or vWf (p=0.07; Figure 
1). Next, pre- and post-reperfusion biopsies of LD kidneys were compared. There was a 
trend towards a decrease in CD34 positive cells after reperfusion (p=0.08, data not shown), 
whereas vWf staining of ECs showed a significant decrease in expression after reperfusion 





Figure 1: vWf staining decreased after reperfusion. Staining for vWf showed a characteristic 
positive endothelial pattern. Typical example of vWf staining in A a pre-reperfusion biopsy, B a post-
reperfusion biopsy of a LD kidney. C Quantification of vWf staining showed no differences in 
intensity between groups before transplantation (p=0.07). D After reperfusion, vWf signal showed a 
vast decrease (p<0.005) in LD kidneys. The boxes run from the lower to upper quartile, the whiskers 




Figure 1: vWf staining decreased after reperfusion. Staining for vWf showed a characteristic positive 
endothelial pattern. Typical example of vWf staining in A a pre-reperfusion biopsy, B a post-reperfusion 
biopsy of a LD kidney. C Quantification of vWf staining showed no differences in intensity between groups 
before transplantation (p=0.07). D After reperfusion, vWf signal showed a vast decrease (p<0.005) in LD 
kidneys. The boxes run from the lower to upper quartile, the whiskers indicate the 5 to 95 percentile, while 
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Ang-2 is released from the reperfused kidney
Arteriovenous differences for Ang-1 and Ang-2 were assessed over the kidney during 
reperfusion. Ang-1 levels did not change significantly over the reperfused kidney in LD, BDD 
and CDD kidney transplantation, making it unlikely that anti-inflammatory Ang-1 is released 
from the kidney after reperfusion (Figure 2A-C). In contrast Ang-2, a marker for endothelial 
activation, was released from the kidney both early and late after reperfusion (Figure 2D-
F). Ang-2 release was statistically significant in LD kidneys early after reperfusion (3 min., 
p=0,005; 30 min. p=0.064), in BDD kidneys only late after reperfusion (3 min. p=0.15; 30 min., 
p=0.036) and in CDD kidneys both early and late after reperfusion (3 min., p<0.001; 30 min., 
p=0.017). In the total group of deceased donor kidney transplantations, both early and late 
Ang-2 release was statistically significant (3 min., p=0.024; 30 min., p=0.001). The Ang-1/Ang-
2 ratio was consistently higher in the arterial compared to renal venous samples at both time 
points for all donor types, although this trend was statistically not significant (data not shown). 




Figure 2: Ang-2 is released from the kidney during reperfusion. Ang-1 was not released from the 
kidney either 3 or 30 minutes after reperfusion in A LD (3 min. p=0.18; 30 min. p=0.59); B BDD (3 
min. p=0.29, 30 min. p=1.0); C CDD (3 min. p=0.47; 30 min. p=1.0). Ang-2 was significantly 
released from the kidney in D LD kidneys early after reperfusion (3 min. p=0,005; 30 min. p=0.064), 
E in BDD kidneys only later after reperfusion (3 min. p=0.15; 30 min. p=0.036) and F in CDD 
kidneys both early and late after reperfusion (3 min. p<0.001; 30 min. p=0.017). N=6 in each group.  
Bars represent mean and error bars represent SEM.  
 
Figure 2: Ang-2 is released from the kidney during reperfusion. Ang-1 was not released from the 
kidney either 3 or 30 minutes after reperfusion in A LD (3 min. p=0.18; 30 min. p=0.59); B BDD (3 min. 
p=0.29, 30 min. p=1.0); C CDD (3 min. p=0.47; 30 min. p=1.0). Ang-2 was significantly released from the 
kidney in D LD kidneys early after reperfusion (3 min. p=0,005; 30 min. p=0.064), E in BDD kidneys only 
later after reperfusion (3 min. p=0.15; 30 min. p=0.036) and F in CDD kidneys both early and ate after 











































Ang-1 protein and mRNA expression are significantly higher in LD kidneys and are 
reduced after reperfusion 
Protein and mRNA expression of angiopoietins was assessed in the three donor groups. 
Ang-1 protein was expressed in glomeruli and capillary walls (Figure 3A, B). The protein 
expression was already reduced before transplantation in CDD kidneys (p=0.003), not 
BDD kidneys (p=0.17) compared to LD kidneys (Figure 3C, D). Consistently, Ang-1 mRNA 
expression before transplantation was significantly higher in LD kidneys compared to CDD 
kidneys (p=0.006) (Figure 3E). In LD kidney biopsies collected before and 45 minutes after 
reperfusion, there was a significant reduction in both Ang-1 mRNA (p=0.007) and protein 
expression after reperfusion (p=0.001; Figure 3D, F).
Ang-2 protein and RNA expression levels are similar between LD and deceased donors
Ang-2 immunostaining of kidney sections revealed expression in interstitial vessels and 
negative staining in the glomeruli (Figure 4A, B). There were no differences in Ang-2 protein 
and mRNA expression between LD, BDD and CDD kidneys (p=0.69, p=0.73, respectively; 
Figure 4C, E). Quantification of Ang-2 staining showed a decrease of protein expression after 
reperfusion in LD kidneys (p=0.006, Figure 4D). However, mRNA expression of Ang-2 did 
not change after reperfusion in LD kidney transplantation (p=0.72, Figure 4F). The mRNA 
expression of the angiopoietin receptor Tie-2 was similar between the different donor types 












































Figure 3: Ang-1 protein and mRNA expression decreased after reperfusion. Ang-1 staining was 
positive in glomeruli and peritubular capillaries. Typical example of Ang-1 staining in A a pre-
reperfusion biopsy and B a post reperfusion biopsy of a LD kidney. C Quantification of Ang-1 in pre-
transplantation kidney biopsies showed a significantly decrease in CDD (p=0.003) compared to LD 
grafts. D Ang-1 in LD kidney biopsies taken before (pre) and after (post) reperfusion showed a 
significant decrease in Ang-1 protein expression (p=0.001). The boxes run from the lower to upper 
quartile, the whiskers indicate the 5 to 95 percentile, while the horizontal line is set at the median. In 
kidney biopsies mRNA expression of Ang-1 was assessed. E pre-transplantation Ang-1 mRNA 
expression was significantly reduced in CDD kidneys compared to LD kidneys (p=0.006). F when 
 
Figure 3: Ang-1 protein and mRNA expression decreased after reperfusion. Ang-1 staining was 
positive in glomeruli and peritubular capillaries. Typical example of Ang-1 staining in A a pre-
reperfusion biopsy and B a post reperfusion biopsy of a LD kidney. C Quantification of Ang-1 in pre-
transplantation kidney biopsies showed a significantly decrease in CDD (p=0.003) compared to LD 
grafts. D Ang-1 in LD kidney biopsies taken before (pre) and after (post) reperfusion showed a 
significant decrease in Ang-1 protein expression (p=0.001). The boxes run from the lower to upper 
quartile, the whiskers indicate the 5 to 95 percentile, while the horizontal line is set at the median. In 
kidney biopsies mRNA expression of Ang-1 was assessed. E pre-transplantation Ang-1 mRNA 
expression was significantly reduced in CDD kidneys compared to LD kidneys (p=0.006). F when 
Figure 3: Ang-1 protein and mRNA expression decreased after reperfusion. Ang-1 staining was 
positive in glomeruli and peritubular capillaries. Typical example of Ang-1 staining in A a pre-reperfusion 
biopsy and B a post reperfusion biopsy of a LD kidney. C Quantification of Ang-1 in pre-transplantation 
kidney biopsies showed a significantly decrease in CDD (p=0.003) compared to LD grafts. D Ang-1 in LD 
kidney biopsies taken before (pre) and after (post) reperfusion showed a significant decrease in Ang-1 
protein expression (p=0.001). The boxes run from the lower to upper quartile, the whiskers indicate the 5 
to 95 percentile, while the horizontal line is set at the median. In kidney biopsies mRNA expressio  of Ang-
1 was assessed. E pre-transplantation Ang-1 mRNA expression was significantly reduced in CDD kidneys 
compared to LD kidneys (p=0.006). F when comparing biopsies collected before (pre) and after (post) 












































Figure 4: Ang-2 protein and mRNA levels are similar between living and deceased donors.  
Ang-2 staining was positive in interstitial vessels and peritubular capillaries. Typical example of  
Ang-2 staining in A a pre-reperfusion biopsy and B a post-reperfusion biopsy of a LD kidney. C There 
were no differences in Ang-2 protein expression between groups before transplantation (p=0.69). D 
After reperfusion, there was a decrease in Ang-2 protein expression (p=0.006), consistent with 
degranulation of ECs and loss of Ang-2. The boxes run from the lower to upper quartile, the whiskers 
indicate the 5 to 95 percentile, while the horizontal line is set at the median. mRNA expression of 
Ang-2 was assessed in kidney biopsies. E Ang-2 expression was similar before reperfusion in all 
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Figure 4: Ang-2 protein and mRNA levels are similar between living and deceased donors. 
Ang-2 staining was positive in interstitial vessels and peritubular capillaries. Typical example of Ang-2 
staining in A a pre-reperfusion biopsy and B a post-reperfusion biopsy of a LD kidney. C There were 
no differences in Ang-2 protein expression between groups before transplantation (p=0.69). D After 
reperfusion, there was a decrease in Ang-2 protein expression (p=0.006), consistent with degra ulation 
of ECs and loss of Ang-2. The boxes run from the lower to upper quartile, the whiskers indicate the 5 to 
95 percentile, while the horizontal line is set at the median. mRNA expression of Ang-2 was assessed in 
kidney biopsies. E Ang-2 expression was similar before reperfusion in all groups (p=0.73). F In LD kidney 












































Previous studies, primarily exploiting animal models, have revealed that EC activation plays 
a major role in I/R injury and that the angiopoietin balance may be critical in maintaining 
vascular integrity. Enhancement of Ang-1 signaling has been demonstrated to be beneficial in 
renal I/R injury (25). However, thus far, no study has reported on the role of angiopoietins in 
human renal I/R injury or local release of angiopoeitins from the kidney. In this study, the local 
response of the reperfused kidney was assessed by arteriovenous concentration differences 
of angiopoietins during the first 30 minutes after reperfusion in living and deceased donor 
kidney transplantation. Results demonstrate that renal I/R is associated with acute EC 
activation shown by a vast Ang-2 release from both living and deceased donor kidneys shortly 
after reperfusion. 
In the present study, a reduction in CD34 and vWf protein expression was observed in tissue 
biopsies after reperfusion, consistent with either EC death or endothelial injury that induces 
loss of their characteristic epitopes. These findings are consistent with experimental models 
of acute ischemic renal endothelial injury after reperfusion (7,26,27), and recently observed in 
humans as well (28-31). EC activation represents a switch from a quiescent phenotype toward 
one that is involved in the host defense response. This process will result in expression of 
chemokines, cytokines, angiogenic factors and adhesion molecules designed to interact with 
leukocytes and platelets and target inflammation. In our previous study in human living donor 
kidney transplantation no evidence for EC activation was found by absence of local release 
of ICAM-1, P-selectin and vWf (23). However, the angiopoietins and endothelial/pericyte 
interactions were not studied. 
Angiopoietins have been shown to play a critical role in the maintenance of the microvasculature 
(15). This study focused on the release of these factors from both living and deceased donor 
kidneys. Results show that Ang-1 was not released from the kidney during reperfusion in 
any of the three groups, consistent with the theory that Ang-1 is constitutively expressed 
and dynamic changes in Tie-2 signaling are mediated via Ang-2. Consistent with previous 
reports, Ang-1 protein was found in glomeruli and capillary walls (32). Interestingly, we show 
that Ang-1 mRNA and protein expression decreased after reperfusion in human renal I/R 
injury. In contrast, in rodents Ang-1 expression has been shown to increase after chemical 
or ischemic kidney injury (33,34). However, these observations in experimental animals were 
done days after the injury, in contrast to the immediate changes observed in our patients. The 
loss of Ang-1 signal may indicate loss of vital pericytes, since pericytes are the main Ang-1 
producing cells. However, decreased Ang-1 protein in renal tissue may also be related to the 










































and release of Ang-1 may have the same mechanism as that of Ang-2 (35). Loss of Ang-1 
signaling appears important in many disease processes, and enhancement of Ang-1 signaling 
was beneficial in sepsis and renal I/R injury (25,36). 
High Ang-2 levels have repeatedly been shown in pathological conditions, such as in diabetes 
mellitus, renal failure and in myocardial I/R injury (37-39). Ang-2 triggers an inflammatory 
response by inducing permeability of the vascular lining (40), possibly mediated by the Ang-
2 induced loss of pericytes (41). Results of this study show a vast Ang-2 release from both 
living and deceased donor kidneys shortly after reperfusion. This indicates injury to ECs, 
which can release Ang-2 from Weibel-Palade bodies upon activation (42). Since expression 
of Ang-2 did not change upon reperfusion, the arteriovenous difference may reflect Ang-2 
release from Weibel-Palade bodies upon stress. This was confirmed by decreased endothelial 
Ang-2 tissue biopsy staining after reperfusion, consistent with exocytosis of Ang-2 containing 
granulae. In contrast to Ang-1, there was no expression of Ang-2 in the glomeruli, and positive 
signal was mainly seen on peritubular capillaries (32). The Ang-2 release from the kidney 
may induce continuing endothelial damage, ultimately leading to pericyte dropout, loosening 
contacts between endothelial and perivascular cells, with subsequent vessel destabilization 
and fibrosis. 
In our arteriovenous measurements directly over the reperfused graft no release of vWf itself 
or its propeptide was observed, while Ang-2, another constituent of Weibel-Palade bodies 
was released. Possible explanations include that Ang-2 may be more easily detectable by 
arteriovenous measurements due to a shorter half-life, or that Ang-2 release from Weibel-
Palade bodies is regulated independent from vWf release (43). Moreover, when vWf multimers 
are secreted from stimulated ECs they may remain anchored to the endothelial surface (44). 
This early retention of vWf to endothelium may provide a further explanation for the lack of a 
detectable release of vWf into the renal vein. 
A limitation of our study was the fact that sampling time was restricted to maximally 45 minutes 
following reperfusion. Although endothelial damage is considered to be initiated during cold 
ischemia and expected to be vast around reperfusion, we cannot exclude continuing damage 
after 45 minutes. Another limitation is that we had to include different patient cohorts for 
arteriovenous measurements and collection of biopsies. Since for ethical reasons from every 
patient only one biopsy could be obtained, either DNA isolation or immunohistochemistry was 
done. Although one cohort for all sampling may have been preferable, our sampling is not 
expected to have influenced the conclusions from this study, since no correlations with patient 
characteristics are made. The aim of this study was to explore the endothelium-pericyte 
interactions in the pathophysiology of renal I/R injury. In future studies correlations between 
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In conclusion, human renal I/R injury induces EC activation after reperfusion which leads 
to Ang-2 release from the kidney in both living and deceased donor kidney transplantation. 
This is accompanied by loss of ECs and diminished Ang-1 protein and mRNA expression. 
Moreover, compared to living donors expression of Ang-1 was significantly reduced in 
deceased donors. Interventions aimed at maintenance of vascular integrity by modulation of 




Eighteen patients undergoing renal allograft transplantation were included for arteriovenous 
sampling, 6 living donor (LD), 6 brain dead donor (BDD), and 6 cardiac dead donor (CDD) kidney 
recipients. BDD and CDD together are referred to as deceased donors (DD). Twenty-three 
other patients receiving a kidney from a LD (n=10), a BDD (n=7) or a CDD (n=6) were included 
for mRNA isolation from renal biopsies. Immunohistochemical analyses were performed on 
biopsies of 10 LD, BDD and CDD kidney graft recipients. Patient characteristics are shown in 
Supplemental Table 1. All kidneys were still functioning at 1 year after transplantation, except 
for one patient in the arteriovenous sampling cohort who received a kidney from a CDD (the 
recipient was not compliant with immunosuppressive medication) and one patient in the 
PCR cohort, that received a BDD kidney transplant and died 6 months after transplantation 
(because of veno-occlusive disease ultimately causing hepatic failure). For technical reasons 
(renal vein sampling) only patients receiving a left kidney were included in the arteriovenous 
group. The reason for including different cohorts was to minimize patient burden by collecting 
one type of material per patient, i.e. either blood or a single renal biopsy. The study protocol 
was approved by the local ethics committee, and informed consent was obtained from each 
patient.
Operation and materials
Kidney transplantations were performed according to local standardized protocol. In LD 
minimally invasive nephrectomy was performed. For cold perfusion and storage of the 
kidney, Custodiol® Histidine–tryptophan–ketoglutarate solution (HTK) solution (Tramedico, 
Weesp, The Netherlands) was used. DD kidneys were perfused and stored with University of 
Wisconsin solution (UW) or HTK. The immunosuppressive regimen was based on induction 
therapy with an interleukin-2 receptor blocker (basiliximab, day 0 and day 4) and maintenance 
treatment with tacrolimus or cyclosporine A, in addition to mycophenolate mofetil and steroids 










































Arterial and renal venous blood samples were obtained as described before in detail (23). 
In short, via a small catheter placed in the renal vein, blood aliquots were sampled at 3, and 
30 minutes after reperfusion. Paired arterial blood samples were obtained simultaneously. 
All samples were collected in tubes containing EDTA and immediately placed on ice. Blood 
samples were centrifuged (1,550 g, 20 min, 4ºC) and the derived plasma was subsequently 
centrifuged to deplete it from leukocytes and platelets (1,550 g, 20 min, 4ºC). Plasma was 
aliquotted and stored at -70°C until assayed.
Immunohistochemical analysis
A renal cortical biopsy was obtained after cold storage from LD, BDD and CDD kidney graft 
recipients. For logistical reasons, only in the LD group a second biopsy 45 minutes after 
reperfusion was collected as well. Immunohistochemical analyses were performed on 4 µm 
cryostat kidney tissue sections fixed in acetone. Slides were washed and incubated with 
peroxidase blocking solution and blocked with PBS containing 5% normal human serum 
(NHS) and 1% BSA. Then slides were incubated with the following primary antibodies: Ang-1 
mouse monoclonal IgG, 1:800 (R&D systems), Ang-2 mouse monoclonal IgG, 1:100 (Novus 
Biologicals), ECs (CD34) mouse polyclonal IgG, 1:3200 (Dako), vWf, rabbit polyclonal, 1:2500 
(Dako). Next, the following peroxidase-conjugated secondary antibodies were applied: goat 
anti-rabbit IgG, 1:200 (Dako); goat anti-mouse IgG, 1:200 (Dako); or rabbit anti-goat IgG, 
1:200 (Dako), followed by sequential fluorescein isothiocyanate (FITC, amplification reagent) 
and anti-fluorescein-HRP. Staining was completed by incubation with 3,3’ diaminobenzidine 
tetrahydrochloride (DAB)/ hydrogen peroxide and counterstained with Mayer’s Hematoxylin 
Solution (Merck, Darmstadt, Germany). At 100 × magnification, 10 microscopic fields of each 
kidney section were quantified using computerized image analysis (ImageJ). 
Plasma measurements of endothelial cell activation
Activation of the endothelium was assessed by measuring the local release of endothelial 
activation markers from the kidney. Release of Ang-1 and Ang-2 from the kidney was 
assessed by ELISA (R&D Systems, Minneapolis, MN, USA) according to the manufacturer’s 
protocol. The paired arteriovenous samples were also analyzed on more classical markers 
of endothelial activation; von Willebrand factor (vWf) and vWf propeptide. The propeptide 
has a shorter circulating half-time (2–3 h), compared with vWf itself (>12 h), and may 
therefore be a more sensitive marker of acute endothelial activation. Plasma levels of vWf 
and vWf propeptide were determined using a semi-automated ELISA. Plates were coated 
overnight with coating buffer, consisting of sodium carbonate, sodium bicarbonate and NaN3. 
Commercial antibody duo sets, optimized for ELISA, were used (rabbit anti-human vWf and 
peroxidise-conjugated rabbit anti-human vWf, A00082 and P0226, Dako, Glostrup, Denmark). 
vWf propeptide, rabbit-anti-propeptide, and rabbit-anti-propeptide-biotine were used for the 
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mRNA expression in human kidney biopsies
A renal cortical biopsy was obtained after cold storage from LD, BDD and CDD kidneys, 
and a second biopsy was collected 45 minutes after reperfusion from LD kidneys. Biopsies 
were immediately snap frozen in liquid nitrogen and stored at -70ºC. Total RNA was extracted 
from renal tissues using RNAzol (Campro Scientific, Veenendaal, The Netherlands) and 
glass beads (46). The integrity of each RNA sample was examined by Agilent Lab-on-
a-chip technology using the RNA 6000 Nano LabChip kit and a bioanalyzer 2100 (Agilent 
Technologies, Amstelveen, The Netherlands). RNA preparations were considered suitable for 
further processing if samples showed intact 18S and 28S rRNA bands, and displayed no 
chromosomal peaks or RNA degradation products (RNA Integrity Number >8.0) (47). cDNA 
was synthesized from 1 µg total RNA, using an oligo dT primer, RNase-OUT, M-MLV reverse 
transcriptase, 0.1 M-DTT and buffers in a volume of 20 µL (all purchased from Invitrogen, 
Breda, The Netherlands). Quantitative real-time PCR was performed in duplicate by using iQ 
SYBR Green Supermix on iCycler Real-Time Detection System (BioRad). The amplification 
reaction volume was 20 µL, consisting of 10 µL iQ SYBR Green PCR mastermix, 1 µL primers, 
1 µL cDNA, and 8 µL water. Data were analyzed using Gene Expression Analysis for iCycler 
Real-Time PCR Detection System (BioRad). Expression of each gene was normalized against 
mRNA expression of the housekeeping gene GAPDH. The primer sequences are shown in 
Supplemental Table 2.
Analysis
Clinical donor data were retrieved from Eurotransplant Foundation (Leiden, The Netherlands). 
Delayed graft function (DGF) was defined as the need for dialysis within one week after 
transplantation. Acute rejection was defined as biopsy proven rejection within 60 days after 
transplantation. Statistical analysis was performed using SPSS 17.0 statistical analysis 
software (SPSS Inc, Chicago, Ill). Paired, non-parametric test (Wilcoxon) was applied to 
assess differences between arterial and venous concentration, and between pre- and post-
reperfusion samples. Graph error bars represent the standard error of the mean (SEM), unless 
otherwise stated. A P-value of less than 0.05 was considered significant.
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Supplemental figure 1: No vWf or vWf propeptide release from the reperfused kidney. vWf was 
not released from the reperfused graft both early (3 min.) and later (30 min.) after reperfusion in 
kidney transplantation with A LD (p=0.89, p=0.78), B BDD (p=0.89, p=0.33) and C CDD (p=0.40, 
p=0.18) respectively. The shorter lived and more dynamic vWf propeptide, was not released either 
from the kidney in D LD (p=0.78, p=0.62), E BDD (p=0.19, p=0.89) and F CDD (p=0.35, p=0.74) 
kidney transplantation. Bars represent mean and error bars represent SEM. 
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not released from the reperfused graft both early (3 min.) and later (30 min.) after reperfusion in kidney 
transplantation with A LD (p=0.89, p=0.78), B BDD (p=0.89, p=0.33) and C CDD (p=0.40, p=0.18) 
respectively. The shorter lived and more dynamic vWf propeptide, was not released either from the kidney 
in D LD (p=0.78, p=0.62), E BDD (p=0.19, p=0.89) and F CDD (p=0.35, p=0.74) kidney transplantation. 





























































































































































































































































































































































































































































































































































































































































































































































































































































Supplemental table 2: Primer sequences used for quantitative real-time polymerase chain reaction.
Gene Forward primer 5’->3’ Reverse primer 5’->3’ Supplier
GAPDH TTCCAGGAGCGAGATCCCT CACCCATGACGAACATGGG Biolegio
Ang-1 GCAACTGGAGCTGATGGACACA CATCTGCACAGTCTCTAAATGGT Biolegio
Ang-2 TGGGATTTGGTAACCCTTCA GTAAGCCTCATTCCCTTCCC Biolegio
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Background: Diabetes mellitus (DM) is associated with a range of microvascular 
complications including diabetic nephropathy (DN). Microvascular abnormalities in the 
kidneys are common histopathologic findings in DN, which represent one manifestation of 
ongoing systemic microvascular damage. Recently, sidestream dark-field (SDF) imaging has 
emerged as a noninvasive tool that enables one to visualize the microcirculation. In this study, 
we investigated whether changes in the systemic microvasculature induced by DM and an 
atherogenic diet correlated spatiotemporally with renal damage.
Methods: Atherosclerotic lesion development was triggered in streptozotocin-induced DM 
pigs (140 mg/kg body weight) by administering an atherogenic diet for approximately 11 
months. Fifteen months following induction of DM, microvascular morphology was visualized 
in control pigs (n=7), non-diabetic pigs fed an atherogenic diet (ATH, n=5), and DM pigs fed 
an atherogenic diet (DM+ATH, n=5) using SDF imaging of oral mucosal tissue. Subsequently, 
kidneys were harvested from anethesized pigs and the expression levels of well-established 
markers for microvascular integrity, such as Angiopoietin-1 (Angpt1) and Angiopoietin-2 
(Angpt2) were determined immunohistochemically, while endothelial cell (EC) abundance 
was determined by immunostaining for von Willebrand factor (vWF).
Results: Our study revealed an increase in the capillary tortuosity index in DM+ATH pigs 
(2.31±0.17) as compared to the control groups (Controls 0.89±0.08 and ATH 1.55±0.11; 
p<0.05). Kidney biopsies showed marked glomerular lesions consisting of mesangial expansion 
and podocyte lesions. Furthermore, we observed a disturbed Angpt2/ Angpt1 balance in the 
cortex of the kidney, as evidenced by increased expression of Angpt2 in DM+ATH pigs as 
compared to Control pigs (p<0.05). 
Conclusion: In the setting of DM, atherogenesis leads to the augmentation of mucosal 
capillary tortuosity, indicative of systemic microvascular damage. Concomitantly, a dysbalance 
in renal angiopoietins was correlated with the development of diabetic nephropathy. As 
such, our studies strongly suggest that defects in the systemic microvasculature mirror the 












































Diabetes mellitus (DM) is associated with macrovascular and microvascular complications that 
lead to retinopathy, neuropathy and nephropathy. Diabetic nephropathy is the leading cause 
of chronic kidney disease (CKD) worldwide [1,2]. In this disease setting, the combination of 
endothelial dysfunction and an imbalanced angiogenic response play an important role in 
the development of microvascular complications.  Recently, the angiopoietins have gained 
much attention as critical regulators of of diverse pathological angiogenic conditions, including 
vascular complications associated with diabetes.  The tight control of Angiopoietin-1 (Angpt1) 
and Angiopoietin- 2 (Angpt2) levels is critical in minimizing microvascular derangements that 
are the direct result of negative interference of Angpt2 with Angpt1-mediated Tie-2 signaling. 
This in turn disturbs the expression levels of key angiogenic factors such as von Willebrand 
factor (vWF) and vascular endothelial growth factor (VEGF). The ensuing loss of EC-
pericyte interactions is responsible for destabilization of the capillary network and the loss of 
microvascular integrity. [3,4]-[5,6]. 
Histopathological findings in patients with diabetic nephropathy (DN) include mesangial 
expansion, mesangial sclerosis and vascular lesions such as hyalinosis [7]. These renal 
abnormalities could potentially be indicative of the systemic microvascular damage [8]. 
However, the detection of such pathophysiologies in DN is complex, as it is asymptomatic in 
early stages, while at later stages the direct demonstration of renal injury requires renal biopsy 
material, which is an unattractive tool for screening purposes due to the invasive nature of 
the procedure. Therefore, methods geared towards the non-invasive monitoring for early 
signs of microvascular changes is of clinical importance in patients with DM. However, at 
present these tools do not exist. Sidestream dark-field (SDF) imaging is a relatively new, non-
invasive tool that enables one to visualize the microcirculation without the use of fluorescent 
dyes [9]. Recently, we used this apparatus to assess labial mucosal capillary tortuosity and 
density in diabetic patients compared with healthy non-diabetic controls, studies that revealed 
increased capillary density and tortuosity in diabetic patients [10]. These studies focused on 
the effects of prolonged diabetes in patients (24 ± 14 years). However, at present there is 
limited data regarding how disturbance of the microvasculature in early diabetes correlates 
with renal damage.
In light of these considerations, we sought to investigate whether an atherogenic diet in the early 
stages of DM could accelerate microvascular disease, and could serve as a diagnostic tool for 
DM-induced renal damage. Using SDF imaging, we show that an atherogenic diet during the 
early stages of DM leads to microvascular abnormalities, and immunohistochemically confirm 
that these systemic effects are associated with renal endothelial dysfunction, as evidenced by 












































The experimental protocol was performed in compliance with the ARRIVE guidelines on 
animal research [11]. Protocols describing the management, surgical procedures, and animal 
care were reviewed and approved by the ASG-Lelystad Animal Care and Use Committee 
(Lelystad, The Netherlands) and by the Institutional Review Board for animal experimentation 
of the Erasmus University Medical Center (Rotterdam, The Netherlands). Ten neutered male 
domestic pigs (Landrace x Yorkshire, T-line) with an age ~11 weeks and a body weight of ~30 
kg entered the study. After one week of acclimatization, DM was induced in a subgroup of 
5 pigs by slow intravenous injection of streptozotocin (STZ 140 mg/kg; Enzo Life Sciences, 
Raamsdonkveer, The Netherlands) as described previously [12–15]. Five non-diabetic pigs 
received placebo treatment. Three weeks after DM induction, all of the pigs were gradually 
introduced to an atherogenic diet (ATH), containing 25% of saturated fats and 1% of cholesterol 
(16). The 5 diabetic pigs (DM+ATH) and 5 non-diabetic pigs (ATH) were subsequently 
followed for up to 15 months, during which similar growth patterns were observed in both 
groups by adjusting individual caloric intake. In the diabetic pigs, glucose and ketone levels 
in plasma and urine were regularly checked in the 15-month follow-up period. Insulin therapy 
was started only in instances where plasma ketones were detected. Following 12 months, 
24h urine samples were obtained from all pigs, while microcirculatory imaging and plasma 
samples were obtained from anesthetized pigs (20mg/kg ketamine + 1 mg/kg midazolam+ 1 
mg atropine, i.m. and 12mg/kg thiopental, i.v.) at 14 and 15 months of follow up, respectively. 
At 15 months, the pigs were sacrificed by intravenous injection of an overdose of pentobarbital 
via the jugular vein catheter at 15 months, at which point plasma samples were obtained and 
the kidneys were harvested for histological examination. Invasive imaging analyses prompted 
us to choose this time frame as after 12 months of follow up more complex atherosclerotic 
lesions were present in the coronary arteries of the studied pigs (23).
In addition, we also studied a separate control group (Controls) of 7 female domestic pigs 
(Landrace) at the age of 5 months with a body weight of ~78 kg, who were fed a standard diet 
for growing pigs. 
Microcirculatory imaging and analysis of SDF measurements
SDF microscanning (MicroVision Medical Inc., Wallingford, PA, U.S.A) and analysis of images 
was performed as described earlier with minor modifications [10,16]. Anaesthetized pigs were 
imaged at 14 months of study duration. All pigs were studied during standardized conditions 












































Serum Angpt1 and Angpt2 concentrations were measured after 12 months by enzyme-linked 
immunosorbent assay (ELISA) (Bioconnect, Huissen, The Netherlands and Antibodies-
online, Atlanta, USA). At 12 months, protein and creatinine levels were measured in 24h urine 
samples. To calculate the urinary albumin-creatinine ratio, we measured albumin excretion 
by ELISA (ITK diagnostics, Uithoorn, The Netherlands), and urinary creatinine concentration 
was measured by standard laboratory methods. Both the plasma and urinary creatinine levels 
were measured as previously described. Plasma samples collected at 15 months were used 
to measure concentrations of glucose, total cholesterol, triglycerides and low and high-density 
lipoproteins (LDL and HDL) and creatinine by standardized methods at the clinical chemical 
laboratory of the Erasmus Medical Center (Rotterdam, The Netherlands). In the absence of 
an established mathematicalformula to estimate creatinine clearance in pigs, we expressed 
creatinine levels in μmol/L/kg to adjust for body weight. Blood collection tubes were centrifuged 
for 10 minutes at 3000 rpm after which serum was stored in microcentrifuge tubes at -20oC 
until required for analysis. 
Histological analysis of the kidney
Immunohistochemical analyses of snap-frozen porcine kidney cortex sections  (4 µm) were 
air-dried and acetone fixed as previously described [17]. Monoclonal antibodies utilized were 
directed against mouse anti-human Angpt1 (clone 171718; R&D Systems, Abingdon, UK), 
mouse anti-human VEGF (sc-7269 Santa Cruz Biotechnology, Huissen, the Netherlands) 
and mouse anti-human plasminogen activator inhibitor-1 (clone HD-PAI-1 14.1) (American 
Diagnostica, Pfungstadt, Germany). Polyclonal antibodies were used directed against goat anti-
mouse Angpt2 (clone F18; sc-7017; Santa Cruz Biotechnology, Huissen, the Netherlands) and 
rabbit anti-human vWF (Codenr A0082; Dako, Glostrum, Germany). Primary antibody binding 
was detected using the following isotype-matching secondary horseradish peroxidase (HRP)-
labeled antibodies; goat anti-mouse IgG (Angpt1), rabbit anti-goat IgG (Angpt2), anti-mouse 
Envision K4007 (VEGF) or goat anti-rabbit IgG (vWF) (all purchased from Dako, Glostrum, 
Germany). Quantification of immunohistochemistry was performed in a blinded manner by 
assessing 10 consecutive high power fields (magnification, ×200) using Image J software. 
Glomerular and large vessels were excluded from analysis. Data are presented in terms of the 
Angpt2/Angpt1 ratio as previously described[18,19]. Immuofluorescent double stainings were 
performed for desmin (pericyte marker; mouse anti-pig clone DE-B-5; Millipore, Amsterdam, 
the Netherlands)/Angpt1 (goat anti-human; clone N-18; sc-6319; Santa Cruz Biotechnology, 
Huissen, the Netherlands) and vWF/Angpt2. Secondary antibodies were Alexa-488 labeled 
donkey anti- rabbit (vWF) and alexa-546 labelled rabbit anti-mouse (desmin), Furthermore, 
HRP labelled rabbit anti-goat (Angpt1) and donkey anti-goat (Angpt2) were used. Nuclei were 
visualized using Hoechst (Molecular Probes, Leiden, the Netherlands). Photomicrographs 










































Next, we performed periodic acid-Schiff (PAS) staining on paraffin sections of renal cortex for 
the evaluation of histopathological changes and morphometric analysis of the glomeruli. In a 
blinded fashion, 25 consecutive glomeruli were selected from both superficial and deep cortex 
and the mesangial expansion index was scored. Subsequently, we determined the extent of 
increase in mesangial matrix (defined as mesangial area) by quantitating PAS-positive and 
nuclei-free areas in the mesangium using Image J [20,21]. Evaluation of histopathological 
lesions was performed by a pathologist who was blinded to the code of the sections.
Electron microscopy
Kidney tissues for electron microscopy were processed as described previously [22]. In typical 
cases from the ATH and DM+ATH groups, the glomerular basement membrane (GBM) width 
was measured.
RNA isolation and Real-Time PCR
To analyze renal Angpt1 and Angpt2 mRNA levels, RT-PCR was performed as described 
previously [23]. Expression was normalized against β-actin mRNA levels. RT-PCR analysis 
for biological replicates was performed in duplicate. The primer sequences were as follows: 
β-actin (forward5’-ATCGTGCGGGACATCAAGGA-3’ and reverse 5’-AGGAAGGAGGGCTGG-
AAGAG-3’), Angpt1 (forward 5’-AGGAGCAAGTTTTGCGAGAG-3’ and reverse 5’-CTCA-
GAGCGTTTGTGTTGT-3’) and Angpt2 (forward 5’-AAAGTTGCTGCAGGGAA-AGA-3’ and 
reverse 5’-TCACAGCTCAGAGCGAAGAA-3’).
Statistical analysis
All data are presented as mean ± standard error of the mean (SEM). Differences between 
experimental groups were analyzed using one way-analysis of variance followed by post-hoc 
testing with an unpaired Student’s t-test. Analyses were performed with GraphPad software 














































Initial plasma profiling of DM+ATH and ATH pigs revealed that DM significantly influenced 
glucose levels (17.64 ± 4.54 mmol/L vs. 5.12±0.42 mmol/L; p<0.05) (Table 1) at 15 months. 
Total cholesterol, triglycerides, HDL and LDL were not significantly affected by the induction 
of DM in pigs. Two pigs were administered insulin during the study period due to elevated 
plasma ketone levels. The mean body weight at the time of microvascular imaging was 
comparable between DM+ATH (96±2.8kg) and ATH group (93±0.4kg,p>0.05). At the time of 
sacrifice, substantial coronary lesions as well as generalised atherosclerosis for example in 
the aorta were observed in both DM+ATH and ATH groups, as described previously [24]. 
Table 1: Model characteristics at 15 months of follow up
Controls (N=7) ATH (N=5) DM+ATH (N=5)
Glucose (mmol/l) 4.26±0.29 5.12±0.42 17.64±4.54*#
Triglycerides (mmol/l) 0.18±0.02 0.64±0.2 1.26±0.50*
Total Cholesterol (mmol/l) 1.50±0.05 18.10±2.66* 16.82±1.72*
LDL (mmol/l) 0.76±0.29 14.87±2.45* 13.63±1.3*
HDL (mmol/l) 0.60±0.03 5.70±0.35* 5.12±0.40*
All data are mean ±SEM. ATH: pigs on atherogenic diet. DM+ATH: pigs with diabetes mellitus on 
atherogenic diet. Controls: healthy control pigs on a standard diet. LDL: Low density lipoprotein. HDL: 
High density lipoprotein. * P<0.05 compared with Controls. #P<0.05 compared with ATH pigs.
Early atherogenic diabetes mellitus leads to systemic microvascular damage 
The microvascular morphology of the oral mucosal tissue in DM+ATH pigs was significantly 
disturbed as compared with the Controls (Fig. 1A). Indeed, the capillary tortuosity index 
was significantly increased in DM+ATH pigs (2.3±0.2) as compared with ATH pigs (1.6±0.1, 
p<0.01; Fig. 1B). Furthermore, capillary density was significant lower in the DM+ATH (18.6 
±1.3 capillaries/mm2) pigs as compared with the Controls (24.9 ±0.8 capillaries/mm2, p<0.01; 
































































            








































































            








































































            








































































            

























































            
    
 


































































            


















































Figure 1. Early ather genic DM leads to increased capillary tortuosity A. Sidestream darkfield 
images of the oral mucosa visualizing the microvascular capillaries of a representative pig in the Controls, 
ATH and DM+ATH group. B. Mean tortuosity index of microvascular capillaries in the Controls (n=7), ATH 
(n=5) and DM+ATH pigs (n=5). C. Mean vessel density (capillaries/mm2) in Controls (n=7), ATH (n=5) and 
DM+ATH (n=5) pigs. Data shown are mean±SEM. *P<0.05 compared to Controls or ATH pigs.
Mean vessel density (capillaries/mm2) was calculated by evaluation of number of vessels per selected 
microcirculatory image. Subsequently, tortuosity of capillary loops was assessed according to a validated 
scoring system (0: no twists to 4: four or more twists) and the average of assessed capillary tortuosity was 
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Renal damage after induction of atherogenic DM in pigs
Plasma creatinine levels were elevated in ATH pigs (2.12±0.03 µmol/L/kg) as compared with 
DM+ATH pigs (1.60±0.13 µmol/L/kg, p<0.01) group. However, urinary albumin/creatinine ratio 
was not found to differ between the DM+ATH group (0.045±0.0182 mg/mmol) and ATH pigs 
(0.002±0.0007 mg/mmol, p>0.05). 
PAS-stained renal sections revealed marked tubular changes with foamy cytoplasm and 
hyalin droplets in all DM+ATH pigs and there were glomerular lesions consisting of mesangial 
expansion and podocyte lesions, also with foamy cytoplasm and hyaline droplets in four 
DM+ATH pigs (Fig. 2A). In contrast, but one ATH pig displayedsimilar lesions (Fig. 2A). 
Some glomeruli were found to have dilated capillaries containing numerous red blood cells, 
a phenomenon that is highly reminiscent of microangiopathic injury lesions that have been 
described to be the result of fibrinolytic/proteolytic activation system in combination with 
increased PAI-1 staining [25]. In keeping with this notion, we observed both co-localization 
and increased PAI-1 staining in the herein described lesions (Fig. 2A).
Next, we determined the mesangial expansion index in renal cross-sections. These studies 
showed significantly higher scores in the ATH pigs (0.62±0.05, p=0.03) and a trend towards 
increased scores in the DM+ATH (0.58±0.05,p=0.066) compared with the Controls (0.49±0.03; 
Fig. 2B). Interestingly, the width of the GBM increased from 215 nM in a Controls animal to 252 
and 279 nM in cases with mild and severe DN of the DM+ATH group, respectively. Moreover, 










































































































































































































































































Controls DM+ATH ATH 
Figure 2. Early stages of atherogenic DM leads to renal damage. A: Representative illustration of 
PAS stained glomeruli from a DM+ATH pig, showing mesangial proliferation and matrix expansion with 
capillary loops lying arou d the mesangium as a corona, reminiscent of a beginning Kimmelstiel-Wilson 
nodule (left panel; thin black arrow). Dilated capillary loops with red cell fragments show intense PAI-1 
staining on consecutive slides (right panel; thick black arrow). B: Mesangial expansion index in Controls 
(n=7), ATH (n=5) and DM+ATH (n=5) pigs. C. Electron microscopy images illustrating a normal GBM 
architecture (left panel; thick arrow) of the Controls pig. In ATH, there is slight effacement of the podocyte 
pedicles (middle panel; thick arrow). In DM+ATH, marked lipid deposits were found (right panel). Data 
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Diabetes and atherogenic diet induces Angpt2/Angpt1dysbalance in pigs
Serum Angpt-1 levels in the DM+ATH pigs were increased as compared to control pigs 
(26035±1228 pg/ml versus 18061±1228 pg/ml, p<0.01). There were no significant differences 
in serum Ang-1 levels between DM+ATH and ATH pigs (19832±1166 pg/ml, p>0.05). Angpt-2 
levels were not detectable in the circulation of the different groups.
With regard to Angpt1 staining in the kidneys, we observed positive Angpt1 staining in the 
glomeruli and in a capillary-like pattern between the tubuli of pigs in the Controls group (Fig. 
3A). We found no difference in renal Angpt1 protein expression between ATH (78020±12216 
pixels/area) and DM+ATH (46763±12360 pixels/area, p>0.05) pigs, but Angpt1 expression 
was significantly higher in the Controls group (91788±9777 pixels/area, p < 0.05; Fig. 3B). 
The Angpt1 mRNA levels in the kidney were significantly lower in the DM+ATH and ATH group 
compared with the Controls pigs (Fig. 3C). Double staining of Angpt1 and the pericyte marker 
desmin revealed predominantly expression of desmin in the glomeruli and Angpt1 expression 
in the same pattern as described above (Fig. 3D; left panel). However, no co-localization was 
observed, suggesting that other cells than pericytes might produce Angpt1 in the glomerulus.
Angpt2 staining was predominantly present in glomeruli and tubuli and showed a significant 
increase in DM+ATH (54813±3140 pixels/area) pigs compared to the Controls (22862±3354 
pixels/area, p<0.001) and ATH (31005±5011 pixels/area, p<0.01) pigs (Fig. 3AB). 
Consequently, a higher Angpt2/ Angpt1 ratio was observed in DM+ATH (1.63±0.43) pigs 
compared with Controls (0.28±0.07, p<0.001) and ATH (0.43±0.07, p<0.01) group (Fig. 3B). 
The Angpt2 mRNA levels in the kidney did not significantly differ between groups (Fig. 3C). 
Importantly, additional staining of vWF and Angpt2 revealed co-expression, suggesting that 
endothelial cells produce Angpt2 (Fig. 3D; middle and right panel).
Staining of the endothelial marker vWF showed expression in the glomeruli and peritubular 
space, in the same pattern as Angpt1 (Fig. 3E). No significant differences were observed in 
vWF expression between the Controls (86611±6163 pixels/area), ATH (84547±9000 pixels/
area) and DM+ATH pigs (102961±13633 pixels/area) (p>0.05).
VEGF staining revealed expression in podocytes, parietal epithelial cells and tubuli (most 
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Figure 3. TheAngpt2/Angpt1 balance is disturbed in atherogenic DM pigs. A. Representative 
illustrations of kidney sections stained with Angpt1 (upper panels; arrow: glomerulus; arrowhead: 
peritubular area) or Angpt2 (lower panels; arrow: glomerulus; arrowhead: tubular staining) in Controls, 
ATH, and DM+ATH pigs. B. Quantitative analysis of Angpt1, Angpt2 and Angpt2/Angpt1 ratio. C. Relative 
mRNA expression of Angpt1 and Angpt2. D. Immunofluorescent double staining of representative 
kidney sections for desmin (green)/Angpt1 (red;left panel) and vWF (green/Angpt2 red; middle/right 
panel). Insets: double positivity for vWF/Angpt2 staining in yellow. E. Representative illustrations of 
kidney sections stained with endothelial marker vWF (arrow: glomerulus; arrowhead: peritubular area) 
in Controls, ATH, and DM+ATH pigs. F. Representative images of kidney sections stained with VEGF in 
Controls, ATH, and DM+ATH pigs showing expression in podocytes (arrow head), parietal epithelial cells 
(thin arrow) and tubuli (asterix). Data are shown as mean ± SEM. *P<0.05 compared to Controls or ATH 










































Angpt2/Angpt1 dysbalance and creatinine levels are correlated with capillary tortuosity
Correlation analyses were performed between renal Angpt1, Angpt2, Angpt2/Angpt1 ratio, 
creatinine levels and albumin/creatinine ratio and oral mucosal capillary tortuosity and density 
indices. No correlation was found between capillary density index and renal angiopoietin 
expression or urinary markers for renal function. However, a negative correlation was found 
between renal Angpt1expression and microvascular tortuosity index (r=-0.60, p=0.0100; Fig. 
4A). Moreover, we demonstrated a positive correlation between capillary tortuosity and Angpt2 
staining (r=0.70, p=0.0017; Fig. 4B) and Angpt2/Angpt1ratio (r=0.80, p=0.0002; Fig. 4C). 
No significant correlation was found between urinary albumin/creatinine ratio, creatinine levels 
and capillary tortuosity index.
Figure 4 
A.                                                                     B. 
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Figure 4. Correlation between capillary tortuosity and Angpt2/Angpt1 balance and creatinine 
levels. Scatter plot showing the correlation of renal protein expression of Angpt1(A), Angpt2 (B), Angpt2/












































In the present study, we show that the combination of an atherogenic diet and recent onset 
of DM leads to abnormalities in the systemic microvasculature, yielding SDF-detectable 
increases in capillary tortuosity and increased levels of serum Angpt1. Furthermore, we 
discovered that glomerular lesions develop during the early stages of DN and that the tight 
control of the Angpt2/Angpt1 balance is perturbed in the kidneys of diabetic atherogenic pigs. 
Microvascular dysfunction is one of the most important causes of persistent diabetic 
complications This is the result of disturbed hemodynamics and impaired endothelial 
function induced by metabolic alterations [26,27]. However, the early events involved in the 
pathogenesis of diabetic microvascular complications are not well understood, and are difficult 
to study in humans without the use of invasive techniques. SDF imaging allows for the easy, 
and rapid assessment of the presence of systemic microvascular derangements that could 
precede the development of diabetic macrovascular complications. In our study, we observed 
increased capillary tortuosity between the DM+ATH and ATH groups, already at ~15 months 
following DM induction. Using SDF imaging, we recently demonstrated increased capillary 
tortuosity in diabetes patients, and reversal of microvascular tortuosity after simultaneous 
pancreas-kidney transplantation [16]. Moreover, we have previously shown that increased 
capillary tortuosity in diabetic patients was associated with macrovascular disease [10]. In 
concordance with our observations, Sasongko et al demonstrated increased tortuosity in 
patients with diabetic retinopathy, suggesting that this may be an early sign of microvascular 
damage in DM [28,29]. However, these studies did not include patients with early stage DM 
and did not focus on the role of angiopoietins in microvascular alterations and renal injury in 
atherogenic DM. 
In addition to increased microvascular tortuosity, we also observed increased serum levels of 
Angpt-1 in DM+ATH pigs compared with the control group. These data are in line with previous 
clinical studies in patients with moderate and severe non-proliferative diabetic retinopathy [30] 
and in patients with hypertension [31] that showed increased Angpt1 serum levels in these 
patients as well. While serum Angpt1 levels were increased in DM+ATH pigs, we found a 
decrease in Angpt1 protein and mRNA expression in kidneys of diabetic pigs compared to 
control groups. This observation suggests shedding of Angpt1 from renal vasculature into the 
circulation. 
Interestingly, DM+ATH pigs were characterized by higher expression levels of Angpt2 protein 
as compared to the ATH group, resulting in a higher Angpt2/ Angpt1 ratio in the DM+ATH 










































both Angpt1 and Angpt2 protein levels are increased in the early phase of STZ-induced 
DM in rats [32]. However, disease progression was found to trigger a decrease in Angpt1 
expression while Angpt2 continued to increase, a switch that both markedly alters but also 
disturbs the Angpt2/Angpt1 balance [32]. Although a difference in angiopoietin expression 
between rats and pigs cannot be excluded, these findings suggest that angiopoietins undergo 
time-dependent changes in expression at different stages of DM. Our identification that an 
increased urinary albumin/creatinine ratio is associated with a higher Angpt2/Angpt1 ratio 
(in DM+ATH pigs) is in keeping with recent studies that demonstrated an inability to express 
Angpt1 leads to extensive glomerular damage and proteinuria, indicating a protective role 
of Angpt1 [33]. These data suggest that angiopoietins might play an important role in the 
pathophysiology of glomerular disease in DN. 
Aside from angiopoietins, numerous other mechanisms have been proposed to be causal for 
microvascular complications in DM, such as VEGF. Under pathological conditions, Angpt2 acts 
in concert with VEGF to induce inflammatory angiogenesis. By promoting pericyte dropout, 
Angpt2 will lead to destabilization between ECs and pericytes. In the presence of VEGF, 
Angpt2 can eventually lead to an active, sprouting state of ECs, but when VEGF is absent, 
Angpt2 promotes vessel regression [34–36]. Our immunohistochemical assessment of VEGF 
protein in the different groups revealed high expression levels in podocytes and parietal– and 
tubular epithelial cells, which is in keeping with literature [34,37–40]. However, in contrast to 
previous studies, we did not observe differences between the different groups. 
An additional observation we made was the marked increase in PAI-1 expression in regions 
of microvascular injury. PAI-1, a protease and fibrinolysis inhibitor that is poorly expressed 
in healthy kidneys, which is a critical player in angiogenesis and vascular remodeling [41]. 
Our observation that glomerular and tubular expression of PAI-1 is increased in DM+ATH 
pigs is noteworthy due to the fact that: 1) PAI-1 was found to be prominently expressed in 
Kimmelstiel-Wilson nodules, in particular those with active microvascular damage [25]; 2) 
unilateral ureteral obstruction [42] and glomerulonephritis [43] have also been associated with 
increased expression of tubular PAI-1; and 3) endogenous PAI-1 deficiency protects diabetic 
mice from glomerular injury [44]. Collectively, these data support for a pathogenic role for PAI-
1 in diabetic renal disease.
In the current study, there was a tendency towards increased mesangial expansion in the 
DM+ATH pigs, and significantly more mesangial expansion in kidneys of ATH pigs. The 
data confirm previous reports on pig studies which revealed that consumption of high-fat 
diet leads to the development of renal injury, characterized by mesangial expansion and 
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hyperlipidemia exacerbates the development and progression of renal diseases, including DN 
[47,48]. Furthermore, our study also showed higher creatinine levels in the ATH group than 
the DM+ATH and Controls, which could be explained by the increased mesangial expansion 
observed in ATH pigs. The latter has been associated with obliteration of capillary lumen and 
decreased capillary perfusion in previous studies [49]. Furthermore, our study suggests that 
the combined hyperglycemia and hyperlipidemia in the DM +ATH pigs, induces a dysbalance 
in renal angiopoietins that results in albuminuria and endothelial damage in the kidney. The 
potential contribution of tubular injury to albuminuria needs to be addressed in additional 
studies. 
Some aspects of our porcine study require further discussion. First, it would have been 
interesting to study an additional group of pigs with only diabetes (i.e. without ATH) to explore 
the early effects of only hyperglycemia on the microvasculature. However, the clinically most 
relevant group of DN also reflects DM patients with some presence of atherosclerosis as well. 
Secondly, it could be argued that the differences in gender, age and weight between healthy 
control pigs (Controls) versus DM+ATH and ATH pigs may explain part of the difference in the 
observed capillary tortuosity between these groups. This is, however, unlikely as in a human 
study, age did not influence capillary tortuosity [16]. 
In conclusion, we present SDF imaging as a novel means of documenting capillary tortuosity, 
an event that is illustrative of renal injury in the setting of early DM and atherosclerosis. This 
technique enables one to non-invasively detect systemic microvascular damage. Furthermore, 
we also identified changes in the Angpt2/Angpt1 balance may represent initiating events of 
renal injury in early DM. We propose that the targeted intervention of angiopoietins signaling 
could be an effective modality in minimizing microvascular damage that could serve as an 
early initiator of DN.
Acknowledgement












































 1.  Cumbie BC, Hermayer KL (2007) Current concepts in targeted therapies for the pathophysiology 
of diabetic microvascular complications. Vasc Health Risk Manag 3: 823-832.
 2.  Tooke JE (1996) Microvasculature in diabetes. Cardiovasc Res 32: 764-771. 0008636396000910 
[pii].
 3.  Feng D, Bursell SE, Clermont AC, Lipinska I, Aiello LP, Laffel L, King GL, Tofler GH (2000) von 
Willebrand factor and retinal circulation in early-stage retinopathy of type 1 diabetes. Diabetes 
Care 23: 1694-1698.
 4.  Targher G, Bertolini L, Zoppini G, Zenari L, Falezza G (2005) Increased plasma markers of 
inflammation and endothelial dysfunction and their association with microvascular complications 
in Type 1 diabetic patients without clinically manifest macroangiopathy. Diabet Med 22: 999-
1004. DME1562 [pii];10.1111/j.1464-5491.2005.01562.x [doi].
 5.  Fiedler U, Augustin HG (2006) Angiopoietins: a link between angiogenesis and inflammation. 
Trends Immunol 27: 552-558. S1471-4906(06)00293-6 [pii];10.1016/j.it.2006.10.004 [doi].
 6.  Hammes HP, Lin J, Renner O, Shani M, Lundqvist A, Betsholtz C, Brownlee M, Deutsch U 
(2002) Pericytes and the pathogenesis of diabetic retinopathy. Diabetes 51: 3107-3112.
 7.  Tervaert TW, Mooyaart AL, Amann K, Cohen AH, Cook HT, Drachenberg CB, Ferrario F, 
Fogo AB, Haas M, de HE, Joh K, Noel LH, Radhakrishnan J, Seshan SV, Bajema IM, Bruijn 
JA (2010) Pathologic classification of diabetic nephropathy. J Am Soc Nephrol 21: 556-563. 
ASN.2010010010 [pii];10.1681/ASN.2010010010 [doi].
 8.  Edwards MS, Wilson DB, Craven TE, Stafford J, Fried LF, Wong TY, Klein R, Burke GL, Hansen 
KJ (2005) Associations between retinal microvascular abnormalities and declining renal 
function in the elderly population: the Cardiovascular Health Study. Am J Kidney Dis 46: 214-
224. S0272-6386(05)00618-9 [pii];10.1053/j.ajkd.2005.05.005 [doi].
 9.  Goedhart PT, Khalilzada M, Bezemer R, Merza J, Ince C (2007) Sidestream Dark Field (SDF) 
imaging: a novel stroboscopic LED ring-based imaging modality for clinical assessment of the 
microcirculation. Opt Express 15: 15101-15114. 144629 [pii].
 10.  Djaberi R, Schuijf JD, de Koning EJ, Wijewickrama DC, Pereira AM, Smit JW, Kroft LJ, de 
RA, Bax JJ, Rabelink TJ, Jukema JW (2012) Non-invasive assessment of microcirculation by 
sidestream dark field imaging as a marker of coronary artery disease in diabetes. Diab Vasc Dis 
Res. 1479164112446302 [pii];10.1177/1479164112446302 [doi].
 11.  Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG (2012) Improving bioscience 
research reporting: the ARRIVE guidelines for reporting animal research. Osteoarthritis 
Cartilage 20: 256-260. S1063-4584(12)00082-9 [pii];10.1016/j.joca.2012.02.010 [doi].
 12.  Gerrity RG, Natarajan R, Nadler JL, Kimsey T (2001) Diabetes-induced accelerated 
atherosclerosis in swine. Diabetes 50: 1654-1665.
 13.  van den Heuvel M, Sorop O, Koopmans SJ, Dekker R, de VR, van Beusekom HM, Eringa EC, 
Duncker DJ, Danser AH, van der Giessen WJ (2012) Coronary microvascular dysfunction in 
a porcine model of early atherosclerosis and diabetes. Am J Physiol Heart Circ Physiol 302: 
H85-H94. ajpheart.00311.2011 [pii];10.1152/ajpheart.00311.2011 [doi].
 14.  Koopmans SJ, Mroz Z, Dekker R, Corbijn H, Ackermans M, Sauerwein H (2006) Association 
of insulin resistance with hyperglycemia in streptozotocin-diabetic pigs: effects of metformin 
at isoenergetic feeding in a type 2-like diabetic pig model. Metabolism 55: 960-971. S0026-
0495(06)00102-8 [pii];10.1016/j.metabol.2006.03.004 [doi].
 15.  Koopmans SJ, Dekker R, Ackermans MT, Sauerwein HP, Serlie MJ, van Beusekom HM, van den 
Heuvel M, van der Giessen WJ (2011) Dietary saturated fat/cholesterol, but not unsaturated fat 
or starch, induces C-reactive protein associated early atherosclerosis and ectopic fat deposition 









































Early atherogenic DM and systemic microvascular and renal damage
83
4
 16.  Khairoun M, de Koning EJ, van den Berg BM, Lievers E, de Boer HC, Schaapherder AF, Mallat 
MJ, Rotmans JI, van der Boog PJ, van Zonneveld AJ, de Fijter JW, Rabelink TJ, Reinders 
ME (2013) Microvascular damage in type 1 diabetic patients is reversed in the first year after 
simultaneous pancreas-kidney transplantation. Am J Transplant 13: 1272-1281. 10.1111/
ajt.12182 [doi].
 17.  Khairoun M, van der Pol P, de Vries DK, Lievers E, Schlagwein N, de Boer HC, Bajema IM, 
Rotmans JI, van Zonneveld AJ, Rabelink TJ, van KC, Reinders ME (2013) Renal ischemia-
reperfusion induces a dysbalance of angiopoietins, accompanied by proliferation of pericytes 
and fibrosis. Am J Physiol Renal Physiol 305: F901-F910. ajprenal.00542.2012 [pii];10.1152/
ajprenal.00542.2012 [doi].
 18.  David S, Kumpers P, Hellpap J, Horn R, Leitolf H, Haller H, Kielstein JT (2009) Angiopoietin 2 
and cardiovascular disease in dialysis and kidney transplantation. Am J Kidney Dis 53: 770-
778. S0272-6386(09)00027-4 [pii];10.1053/j.ajkd.2008.11.030 [doi].
 19.  David S, Kumpers P, Lukasz A, Fliser D, Martens-Lobenhoffer J, Bode-Boger SM, Kliem V, 
Haller H, Kielstein JT (2010) Circulating angiopoietin-2 levels increase with progress of chronic 
kidney disease. Nephrol Dial Transplant 25: 2571-2576. gfq060 [pii];10.1093/ndt/gfq060 [doi].
 20.  Sugaru E, Sakai M, Horigome K, Tokunaga T, Kitoh M, Hume WE, Nagata R, Nakagawa T, Taiji 
M (2005) SMP-534 inhibits TGF-beta-induced ECM production in fibroblast cells and reduces 
mesangial matrix accumulation in experimental glomerulonephritis. Am J Physiol Renal Physiol 
289: F998-1004. 00065.2005 [pii];10.1152/ajprenal.00065.2005 [doi].
 21.  Sugaru E, Nakagawa T, Ono-Kishino M, Nagamine J, Tokunaga T, Kitoh M, Hume WE, Nagata 
R, Taiji M (2006) SMP-534 ameliorates progression of glomerular fibrosis and urinary albumin 
in diabetic db/db mice. Am J Physiol Renal Physiol 290: F813-F820. 00357.2005 [pii];10.1152/
ajprenal.00357.2005 [doi].
 22.  Trouw LA, Groeneveld TW, Seelen MA, Duijs JM, Bajema IM, Prins FA, Kishore U, Salant DJ, 
Verbeek JS, van KC, Daha MR (2004) Anti-C1q autoantibodies deposit in glomeruli but are only 
pathogenic in combination with glomerular C1q-containing immune complexes. J Clin Invest 
114: 679-688. 10.1172/JCI21075 [doi].
 23.  van der Pol P, Schlagwein N, van Gijlswijk DJ, Berger SP, Roos A, Bajema IM, de Boer HC, de 
Fijter JW, Stahl GL, Daha MR, van KC (2012) Mannan-binding lectin mediates renal ischemia/
reperfusion injury independent of complement activation. Am J Transplant 12: 877-887. 
10.1111/j.1600-6143.2011.03887.x [doi].
 24.  van Ditzhuijzen NS, van den Heuvel M, Sorop O, van Duin RW, Krabbendam-Peters I, van 
HR, Ligthart JM, Witberg KT, Duncker DJ, Regar E, van Beusekom HM, van der Giessen WJ 
(2011) Invasive coronary imaging in animal models of atherosclerosis. Neth Heart J 19: 442-
446. 10.1007/s12471-011-0187-0 [doi].
 25.  Paueksakon P, Revelo MP, Ma LJ, Marcantoni C, Fogo AB (2002) Microangiopathic injury 
and augmented PAI-1 in human diabetic nephropathy. Kidney Int 61: 2142-2148. kid384 
[pii];10.1046/j.1523-1755.2002.00384.x [doi].
 26.  Kalani M (2008) The importance of endothelin-1 for microvascular dysfunction in diabetes. Vasc 
Health Risk Manag 4: 1061-1068.
 27.  Kuryliszyn-Moskal A, Dubicki A, Zarzycki W, Zonnenberg A, Gorska M (2011) Microvascular 
abnormalities in capillaroscopy correlate with higher serum IL-18 and sE-selectin levels in 
patients with type 1 diabetes complicated by microangiopathy. Folia Histochem Cytobiol 49: 
104-110.
 28.  Sasongko MB, Wong TY, Nguyen TT, Cheung CY, Shaw JE, Wang JJ (2011) Retinal vascular 
tortuosity in persons with diabetes and diabetic retinopathy. Diabetologia 54: 2409-2416. 
10.1007/s00125-011-2200-y [doi].
 29.  Sasongko MB, Wong TY, Donaghue KC, Cheung N, Jenkins AJ, Benitez-Aguirre P, Wang JJ 
(2012) Retinal arteriolar tortuosity is associated with retinopathy and early kidney dysfunction 











































 30.  Patel JI, Hykin PG, Gregor ZJ, Boulton M, Cree IA (2005) Angiopoietin concentrations in diabetic 
retinopathy. Br J Ophthalmol 89: 480-483. 89/4/480 [pii];10.1136/bjo.2004.049940 [doi].
 31.  Nadar SK, Blann A, Beevers DG, Lip GY (2005) Abnormal angiopoietins 1&2, angiopoietin 
receptor Tie-2 and vascular endothelial growth factor levels in hypertension: relationship to 
target organ damage [a sub-study of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)]. 
J Intern Med 258: 336-343. JIM1550 [pii];10.1111/j.1365-2796.2005.01550.x [doi].
 32.  Rizkalla B, Forbes JM, Cao Z, Boner G, Cooper ME (2005) Temporal renal expression of 
angiogenic growth factors and their receptors in experimental diabetes: role of the renin-
angiotensin system. J Hypertens 23: 153-164. 00004872-200501000-00026 [pii].
 33.  Jeansson M, Gawlik A, Anderson G, Li C, Kerjaschki D, Henkelman M, Quaggin SE (2011) 
Angiopoietin-1 is essential in mouse vasculature during development and in response to injury. 
J Clin Invest 121: 2278-2289. 46322 [pii];10.1172/JCI46322 [doi].
 34.  Jain RK (2003) Molecular regulation of vessel maturation. Nat Med 9: 685-693. 10.1038/
nm0603-685 [doi];nm0603-685 [pii].
 35.  Kim KL, Shin IS, Kim JM, Choi JH, Byun J, Jeon ES, Suh W, Kim DK (2006) Interaction between 
Tie receptors modulates angiogenic activity of angiopoietin2 in endothelial progenitor cells. 
Cardiovasc Res 72: 394-402. S0008-6363(06)00354-3 [pii];10.1016/j.cardiores.2006.08.002 
[doi].
 36.  Lobov IB, Brooks PC, Lang RA (2002) Angiopoietin-2 displays VEGF-dependent modulation 
of capillary structure and endothelial cell survival in vivo. Proc Natl Acad Sci U S A 99: 11205-
11210. 10.1073/pnas.172161899 [doi];172161899 [pii].
 37.  Baelde HJ, Eikmans M, Doran PP, Lappin DW, de HE, Bruijn JA (2004) Gene expression 
profiling in glomeruli from human kidneys with diabetic nephropathy. Am J Kidney Dis 43: 636-
650. S0272638604000083 [pii].
 38.  Baelde HJ, Eikmans M, Lappin DW, Doran PP, Hohenadel D, Brinkkoetter PT, van der Woude 
FJ, Waldherr R, Rabelink TJ, de HE, Bruijn JA (2007) Reduction of VEGF-A and CTGF 
expression in diabetic nephropathy is associated with podocyte loss. Kidney Int 71: 637-645. 
5002101 [pii];10.1038/sj.ki.5002101 [doi].
 39.  Cooper ME, Vranes D, Youssef S, Stacker SA, Cox AJ, Rizkalla B, Casley DJ, Bach LA, Kelly 
DJ, Gilbert RE (1999) Increased renal expression of vascular endothelial growth factor (VEGF) 
and its receptor VEGFR-2 in experimental diabetes. Diabetes 48: 2229-2239.
 40.  Hohenstein B, Hausknecht B, Boehmer K, Riess R, Brekken RA, Hugo CP (2006) Local VEGF 
activity but not VEGF expression is tightly regulated during diabetic nephropathy in man. Kidney 
Int 69: 1654-1661. 5000294 [pii];10.1038/sj.ki.5000294 [doi].
 41.  Stefansson S, McMahon GA, Petitclerc E, Lawrence DA (2003) Plasminogen activator 
inhibitor-1 in tumor growth, angiogenesis and vascular remodeling. Curr Pharm Des 9: 1545-
1564.
 42.  Ishidoya S, Ogata Y, Fukuzaki A, Kaneto H, Takeda A, Orikasa S (2002) Plasminogen activator 
inhibitor-1 and tissue-type plasminogen activator are up-regulated during unilateral ureteral 
obstruction in adult rats. J Urol 167: 1503-1507. S0022-5347(05)65353-0 [pii].
 43.  Barnes JL, Mitchell RJ, Torres ES (1995) Expression of plasminogen activator-inhibitor-1 
(PAI-1) during cellular remodeling in proliferative glomerulonephritis in the rat. J Histochem 
Cytochem 43: 895-905.
 44.  Lassila M, Fukami K, Jandeleit-Dahm K, Semple T, Carmeliet P, Cooper ME, Kitching AR (2007) 
Plasminogen activator inhibitor-1 production is pathogenetic in experimental murine diabetic 
renal disease. Diabetologia 50: 1315-1326. 10.1007/s00125-007-0652-x [doi].
 45.  Deji N, Kume S, Araki S, Soumura M, Sugimoto T, Isshiki K, Chin-Kanasaki M, Sakaguchi M, 
Koya D, Haneda M, Kashiwagi A, Uzu T (2009) Structural and functional changes in the kidneys 









































Early atherogenic DM and systemic microvascular and renal damage
85
4
 46.  Taneja D, Thompson J, Wilson P, Brandewie K, Schaefer L, Mitchell B, Tannock LR (2010) 
Reversibility of renal injury with cholesterol lowering in hyperlipidemic diabetic mice. J Lipid Res 
51: 1464-1470. jlr.M002972 [pii];10.1194/jlr.M002972 [doi].
 47.  Thompson J, Wilson P, Brandewie K, Taneja D, Schaefer L, Mitchell B, Tannock LR (2011) 
Renal accumulation of biglycan and lipid retention accelerates diabetic nephropathy. Am J 
Pathol 179: 1179-1187. S0002-9440(11)00515-3 [pii];10.1016/j.ajpath.2011.05.016 [doi].
 48.  Bonnet F, Cooper ME (2000) Potential influence of lipids in diabetic nephropathy: insights from 
experimental data and clinical studies. Diabetes Metab 26: 254-264. MDOI-DM-09-2000-26-4-
1262-3036-101019-ART1 [pii].
 49.  Steffes MW, Osterby R, Chavers B, Mauer SM (1989) Mesangial expansion as a central 
mechanism for loss of kidney function in diabetic patients. Diabetes 38: 1077-1081.

Chapter 5
Microvascular damage in type 1 diabetic patients  
is reversed in the first year after simultaneous 
pancreas-kidney transplantation
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Background: Simultaneous pancreas-kidney transplantation (SPK) is an advanced 
treatment option for type 1 diabetes mellitus (DM) patients with microvascular disease 
including nephropathy. Sidestream darkfield (SDF) imaging has emerged as a noninvasive 
tool to visualize the human microcirculation. This study assessed the effect of SPK in diabetic 
nephropathy (DN) patients on microvascular alterations using SDF and correlated this with 
markers for endothelial dysfunction.
Methods: Microvascular morphology was visualized using SDF of the oral mucosa in DN 
(n=26) and SPK patients (n=38), healthy controls (n=20), DM1 patients (n=15, DM≥40ml/
min) and DN patients with a kidney transplant (KTx,n=15). Furthermore, 21 DN patients were 
studied longitudinally up to 12 months after SPK. Circulating levels of angiopoietin-1 (Ang-1), 
angiopoietin-2 (Ang-2) and soluble thrombomodulin (sTM) were measured using ELISA.
Results: Capillary tortuosity in the DN (1.83±0.42) and DM≥40ml/min (1.55±0.1) group was 
increased and showed reversal after SPK (1.31±0.3, p<0.001), but not after KTx (1.64±0.1). 
sTM levels were increased in DN patients and reduced in SPK and KTx recipients (p<0.05), 
while the Ang-2/Ang-1 ratio was normalized after SPK and not after KTx alone (from 0.16 ±0.04 
to 0.08 ±0.02, p<0.05). Interestingly, in the longitudinal study reversal of capillary tortuosity 
and decrease in Ang-2/Ang-1 ratio and sTM was observed within 12 months after SPK.
Conclusion: SPK is effective in reversing the systemic microvascular structural abnormalities 












































Diabetes mellitus (DM) is a severe metabolic disease that results in macrovascular as well 
as microvascular complications including retinopathy, nephropathy and neuropathy (1;2). 
The majority of these microvascular complications is associated with endothelial dysfunction, 
and upregulation of different angiogenic growth factors including angiopoietin-2 (Ang-2) (2;3) 
and soluble thrombomodulin (sTM) release in the circulation (4;5). Negative interference of 
Ang-2 with Ang-1 mediated Tie-2 signaling results in disruption of perivascular stromal cell–
endothelial cell interaction, subsequent vessel destabilization and abnormal microvascular 
remodeling (6;7). 
Simultanous pancreas-kidney transplantation (SPK) has become an important option in 
the treatment of diabetic patients with nephropathy and seems to be superior to kidney 
transplantation alone (KTx), since SPK is associated with a better glycemic control as well as 
improved patient survival (8-10). It has been shown that SPK and pancreas transplantation 
alone effectively prevent the recurrence of diabetic nephropathy (DN) (11-15). However, in 
terms of stabilization or improvement of pre-existing neuropathy and retinopathy debate still 
continues on the benefit of SPK (16-20). Early non-invasive monitoring of the microvasculature 
may be of clinical value to assess progression of microvascular disease during diabetes and 
treatment efficacy after SPK. Sidestream darkfield (SDF) imaging has recently emerged as 
a non-invasive tool to visualize the human microcirculation and to assess microvascular 
remodeling (21). We have previously used this validated technique to compare the labial 
mucosal capillary tortuosity, as markers for microvascular disease, in diabetic patients with 
and without coronary artery disease (CAD) and healthy non-diabetic controls. Diabetic patients 
showed increased capillary tortuosity, especially in patients with CAD (22). However, to our 
knowledge no previous studies have used SDF imaging to monitor microvascular alterations 
before and after SPK.
In the present study, the effects of SPK on microvascular damage is assessed in a cross-
sectional and longitudinal study using SDF imaging and correlated with markers for endothelial 













































All procedures were approved by the institutions Medical Ethical Committee. Written 
informed consent has been obtained from all the patients and healthy controls. A total of 114 
persons (64 males and 50 females) were enrolled in this cross-sectional study after giving 
informed consent. Thirty-eight patients with simultaneous SPK were included (SPK group). 
Furthermore, we included 15 patients with a functioning kidney graft (KTx group), consisting of 
patients with a solitary kidney transplantation (n=13) and patients who received SPK and lost 
their pancreatic graft due to vascular thrombosis (n=2) at 2 and 4 days after transplantation. 
Biochemical markers for endothelial dysfunction including Ang-1, Ang-2 and sTM, together 
with mucosal capillary density and morphology were compared to 26 DM type 1 patients with 
nephropathy (DN group) on the waiting list for SPK and DM type 1 patients with an estimated 
glomerular filtration rate (eGFR) of ≥40ml/min (n=15, DM≥40ml/min group). Patients with 
active infection, liver failure, active auto-immune disease, epilepsy or malignancy in the last 
5 years (except patients treated for basal cell carcinoma that were in full remission) were 
excluded from the study. In addition, 21 patients from the DN group who underwent SPK 
were studied longitudinally for 12 months (SPKFU). In this group, SDF and the analysis of 
endothelial dysfunction markers Ang-1, Ang-2 and sTM were assessed at 1 (M1), 6 (M6) 
and 12 (M12) months after transplantation. Mean age and duration of diabetes were similar 
in follow-up patients compared to patients in DN-group and SPK-group. Twenty healthy and 
age matched volunteers served as the control group. None of the control subjects was taking 
medication. 
All transplantations were performed at the Leiden University Medical Center (LUMC), the 
Netherlands. Organs for the SPK group came from brain-dead donors registered at the 
national donor registry. The procedure of SPK transplantation has been described previously 
(23). All SPK transplants were performed through a midline abdominal incision with both 
organs placed intraperitoneally. The kidney was placed in the left iliac fossa, with its vessels 
anastomosed to the common or external iliac vessels in an end-to-side fashion. The ureter 
urinary bladder anastomosis was performed using the Lich–Gregoir technique. Double-J 
stenting of the anastomosis was used. The portal vein of the pancreas graft was anastomosed 
end-to-side to the recipient’s vena cava inferior or right iliac vessels. The superior mesenteric 
and splenic arteries were reconstructed using a donor iliac artery Y graft. In some cases, the 
pancreas graft was procured with the celiac trunk and superior mesenteric artery on the aorta 
patch in which no vascular reconstruction was needed. All pancreas grafts were anastomosed 
end-to-side to the common iliac artery of the recipient. In 22 of the 38 patients (58%) patients 
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the other patients had a direct enteric drainage. SPK patients used at least two types of 
immunosuppression. Type of induction immunosuppression during transplantation was 
dependent on date of transplantation. Patients transplanted before 2008 received induction 
with interleukin-2 receptor blocker daclizumab, (100 mg/day) on the day of transplantation and 
10 days after transplantation, followed by triple therapy with prednisone (tapered to a dose 
of 10 mg by month 3), tacrolimus or cyclosporine and mycophenolate mofetil (MMF) (target 
area under the curve (AUC) 30-60 ng.h/ml). Cyclosporine and tacrolimus AUC were estimated 
using a population based, two-compartment pharmacokinetic model combined with limited 
sampling and Bayesian fitting (24-26). After each AUC assessment, dosage adjustments were 
made to achieve the predefined target AUC: Cyclosporine AUC: 5400 ng.h/ml within the first 6 
wk, which corresponds with a mean average trough level of 225 ng/ml; after 6 wk, 3250 ng.h/
ml, which corresponds to a mean average trough level of 125 ng/ml; tacrolimus AUC: 210 ng.h/
ml within the first 6 wk, which corresponds to a mean average trough level of 12.5 ng/ml; after 
6 wk, 125 ng.h/ml, which corresponds with a mean average trough level of 7.5 ng/ml. Patients 
transplanted after 2008 received induction therapy with anti-CD52 antibody alemtuzumab (15 
mg/day, subcutaneously) for two days followed by glucocorticoid-free therapy with MMF and 
tacrolimus (n=12). In the SPKFU group, twenty patients received alemtuzumab as induction 
therapy and one patient received basiliximab (20 mg/day) at day 0 and 4.
Patients that received a KTx were transplanted in the following way: the iliac vessels were 
reached through a pararectal incision. The donor’s renal vessels were anastomosed end-to-
side to the common or external iliac vessels of the recipient. The ureter was anastomosed to 
the urinary bladder using the Lich–Gregoir technique. Double-J stenting for the vesico-ureteric 
anastomosis was used (27). Patients received daclizumab as induction therapy after solitary 
KTx (100 mg/day on the day of transplantation and 10 days after transplantation) followed 
by triple therapy with prednisone (tapered to a dose of 10 mg by 6 weeks), tacrolimus (AUC 
210 ng.h/ml first 6 weeks, then 125 ng.h/ml) or cyclosporine (AUC 5400 ng.h/ml first 6 weeks 
then 3250 ng.h/ml) and MMF (AUC 30-60 ng.h/ml). Patients were treated routinely with oral 
val-ganciclovir prophylaxis for 3 months, except for a CMV negative donor recipient status.
Microcirculatory imaging
The SDF microscan (MicroVision Medical Inc., Wallingford, PA, U.S.A) was performed 
as described earlier with minor modifications (22). In short, all patients were measured in 
supine position in a temperature controlled room (22oC) by a trained observer. Oral mucosal 
microvasculature in the labial area was visualized with a 5x objective with a 0.2 NA providing a 
325-fold magnification on screen and were sized 720 x 576 pixels (8 bit grey-scale). Ten video 
files (50 frames each) were obtained of capillary loops in labial mucosa from each quadrant 
of the lips and saved as Y800-AVI files using ICcapture imaging software (The Imaging 










































to a computer and monitor via an analog to digital converter (Domino melody framegrabber, 
Euresys s.a., Angleur, Belgium). A concise review about the SDF imaging technique has been 
described previously (21).
Analysis of SDF measurements
Before analysis, the video files were anonymized so that the assessor was blinded to the 
subject’s identity. Capillary loops were assessed by two individual assessors in a randomized, 
blind fashion. From the forty video files obtained of the microcirculation, the four technically 
best files were selected from each quadrant of the lip for analysis. Mean vessel density 
(capillaries/mm2) was calculated by observation of number of vessels per screen shot. 
Subsequently, tortuosity of capillary loops was assessed according to a validated scoring 
system described previously and the average of assessed capillary tortuosity was used to 
calculate mean tortuosity index per patient (22).
Laboratory assessment and endothelial structure evaluation
All persons enrolled in this study underwent routine venous blood sampling before the 
morning intake of immunosuppression. The following data were evaluated: creatinin, urea, 
HbA1c, glucose, hemoglobin and proteinuria in 24 hours urine. Glomerular filtration rate 
was calculated with creatinin concentration using the Modification of Diet in Renal Disease 
(MDRD) formula. Simultaneously, blood was collected for analysis of serum Ang-1, Ang-2 and 
sTM. Blood collection tubes were centrifuged for 10 minutes at 3000 rpm after which serum 
was stored in microcentrifuge tubes at -20oC until required for analysis. Ang-1, Ang-2 and 
sTM concentrations were measured by enzyme-linked immuno sorbent assay (ELISA) (R&D 
Systems, Minneapolis, MN, USA and Diaclone Research, Besançon, France) according to the 
manufacturer supplied protocol. The intra-and inter-assay coefficients of variation were 3.3% 
and 6.4% for Ang-1, 6.5% and 9.1% for Ang-2 levels and 3.9% and 9.8%, respectively, for sTM 
levels. Since the Ang-2/Ang-1 ratio, rather than the absolute levels of either cytokine has been 
considered to determine the functional status of the microvasculature, we calculated this ratio 
in the different groups (44; 45).
Statistical analyses 
Continuous normally distributed data are presented as mean ± standard error of the mean 
(SEM), unless stated otherwise. Differences between two groups in the cross-sectional study 
were analyzed using the unpaired two-sample T-test. When criteria for parametric testing were 
not met, median and interquartile range (IQR) are presented and tested with the Mann-Whitney 
test. Categorical variables were analyzed by a Chi-square test. In addition, multivariable linear 
regression was used to adjust for possible confounders. Comparisons of mean differences 
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Correlations between interval variables were calculated using the Spearman rank correlation. 
Differences were considered statistically significant with p<0.05. Data analysis was performed 
using SPSS version 17.0 (SPSS Inc, Chicago, IL) and GraphPad Prism, version 5.0 (GraphPad 
Prism Software Inc, San Diego, CA).
Results
Patient characteristics 
Baseline subject characteristics of DN, DM≥40ml/min, SPK and KTx groups in the cross-
sectional study are presented in Table 1. There were no significant differences in patient 
characteristics between the DN and SPK group, with the exception of age, glucose and 
HbA1c levels, proteinuria and eGFR (p<0.05). Compared to the DM≥40ml/min patients, DN 
group had significantly higher systolic and diastolic blood pressure, decreased eGFR and 
proteinuria levels and higher HbA1c levels (p<0.05). As expected, SPK showed improvement 
in renal function and normalization in blood glucose metabolism compared to DN and 
DM≥40ml/min patients (p<0.05). The median follow up period of patients after SPK was 45.0 
months (I.Q.R 18.5-106.5) and after KTx 38.5 months (I.Q.R 8.5-73.5). Patients in the KTx 
group had significantly better renal function compared with DN patients and higher glucose 
and HbA1c levels compared with SPK patients. 
More than 2 years after transplantation, three patients developed diabetes type II in the SPK 
group of which two were treated with oral antidiabetic medication and one patient with insulin. 
Fourteen of the 38 (37%) patients experienced acute rejection after SPK, which is similar 
to rejection rates reported in other studies after SPK (28). Of these, 10 patients had a renal 
biopsy proven interstitial acute rejection, one of these patients had also vascular rejection. 
Four patients were treated as rejection, without prior transplant biopsy. Seven patients were 
successfully treated with solumedrol, six patients with solumedrol and anti-thymocyte globulin 
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Age (yrs) 44.0 ± 6 44.4 ± 6 45.0 ± 6
Sex, male N (%) 16 (76%) - -
Smoking, N (%) 0 0 0 
BMI (kg/m2) 23.8* ± 3 24.0 ± 2 24.1 ± 3*
Dialysis, N (%) 0 0 0
Systolic BP (mmHg) 123 ± 22 132 ± 23 130 ± 16
Diastolic BP (mmHg) 75 ± 13 777 ± 13 78 ± 6
eGFR (ml/min/1,73 m2) 56.5 ± 23 * 55.2 ± 15 * 54.1 ± 10 *
Median proteinuria (g/24hr) (IQR) 0.3 (0.3-1.2) 0.3 (0.2-1.0) 0.3 (0.1-0.7)
HbA1c (%) 6.7 ± 2 5.3 ± 0 * 5.4 ± 0 *
Glucose (mmol/L) 6.2 ± 1 * 5.3 ± 1 * 5.7 ± 1 *
Hemoglobin (mmol/L) 6.6 ± 1 7.4 ± 1 7.9 ± 1
Rejection after transplantation, N (%) 0 3 (14%) 2 (10%)
Diabetes after SPK, N (%) 1 (5%) 2 (10%) 0
Acetylsalicylic acid, N (%) 3 (14%) 1 (5%) 4 (19%)

































Statines, N (%) 2 (10%) 2 (10%) 3 (14%)
Steroid-free, Alemtuzumab induction, N (%) 20 (95%) - -




































All data are mean ±SD, unless otherwise specified. * p<0.05 vs DN from Table 1. **Patients were recruited 
from the DN group (see Table 1 for patient characteristics). BMI, body mass index; BP, blood pressure; 
ACE, angiotensin converting enzyme; eGFR, estimated glomerular filtration rate; IQR, interquartile range; 
SPK, simultaneous pancreas kidney transplantation; 
The clinical characteristics of the patients in the longitudinal SPKFU group are shown in 
Table 2. As expected, patients showed normalization of glucose levels (p=0.04) and eGFR 
(p=0.006) at 1 month after SPK. Since all the patients in the SPKFU group were transplanted 
after 2008, immunosuppressive therapy was initially glucocorticosteroid-free, with MMF and 
tacrolimus as maintenance therapy. Twelve months after SPK, two patients were converted 
to everolimus due to side effects of tacrolimus. In four patients treatment with prednisone was 










































tacrolimus (2 patients) or MMF (2 patients). In this group, five patients experienced interstitial 
rejection and one patient had also vascular rejection after transplantation. These patients 
were treated with prednisolone and ATG. Six month after SPK, 2 patient developed diabetes 
type II, which was treated with oral antidiabetic medication.
Reversibility in capillary tortuosity after SPK 
There was no difference in the capillary density in the cross-sectional study between the DN 
(mean 19.88 ±4.1, SEM), DM≥40ml/min (mean 19.03 ±0.5, SEM), SPK (mean 20.79 ±3.1, 
SEM), control (mean 21.34 ±3.1, SEM) and KTx (mean 19.14 ±0.5, SEM) group. However, the 
morphology of the capillaries in the DN and DM≥40ml/min patients was significantly disturbed 
compared to the controls (Fig 1A). We observed significantly more capillary tortuosity in the 
DN patients (mean 1.83 ±0.4, SEM, p<0.001) and DM≥40ml/min patients (mean 1.55 ±0.1, 
SEM, p<0.0001) compared to the controls (mean 1.15 ±0.2, SEM). After KTx (mean 1.64 
±0.1, SEM) there was no significant decrease in capillary tortuosity compared to DN (p=0.06) 
and DM≥40ml/min (p=0.3656) group. However, interestingly, SPK (mean 1.31 ± 0.3, SEM, 
p<0.001) showed reversal in capillary tortuosity compared to DN and DM≥40ml/min group 
(Fig 1B). The three patients who developed diabetes type II after SPK did not show more 
increased capillary tortuosity compared to the other patients in the SPK group. 
Figure 1 .A. Sidestream darkfield images of the oral mucosa visualizing the microvascular capillaries of a representative patient in the control, 
DM≥40ml/min, DN, SPK and KTx group. Black arrows: capillary loops. B. Mean tortuosity index of microvascular capillaries in the control 
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Figure 1. A. Sidestream darkfield images of the oral mucosa visualizing the microvascular capillaries of 
a representative patient in the control, DM≥40ml/min, DN, SPK and KTx group. Black arrows: capillary 
loops. B. Mean tortuosity index of microvascular capillaries in the control (n=20), DM≥40ml/min (n=15), 
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Next, we investigated capillary density and morphology longitudinally in the SPKFU group 
before, 1, 6 and 12 months after SPK. No difference was observed in capillary density before 
and after SPK. Most importantly, SPK showed reversal of capillary tortuosity within 1 year 
after SPK, reaching significance at 6 and 12 months after transplantation (mean 1.52 ±0.1, 
SEM and 1.23 ±0.0 versus DN 1.83 ±0.4, p<0.01 and p<0.001, respectively) (Fig 2AB). The 
differences remained significant in both the cross-sectional and SPKFU group after adjustment 
for age, sex, BMI body mass index (BMI), systolic and diastolic blood pressure and smoking.
Figure 2. A. Sidestream dark field images of the oral mucosa visualizing the microvascular capillaries of a representative DN patient before 
(DN), 1 (M1), 6 (M6) and 12 (M12) months after SPK in the longitudinal SPKFU group. Black arrows: capillary loops. B. Longitudinal course 
of the mean tortuosity index of microvascular capillaries in DN patients before (DN, n=26), 1 (M1, n=21), 6 (M6, n=21) and 12 (M12, n=21) 
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Figure 2. A. Sidestream dark field images of the oral mucosa visualizing the microvascular capillaries of a 
representative DN patient before (DN), 1 (M1), 6 (M6) and 12 (M12) months after SPK in the longitudinal 
SPKFU group. Black arrows: capillary loops. B. Longitudinal course of the mean tortuosity index of 
microvascular capillaries in DN patients before (DN, n=26), 1 (M1, n=21), 6 (M6, n=21) and 12 (M12, 
n=21) months after SPK in the SPKFU group. Data shown are mean±SEM. *P<0.01, M6 compared to 
DN.**P<0.001, M12 compared to DN. 
Correlation between tortuosity, Hb1Ac, renal function and previous rejection 
Next, correlation analyses in the SPK patients was performed for the capillary density and 
tortuosity index with several factors that are known to influence the microvasculature, including 
time since transplantation, eGFR, HbA1c, proteinuria, and previous rejection. No correlation 
was found between capillary density and time since transplantation, eGFR, HbA1c, proteinuria 
and previous rejection. There was a significant correlation between tortuosity with eGFR 
(r =-0.26, p= 0.005), Hb1Ac levels (r =0.40, p<0.0001) and previous rejection (p= 0.0160). 
There was no association between tortuosity index and time since transplantation or 










































Reversal to baseline of Ang-2/Ang-1 ratio after SPK
To evaluate the effects of SPK on the microvascular conditions, we also measured serum 
levels of sTM, Ang-1 and Ang-2 and calculated the Ang-2/Ang-1 ratio as markers for endothelial 
dysfunction. We detected a significant decrease in sTM levels in patients after SPK (mean 
9.7 ±1 ng/ml, SEM, p=0.004) and KTx (mean 6.3 ±1 ng/ml, SEM, p<0.0001) compared to DN 
patients (mean 15.2 ±1 ng/ml, SEM, p=0.004) (Fig 3A). In the SPKFU group, sTM levels started 
to decrease at 1 month (mean 13.35 ±2.0 ng/ml, SEM) after transplantation and remained low 
after 6 months (mean 11.83 ±1.6 ng/ml, SEM), reaching significance at 12 months (10.42 
±1.2 ng/ml, SEM) as compared to before SPK (mean 15.2 ±1 ng/ml, SEM, p<0.01) (Fig 3B). 
In addition, our results demonstrate normalization in Ang-2/Ang-1 ratio after SPK (mean 
0.08 ±0.02, SEM) compared to the DN (mean 0.16 ±0.04, SEM, p=0.04) and DM≥40ml/min 
patients (mean 0.16 ±0.04, SEM, p=0.03), but no significant decrease after KTx (mean 0.20 
±0.04, SEM, p=0.6219 and p=0.5437, respectively) (Fig 3C). In the longitudinal study, the 
Ang-2/Ang-1 ratio started to show a decrease at 6 months (mean 0.09 ±0.03, SEM) after SPK 
and remained decreased at 12 months (mean 0.09 ±0.02, SEM) following transplantation 
compared to before SPK (mean 0.16 ±0.04, SEM), however, statistical significance was not 
reached (p=0.13 and p=0.14, respectively) (data not shown).
Correlation of endothelial function markers with capillary tortuosity, renal function and 
HbA1c
Next, the correlation between the different endothelial dysfunction markers, capillary density 
and morphology, eGFR, HbA1c, previous rejection and time since transplantation was 
analyzed. No correlation between endothelial dysfunction markers and capillary density or 
tortuosity was found. Moreover, there was no correlation between time since transplantation, 
previous rejection and endothelial dysfunction markers. Increased Ang-2 and sTM levels 
correlated significantly with decreased eGFR (r= -0.53, p<0.0001 and r=-0.28, p=0.0083) and 
high Hb1Ac levels with increased Ang-2 (r= 0.23, p=0.0319). Interestingly, Ang-2/Ang-1 ratio 
correlated significantly with capillary tortuosity (r=0.21, p=0.0348), HbA1c (r=0.32, p=0.0038), 
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Figure 3. A. Soluble thrombomodulin serum levels in the control (n=20), DM≥40ml/min 
(n=15), DN (n=26), SPK (n=38) and KTx (n=15) group. *P<0.05. B. Soluble 
thrombomodulin serum levels in DN patients before (DN), 1 (M1), 6 (M6) and 12 (M12) 
months after SPK in the SPKFU group. *P<0.05 compared to DN. C.Ang-2/ Ang-1 ratio in 
the control (n=20), DM≥40ml/min (n=15), DN (n=26), SPK (n=38) and KTx (n=15) group. 
Data shown are mean±SEM. *P<0.05. 
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Figure 3. A. Soluble thrombomodulin serum levels in the control (n=20), DM≥40ml/min 
(n=15), DN (n=26), SPK (n=38) and KTx (n=15) group. *P<0.05. B. Soluble 
thrombomodulin serum levels in DN patients before (DN), 1 (M1), 6 (M6) and 12 (M12) 
months after SPK in the SPKFU group. *P<0.05 compared to DN. C.Ang-2/ Ang-1 ratio in 
the control (n=20), DM≥40ml/min (n=15), DN (n=26), SPK (n=38) and KTx (n=15) group. 
Data shown are mean±SEM. *P<0.05. 
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Figure 3. A. Soluble thrombomodulin serum levels in the control (n=20), DM≥40ml/min (n=15), DN (n=26), 
SPK (n=38) and KTx (n=15) group. *P<0.05. B. Soluble thrombomodulin serum levels in DN patients 
before (DN), 1 (M1), 6 (M6) and 12 (M12) months after SPK in the SPKFU group. *P<0.05 compared to 
DN. C.Ang-2/ Ang-1 ratio in the control (n=20), DM≥40ml/min (n=15), DN (n=26), SPK (n=38) and KTx 











































This study shows increased microvascular tortuosity using SDF imaging, and a dysbalance in 
Ang-2/Ang-1 ratio in DM type 1 patients. Interestingly, we demonstrated reversal of capillary 
tortuosity and normalization of the Ang-2/Ang-1 ratio after SPK, but not after KTx alone. 
Furthermore, increased microvascular tortuosity correlated with increased Ang-2/Ang-1 
ratio. Importantly, the longitudinal study demonstrated that both reversibility of microvascular 
damage and decrease in sTM and Ang-2/Ang-1 balance occurred in the first year after SPK. 
These findings suggest that SPK is effective in reversing systemic microvascular complications 
in DN patients early after transplantation. Assessment of capillary tortuosity, as marker for 
microvascular disease, using the non-invasive SDF imaging can be used to estimate the 
degree of microvascular derangements in DN patients before and after SPK. 
Microvascular disease is one of the most important drivers of diabetic complications (29;30). 
Several mechanisms have been described for the pathogenesis of microvascular disorders in 
patients with diabetes mellitus. The capillaries in diabetic patients tend to be leaky and tortuous, 
lacking the hierarchical arrangement of arteries, capillaries and venules due to perivascular 
stromal cell loss (31-33). Hyperglycemia in particular can initiate disturbances in blood flow and 
afflict the interaction between perivascular stromal cells and microvascular endothelial cells. 
Hereby, the loss of perivascular stromal cells leads to loss of its primary functions, including 
autoregulation of the vessel integrity and compensatory mechanisms for the fluctuating 
hydrostatic pressure. Specifically, this impaired auto regulation of the microvasculature could 
result in disruption of the basement membrane and the failure to maintain the stability of the 
vessel wall against irregular longitudinal traction and transmural pressure leading to dilated 
and tortuous vessels (32-38). Ang-2 has been assumed to destabilize vessels by promoting 
the weakening of perivascular stromal - endothelial cell interaction (39;40). 
The increased microvascular tortuosity in diabetes as observed in the present study concurs 
with previous data on microvascular alterations in diabetic patients as determined by skin 
capillaroscopy (41). Likewise, previous clinical observations using conventional capillaroscopy 
revealed that diabetic retinopathy appeared to be associated with increased tortuosity as 
well, suggesting that this might be an early sign of microvascular damage in diabetes (33). 
However, compared to conventional capillaroscopy, SDF imaging has the advantage to assess 
the microvasculature without injecting fluorescent dyes and it enables measurement of the 
superficial skin and mucous microcirculation in a noninvasive manner (21). We previously 
could demonstrate, using SDF measurements, that the presence of microvascular tortuosity 
is associated with macrovascular disease in diabetics (22). However, the extensiveness of 
microvascular abnormalities has not been measured in DN patients before and after SPK 
using SDF imaging and correlation with markers for endothelial dysfunction and clinical 
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Previous clinical studies showed that 10 years of normoglycemia after pancreas transplantation 
ameliorated the glomerular and tubular lesions that characterize diabetic nephropathy in 
patients with long-term type 1 diabetes who did not receive renal grafts (42). Additional studies 
provided evidence for improvement of diabetic polyneuropathy after pancreatic transplantation 
as well (43;44). Although we observed reversal of microvascular tortuosity after SPK, this 
study did not explore the mechanisms behind these improvements. 
Increased microvascular tortuosity in DN coincided with increased levels of sTM and a 
disturbed Ang-2/Ang-1 balance, which is in line with previous studies that have demonstrated 
a positive correlation with microvascular destabilization and these markers of endothelial 
dysfunction (45;46). Ang-2 is a competitive ligand for the same Tie-2 receptor as for Ang-
1, with competing, antagonistic effects on angiogenesis and microvascular remodeling. 
Increased Ang-2/Ang-1 ratio has been shown to be associated with hyperglycemia, chronic 
kidney disease, acute coronary syndrome, sepsis and variety of diseases known for their 
common characteristic of endothelial dysfunction and microvascular inflammation (45;46). 
The Ang-2/ Ang-1 ratio showed only normalization after SPK, while it was still increased in the 
presence of diabetes and also was not affected by kidney transplantation alone. In addition, 
the Ang-2/Ang-1 ratio correlated to capillary tortuosity underscoring the systemic nature of 
microvascular destabilization in diabetes. (4;5;47-50). (51). 
The strength of our study was the use of a noninvasive tool to visualize the microvasculature 
in a study of SPK and DN patients before and after transplantation. However, our study has 
also some limitations. In this studied cohort there were no patients who received a solitary 
kidney transplant that could be followed longitudinally. Therefore, future longitudinal studies 
should possibly also include such patients to further corroborate the potential contribution of 
reversal of diabetes on the microcirculation. 
In conclusion, the present study revealed a disturbed microvascular morphology in DM 
type 1 patients and SPK resulted in reversal of systemic microvascular derangements and 
normalization of markers for endothelial dysfunction. The use of SDF imaging allows for easy 
non-invasive and sequential monitoring of microvascular disease in patients with diabetes. 
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Chapter 6
Improvement of microvascular damage after living 
donor kidney-transplantation
M. Khairoun, B.M. van den Berg, R. Timal, E. Lievers, D.K de Vries, J.I. Rotmans, 













































Background: Chronic kidney disease (CKD) is associated with endothelial damage and 
microvascular destabilization. Recently, sidestream dark-field (SDF) imaging has emerged as 
a noninvasive tool to visualize the microcirculation. In this study, we investigated whether CKD 
is associated with systemic microvascular damage using SDF imaging. In addition, the effects 
of kidney transplantation (KTx) on microvascular alterations was studied.
Methods: Mean capillary density and microvascular morphology were visualized with SDF 
imaging of the oral mucosa. Twenty-eight CKD patients were studied longitudinally before 
(CKD), 1, 6 and 12 months after living donor KTx. Furthermore, circulating levels of growth 
factors that control microvascular structure, including Angiopoietin-2 (Ang-2) and soluble 
Thrombomodulin (sTM) were measured using ELISA.
Results: We found increased capillary tortuosity in CKD patients compared to controls and 
reversibility starting at 6 months after KTx (respectively mean 1.9±0, SEM and 1.6±0, p<0.05). 
In line with these findings, endothelial destabilization markers Ang-2 (4084±612 pg/ml) and 
sTM (19±6 ng/ml) were increased in CKD patients and showed an improvement starting at 1 
month after KTx (2263±316 pg/ml and 6.1±1 ng/ml respectively, p<0.05). 
Conclusion: The microcirculation, as assessed by SDF, was disturbed in CKD patients 
compared to controls. Interestingly, KTx resulted in an improvement of microvascular tortuosity 
and normalization of angiogenic growth factors. Our findings indicate a clinical implication of 












































Progressive renal disease is characterized by a loss of the microvasculature, which 
is associated with the development of glomerular and tubulointerstitial scarring. The 
development of tubulointerstitial fibrosis is characteristic of chronic kidney disease (CKD) 
of diverse etiologies, and inhibition of its progression has been proposed to be of major 
importance in the preservation of renal function. In both experimental animal models and in 
humans, it has been shown that a significant loss of peritubular capillaries as well as defective 
capillary repair, triggers development of fibrotic changes and ultimately scar formation with 
progressive renal dysfunction (1;2). Besides renal microvascular abnormalities, patients with 
CKD demonstrate abnormalities which may represent manifestations of ongoing systemic 
microvascular damage, including a dysbalance of angiogenic factors and an increased 
incidence of atherosclerosis (3). 
The microvasculature is relatively inaccessible to direct examination. Therefore investigators 
have concentrated on various surrogate markers of endothelial function which include the 
measurement of specific plasma markers including, circulating endothelial cells (CECs), 
angiopoietin-1 (Ang-1), Angiopoietin-2 (Ang-2) and soluble Thrombomodulin (sTM) (4-8). 
Competitive inhibition of Ang-2 to the Tie-2 receptor, destabilizes quiescent endothelium and 
leads to altered endothelial/pericyte interaction with subsequently abnormal microvascular 
remodeling (9-11). Different studies have assessed the expression of these factors in CKD 
and after kidney transplantation (KTx). Indeed, elevated circulating levels of Ang-2 and sTM 
were observed in CKD patients, which normalized after kidney transplantation (5;7). 
An additional method for the assessment of endothelial function in CKD patients includes 
monitoring of the systemic microcirculation. Recently, SDF imaging has been used to visualize 
the human circulation (10;12). Using this non-invasive technique, we could previously 
demonstrate that patients with diabetes mellitus (DM) had significantly more microvascular 
damage compared to healthy controls and simultanous pancreas-kidney transplantation 
(SPK) resulted in restoration of microvascular damage (10). However, there are no studies 
using SDF imaging in CKD patients, to monitor microvascular alterations before and after KTx. 
The aim of our study was to use this validated SDF imaging technique to compare the labial 
mucosal capillary tortuosity, as markers for microvascular disease, in patients with CKD. 
In addition, we investigated whether KTx improves the microvasculature, in a prospective 
longitudinal study up to 1 year after transplantation. Furthermore, we assessed whether 
microvascular alterations were associated with increase in endothelial dysfunction markers. 
We hypothesize that CKD patients have a disturbed systemic microvasculature and that KTx 












































All procedures were approved by the institutions Medical Ethical Committee. Written informed 
consent was obtained from all the patients and healthy controls. A total of 48 persons ( 30 
males and 18 females) were enrolled in the current longitudinal study after giving informed 
consent. We included 28 CKD patients with different dialysis modalities who were receiving 
a living donor KTx including 11 patients on hemodialysis (HD), 4 peritoneal dialysis (PD) 
patients and 13 preemptive kidney transplant recipients. Biochemical markers for endothelial 
dysfunction including Ang-2 and sTM, together with mucosal capillary density and morphology 
were compared to healthy and age matched volunteers who served as control group. None of 
the control subjects was taking medication. Patients with active infection, liver failure, active 
auto-immune disease, epilepsy or malignancy in the last 5 years (except patients treated 
for basal cell carcinoma that were in full remission) were excluded from the study. SDF 
measurements and the analysis of endothelial dysfunction markers were assessed prior to 
transplantation (CKD), and 1 (M1), 6 (M6) and 12 (M12) months after transplantation. 
Transplantation aspects
All kidney transplantations were performed at the Leiden University Medical Center (LUMC) 
between 2010 and 2012 in the Netherlands. Kidney transplantation was performed as 
described previously (10). Patients were treated with basiliximab as induction therapy (20 mg 
on the day of transplantation and 4 days after transplantation) followed by triple therapy with 
prednisone (tapered to a dose of 10 mg by 6 weeks), tacrolimus (area under the curve (AUC) 
210 ng.h/ml first 6 weeks, then 125 ng.h/ml) or cyclosporine (AUC 5400 ng.h/ml first 6 weeks 
then 3250 ng.h/ml) and mycophenolate mofetil (MMF) (AUC 30-60 ng.h/ml). Patients were 
treated routinely with oral valganciclovir prophylaxis for 3 months, except for cytomegalovirus 
(CMV) negative recipients receiving a CMV-negative graft.
Microcirculatory imaging and analysis of SDF measurements
The SDF microscan (MicroVision Medical Inc., Wallingford, PA, U.S.A) and analyses were 
performed as described earlier (10;13). 
Laboratory assessment and endothelial structure evaluation
All persons enrolled in this study underwent routine venous blood sampling before the 
morning intake of immunosuppression. The following data were evaluated: creatinin, urea, 
HbA1c, glucose, hemoglobin and proteinuria in 24 hours urine. Glomerular filtration rate 
(eGFR) was calculated with creatinin concentration using the Modification of Diet in Renal 
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and sTM. Blood collection tubes were centrifuged for 10 minutes at 3000 rpm after which 
serum was stored in microcentrifuge tubes at -20oC until required for analysis. Ang-2 and 
sTM concentrations were measured by enzyme-linked immuno sorbent assay (ELISA) (R&D 
Systems, Minneapolis, MN, USA and Diaclone Research, Besançon, France) according to the 
manufacturer supplied protocol. The intra-and inter-assay coefficients of variation were 6.5% 
and 9.1% for Ang-2 levels and 3.9% and 9.8%, respectively, for sTM levels. 
Statistical analyses 
Continuous normally distributed data are presented as mean ± SEM, unless stated otherwise. 
Comparisons of mean differences between the four time points in the longitudinal study 
were performed using repeated measures ANOVA. Correlations between interval variables 
were calculated using the Spearman rank correlation. Differences between 2 groups were 
analyzed using the unpaired two-sample T-test. When criteria for parametric testing were not 
met, median and interquartile range (IQR) are presented and tested with the Mann-Whitney 
test. Categorical variables were analyzed by a Chi-square test. In addition, multivariable 
linear regression was used to adjust for possible confounders. Differences were considered 
statistically significant with p<0.05. Data analysis was performed using SPSS version 17.0 




Baseline characteristics are shown in Table 1. There were no significant differences between 
CKD patients and healthy controls, with exception for eGFR and hematocrit levels (p<0.05). As 
expected, KTx showed improvement of eGFR and proteinuria (p<0.05). After transplantation, 
2 patients experienced interstitial rejection treated with methylprednisolone. In total 4 patient 
developed diabetes type II (1 patient at M1; 3 patients at M6) treated with oral antidiabetics or 
insulin. In 3 patients diabetes mellitus was resolved at 12 months after transplantation. HbA1c 










































Table 1: Patient characteristics of controls and chronic kidney disease patients before (CKD), 1 month 











Age (years) 44.8 ±1 47.1 ±14 47.3 ±14 47.8 ±14 48.8 ±14
Sex, male N (%) 10 (50%) 20 (71%) - - -
Smoking, N (%) 0 (0%) 3 (11%) - - -
Primary kidney disease, N (%) 
 Glomerulonephritis
 Focal segmental glomerulosclerosis
 Urologic
































0 (0%) 0 (0%) 0 (0%)
Median dialysis duration (years) - 1.0 (1.0-2.0) - - -
Systolic BP (mmHg) 135 ±18 138 ±15 131 ±18 131 ±12 134 ±1
Diastolic BP (mmHg) 83 ±9 84 ±12 78 ±7 79 ±7 81 ±8
eGFR (ml/min/1,73 m2) 92 ±16 8.8 ±4* 51.7 ±15*# 53.5 ±13*# 54.3 ±14*#
Median proteinuria (g/24hr) (IQR) - 1.5 (0.8-2.4) 0.2 (0.2-0.3)# 0.2 (0.2-0.4)# 0.2 (0.2-0.3)#
HbA1c (%) - 5.2 ±0 5.3 ±1 5.5 ±1 5.6 ±1
Glucose (mmol/L) 5.3 ±1 5.3 ±1 6.0 ±2 5.7 ±1 5.8 ±2
Hematocrit (L/L) 0.4 ±0 0.4 ±0 0.4 ±0 0.4 ±0 0.4 ±0















































Statines, N (%) - 13 (46%) 4 (14%) 10 (36%) 10 (36%)
Acetylsalicylic acid, N (%) - 6 (21%) 3 (10%) 2 (7%) 2 (7%)







































 Sex, male N (%)









All data are mean ±SD, unless otherwise specified. * p<0.05 vs controls. # p<0.05 vs CKD. BMI, body 
mass index; BP, blood pressure; ACE, angiotensin converting enzyme; eGFR,estimated glomerular 
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CKD patients have increased capillary tortuosity and angiogenic factors compared 
with controls 
Our study demonstrated a markedly disturbed microvasculature with increased capillary 
tortuosity in CKD patients (mean 1.9 ±0, SEM ) compared with healthy controls (mean 1.6 ±0, 
SEM, p<0.05) (Fig 1A). Dialysis modalities did not influence capillary tortuosity. Mean vessel 
density was not significantly different between CKD (mean 19.9 ±1, SEM ) and controls (mean 
21.4 ±1, SEM, p>0.05). 
Consistently, Ang-2 and sTM levels were elevated in CKD patients (mean 4084 ±612 pg/ml 
and 19 ±6 ng/ml, SEM, respectively) compared with healthy controls (mean 2291 ±326 pg/ml 
and 6.6 ±0 ng/ml, SEM, p<0.05 and p<0.0001, respectively) (Fig 1B-C). 
The difference in capillary tortuosity, Ang-2 and sTM between controls and CKD patients 
remained significant after adjustment for age, sex, body mass index (BMI), blood pressure 







































































































































































































































Figure 1. A. Mean tortuosity index of microvascular capillaries in the control and CKD group. Serum 
levels of Angiopoietin-2 (B) and Soluble thrombomodulin (C) levels in CKD patients and healthy controls. 










































Kidney transplantation leads to reversal of microvascular tortuosity and decrease in 
circulating levels of Ang-2 and sTM 
After KTx a significant decrease in capillary tortuosity was observed as early as 6 months 
(mean 1.6 ±0, SEM, p<0.001) following transplantation (Fig 2A). Mean vessel density did not 
show significant changes between the different time points after KTx (Fig 2B). 
In line with the observed decrease of capillary tortuosity after KTx, Ang-2 levels showed a 
significant decrease already at 1 month (mean 2263 ±316 pg/ml, SEM, p<0.05 ) after KTx and 
remained decreased up to 1 year (mean 2080 ±281 pg/ml, SEM, p<0.01) after transplantation 
(Fig 2C). sTM levels started to decrease at 1 month after transplantation (mean 6 ±1 ng/
ml, SEM, p<0.001) compared with before KTx (Fig 2D). After correction for age, sex, BMI, 
blood pressure, glucose levels and smoking the differences remained significant for capillary 
























































































































































































































































































































































































































































































































































Figure 2. A. Longitudinal course of mean tortuosity index (A) and vessel density (B) before (CKD), 1 (M1), 
6 (M6) and 12 (M12) months after KTx. Longitudinal course of serum levels Angiopoietin-2 (C) and soluble 












































Spearmans correlation analyses were performed between Ang-2, sTM serum levels and 
capillary tortuosity, glucose levels, calcineurin inhibitor use (CNI) and proteinuria. The Ang-2 
(r=0.1893, p=0.05; Fig 3A), sTM (r=0.2917, p=0.0014) and proteinuria (r=0.3036, p=0.0025) 
were positively correlated with microvascular tortuosity. In addition, a negative correlation 
was observed between eGFR, tortuosity (r=-0.5762, p<0.0001; Fig 3B), Ang-2 (r=-0.2352, 
p=0.0114) and sTM (r=-0.4959, p<0.0001). Moreover, sTM correlated positively with 
proteinuria levels (r=0.4188, p<0.001) and no correlation between Ang-2 with proteinuria was 
observed. No correlation was found between the different markers and tortuosity with glucose 
levels and CNI use.Figure 3 
A. 










































































































The present study demonstrated increased capillary tortuosity in CKD patients using SDF 
imaging, and elevated levels of markers for endothelial destabilization Ang-2 and sTM. 
Interestingly, KTx showed reversal of microvascular damage and normalization of Ang-2 and 
sTM levels, within 1 year after transplantation. Furthermore, we found a correlation between 
capillary tortuosity and Ang-2 and sTM. These data suggest that KTx is effective in reversing 
microvascular damage early after transplantation. Early non-invasive monitoring of the 
microvasculature may be of great clinical value to assess progression and treatment efficacy 
of microvascular disease in CKD patients before and after KTx. 
A major contributor to microvascular damage in CKD patients is the accumulation of uremic 
toxins, which leads to changes in renal EC structure and function that favor microvascular 
injury, which may play a role as a trigger for the inflammatory response (14). Microvascular 
destabilization induces local areas of interstitial hypoxia and is associated with a dysbalance 
of angiogenic growth factors (9;11). Increased expression or release of Ang-2 after EC injury 
has been shown to destabilize capillaries and to increase inflammation and vessel leakage, 
by promoting the weakening of pericyte-EC interaction (9). Activation of pericytes will lead 
to differentiation of pericytes into collagen producing myofibroblasts and detachement from 
ECs (1;15-17). This process is accompanied by failure of reparative angiogenesis and 
consequently formation of unstable and tortuous vessels (1;10).
In the current study a significantly disturbed systemic microvasculature was observed in 
patients with CKD compared to healthy controls using SDF imaging. Using this imaging 
technique, we could previously demonstrate increased capillary tortuosity in patients with 
diabetic nephropathy (10). To date, there are no studies investigating the systemic changes 
or abnormalities in non-diabetic CKD patients before and after KTx using SDF imaging and 
correlated this with angiogenic growth factors and renal function. In a study of Snoeijs et 
al, SDF imaging was used to study the human renal microcirculation after KTx by direct 
visualization of cortical peritubular capillaries. In this study, ischemic acute kidney injury was 
associated with reduced cortical microvascular blood flow (12). Moreover, Edwards et al. 
showed an association between retinal microvascular alterations and renal dysfunction (3). 
In our recent study in diabetic nephropathy patients, KTx alone did not result in reversal of 
capillary tortuosity and angiogenic growth factors (10). Previous studies have demonstrated 
that improvement in glucose control with pancreas transplantation, performed simultaneously 
or after KTx, is the most important therapeutic approach of microvascular disease in diabetes 
mellitus patients (18;19). These findings suggest, in concordance with our previous study, 
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restore microvascular damage, but glycemic control is also necessary (10). However, In this 
study, KTx resulted in reversal of microvascular tortuosity within 1 year after transplantation 
and renal function correlated significantly with capillary tortuosity. Thus, in non-diabetic CKD 
patients, normalization of uremic state is able to improve microvascular damage evident in 
these patients.
Another interesting finding is that the observed increase in capillary tortuosity coincided with 
increase in Ang-2 and sTM levels in CKD and showed the same course after KTx. Moreover, 
there was also a correlation between Ang-2, sTM and capillary tortuosity. Our data suggest that 
these factors might participate in the pathogenesis of microvascular tortuosity in CKD. This is 
consistent with previous reports which demonstrated an association between microvascular 
damage and these angiogenic markers (4;6;10;29). Consistent with our observation, David et 
al demonstrated increased Ang-2 levels in serum of CKD patients and normalization after KTx 
(5). Recently, we reported on the relation between endothelial activation and increased renal 
expression of Ang-2 in rats subjected to renal ischemia reperfusion injury (I/R), which was 
accompanied by proliferation of pericytes, endothelial cell loss and development of fibrosis 
(16). Moreover, de Vries et al demonstrated Ang-2 release in the circulation from human 
kidneys grafts shortly after reperfusion (30). 
In conclusion, this study demonstrates systemic microvascular damage in CKD patients, 
reflected by increased capillary tortuosity and angiogenic growth factors. Kidney transplantation 
resulted in reversal of capillary tortuosity and normalization of angiogenic growth factor levels. 
Given the central role of microvascular damage in CKD, therapies aiming at restoring the 
renal microvasculature might be an effective strategy to prevent profibrotic responses in CKD. 
Our findings indicate a clinical implication of SDF imaging to assess microvascular alterations 
after in CKD patients before and after KTx.
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Chapter 7
Acute rejection of kidney transplants is associated 
with a dysbalance in angiopoietins and a sustained 
increase in systemic microvascular tortuosity
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Bernard M. van den Berg, Alexander F. Schaapherder, Ellen Lievers, Marko J.K. Mallat, 
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Background: Microvascular endothelial cells (ECs) are very susceptible to injury, including 
episodes of acute rejection (AR). Whether AR after renal transplantation is associated with 
sustained systemic microvascular damage is unknown.
Methods: Using SDF imaging, microvascular alterations in AR patients (n=13) were compared 
with transplant recipients with stable renal function (n=25). In addition, 11 patients were studied 
longitudinally at 1, 6 and 12 months after rejection. Angiopoietin-1 (Ang-1), Angiopoietin-2 
(Ang-2), Vascular Endothelial Growth Factor-A (VEGF-A) and soluble Thrombomodulin (sTM) 
levels were measured.
Results: Capillary tortuosity was significantly increased in patients with AR (1.74±0.5) 
compared with the stable group (1.41 ±0.13, p<0.05). Furthermore, the Ang-2/Ang-1 ratio 
(0.09±0.02 vs 0.05±0.01 ), VEGF-A (567±188 vs 202±27 pg/ml) and sTM (19667±1809 
vs 9667±921 pg/ml) plasma levels were significantly higher in patients with AR compared 
with stable patients (all p<0.05). Interestingly, patients with AR showed persisting increased 
capillary tortuosity (p<0.05) and a disturbed Ang-2/Ang-1 balance up to 1 year after AR. 
VEGF-A and sTM levels remained significantly elevated up to 1 and 6 months after AR 
(p<0.05), but returned to baseline at 12 months.
Conclusion: AR is associated with increased systemic microvascular tortuosity up to 1 year 
after rejection, which is associated with elevated levels of angiogenic growth factors. SDF 












































Endothelial cells (ECs) line the lumina of all blood vessels and form the interface between 
the blood and tissue. In the context of kidney transplantation, ECs are very susceptible to 
injury during episodes of allograft rejection. ECs get activated in response to cytokines and 
growth factors that are produced as part of the alloimmune response (1-6). These activated 
ECs express adhesion molecules, release cytokines, chemokines and growth factors that 
mediate recruitment of recipient leukocytes (4;7). This will result in perpetual EC damage and 
promotion of angiogenesis within the allograft (1;3;4). This process is mediated by different 
pro-inflammatory and angiogenic growth factors, most notably Vascular Endothelial Growth 
Factor (VEGF) and Angiopoietin-2 (Ang-2), which play a central role in the angiogenic and 
inflammatory responses (1-3;6;8-10). The upregulation of Ang-2 destabilizes the endothelial 
cell lining and promotes the dissociation of pericytes from ECs, which results in the formation 
of abnormal capillary networks and abnormal blood flow. Local areas of interstitial hypoxia 
trigger fibrotic and inflammatory changes and ultimately lead to the development of interstitial 
fibrosis and tubular atrophy (IFTA) (1;2;4;9;11;12).
The endothelium is relatively inaccessible to direct examination. Therefore, investigators 
have concentrated on various surrogate markers of endothelial function which includes 
measurement of specific plasma markers including angiopoietins, VEGF and serum soluble 
Trombomodulin (sTM) (13-16). In allograft rejection different studies showed elevated 
circulating levels of VEGF and sTM in patients after solid organ transplantation, suggesting 
(systemic) endothelial cell activation (1;13;17-23).
An additional method for the assessment of endothelial function includes monitoring of the 
microvasculature. Recently, sidestream darkfield (SDF) imaging has emerged as a non-
invasive tool to visualize the human microcirculation and to assess microvascular remodeling 
(24). We have previously validated this technique and used it to investigate the labial mucosal 
capillary tortuosity, as marker for systemic microvascular disease in diabetes mellitus 
type I (DM) patients before and after simultaneous pancreas kidney transplantation (SPK) 
(24;25). Diabetic patients showed increased capillary tortuosity compared to healthy non-
diabetic controls and SPK resulted in reversal of microvascular damage within 1 year after 
transplantation (24). 
To our knowledge no previous studies have studied whether inflammatory changes in the 
transplanted organ can impact on the systemic microcirculation. In the present study, we 
therefore assessed whether AR is associated with systemic microvascular damage in a cross-
sectional study using SDF imaging and correlated this with markers for endothelial function. 
In addition, we investigated the long-term effects of AR on the systemic microvasculature in a 












































All procedures were approved by the institutions Medical Ethical Committee. Informed consent 
was obtained from all the patients. A total of 38 patients (24 males and 14 females) were 
enrolled in the cross-sectional study after given informed consent. Thirteen patients were 
included because of a decrease in renal function and biopsy proven acute cellular rejection 
(AR group). Of these patients, 11 had interstitial acute rejection, and the two other patients 
had vascular rejection. Ten patients were treated with methylprednisolone, one patients with 
anti-thymocyte globulin (ATG), one patient with methylprednisolone followed by alemtuzumab 
treatment and one patients with methylprednisolone followed by ATG. Of the 13 AR patients, 
1 had donor specific antibodies against HLA class I antigens and none of the patients had 
positive HLA class II antibodies. Biochemical markers for endothelial function including, 
Ang-1, Ang-2, sTM and VEGF-A, together with mucosal capillary density and morphology 
were compared to 25 kidney transplant recipients with stable renal function (eGFR of 30 ml/
min or more, stable group). In addition, analyses were performed in 10 patients from the 
stable renal funtion group with an eGFR similar to the AR patients, to differentiate between 
the effects of renal function and rejection on microvascular parameters. Patients with SPK, 
active infection, liver failure, active auto-immune disease, epilepsy or malignancy in the last 
5 years (except patients treated for basal cell carcinoma who were in full remission) were 
excluded from the study. The patients in the AR group were also studied prospectively in a 
longitudinally study at 1 (M1, n=13), 6 (M6, n=13) and 12 months (M12, n=11, two patients 
discontinued their participation) after rejection. All measurements were performed before 
patients received treatment for AR. None of the 38 patients had signs of infection at the time 
of the measurements.
Transplantation aspects
All patients underwent solitary kidney transplantation at the Leiden University Medical Center 
(LUMC) between 2003 and 2012. Kidney transplantation was performed as described 
previously (24). 
Patients were treated with prednisone (tapered to a dose of 10 mg by 6 weeks and a dose 
of 7.5 mg by 3 months), cyclosporine (targeted to an area under the curve (AUC) 5400 ng.h/
ml first 6 weeks then 3250 ng.h/ml) or tacrolimus (AUC 210 ng.h/ml first 6 weeks, then 125 
ng.h/ml) and mycophenolate mofetil (MMF) (AUC 30-60 ng.h/ml). In case of side effects 
patients were converted to everolimus (AUC 120-150 ng.h/ml). All patients received induction 
treatment with basiliximab (40 mg at day 0 and 4) or daclizumab (100 mg/day on the day of 
transplantation and 10 days after transplantation). Patients were treated routinely with oral 
valganciclovir prophylaxis for 3 months, except for cytomegalovirus (CMV) negative recipients 
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Laboratory and urinary assessments 
All persons enrolled in this study underwent routine venous blood sampling that was collected 
before the morning intake of immunosuppression to assess creatinine, urea, HbA1c, glucose 
and hemoglobin. Proteinuria was measured in collected 24-hours urine. The eGFR was 
calculated with plasma creatinine concentration using the Modification of Diet in Renal Disease 
(MDRD) formula. At the same time, blood sampling for routine laboratory measurements, 
blood was collected for analysis of serum Ang-1, Ang-2, VEGF-A and sTM concentrations. 
Both Ang-1 and Ang-2 were measured by ELISA (R&D Systems, Minneapolis, MN, USA) 
according to the manufacturer supplied protocol. Likewise, VEGF-A and sTM (Gen-Probe 
Diaclone Research, Besançon, France) levels were assessed. Since the Ang-2/Ang-1 rather 
than the absolute levels of either cytokine has been considered to determine the functional 
status of the microvasculature (9;10;14), this ratio was calculated for the different groups and 
time points.
Microcirculatory imaging
The SDF microscan (MicroVision Medical Inc., Wallingford, PA, U.S.A) was performed as 
described previously (24;25). Before analysis, the video files were anonymized so that 
the assessor was blinded to the subject’s identity. Capillary loops were assessed by two 
individual assessors in a randomized, blind fashion. From the forty video files obtained of 
the microcirculation in each subject, four technically best files were selected from each lip 
quadrant for analysis. Mean vessel density (capillaries/mm2) was calculated by counting the 
number of vessels per screen shot. Subsequently, tortuosity of capillary loops was assessed 
using a validated scoring system described previously and the average of assessed capillary 
tortuosity was used to calculate mean tortuosity index per patient (25).
Statistical analyses 
Continuous normally distributed data are presented as mean ± SEM, unless stated otherwise. 
Differences between two groups in the cross-sectional study were analysed using the unpaired 
two-sample T-test. When criteria for parametric testing were not met, median and interquartile 
range (IQR) are presented and tested with the Mann-Whitney test. For categorical variables 
cross-tables were used and analysed with the chi-square test. In addition, multivariable linear 
regression was used to adjust for possible confounders. Comparisons of mean differences 
between the different time points in the longitudinal study were performed using ANOVA 
analysis.
Correlations between interval variables were calculated using the Spearman rank correlation 
coefficient. Differences were considered statistically significant with p<0.05. Data analysis was 
performed using SPSS version 17.0 (SPSS Inc, Chicago, IL) and GraphPad Prism, version 











































Characteristics of transplant recipients with stable renal function and patients with AR 
Baseline subject characteristics are presented in Table 1. Renal function of the patients with 
stable allograft function (47.2±13 ml/min/1.73 mm2) was better compared to AR patients 
(38.1±13 ml/min/1.73 mm2, p<0.05). In order to elucidate if renal function itself affect capillary 
tortuosity and levels of angiogenic growth factors, we selected a subgroup of 10 patients with 
stable renal allograft function with comparable allograft function (36.7±6 ml/min/1.73 mm2) 
as patients with AR (38.1±13 ml/min/1.73 mm2, p>0.05) group. Patients in this subgroup had 
comparable age (52.6±14 years), body mass index (BMI) (25.2±4 kg/m2), systolic (131±12 
mmHg) and diastolic (84±12 mmHg) blood pressure as AR patients (52.7±10 years, 24.3±3 
kg/m2, 142±19 and 83±13 mmHg, respectively, p>0.05). Patients with AR (8.3±3 mmol/L) had 
increased glucose levels compared to stable patients (6.0± 2 mmol/L) and also compared to 
the subset of 10 stable patients (5.6±2 mmol/L, both p<0.05). In the AR group, 2 patients were 
treated for type II diabetes (both with insulin) which was not significantly different from the 
stable group (n=4, 3 patient treated with insulin and 1 with oral anti-diabetics). In addition, 4 
patients with AR and 4 stable patients stopped MMF due to side effects. In 1 patient from the 
stable group, tacrolimus was replaced by everolimus because of side effects. 
In the longitudinal study (Table 1) patients showed significant decreased renal function during 
all time points after AR compared to stable patients. Glucose levels were increased during AR 
and showed a significant decrease at 1 and 12 (p<0.05) months following rejection. Moreover, 
one patient developed new-onset diabetes after treatment with methylprednisolone and 
was treated with oral anti-diabetics. In four patients MMF was discontinued before rejection, 
due to side effects. In 2 patients treatment with tacrolimus was added, because of rejection 
under dual therapy with prednisone and MMF. In 1 patient tacrolimus was given instead of 
cyclosporine because of rejection. 
Patients with AR have increased capillary tortuosity compared to stable patients
Patients with AR (1.70 ±0.1, p<0.01) showed significantly increased capillary tortuosity 
compared to stable patients (mean 1.41 ±0.06) (Fig 1AB), also after adjustment for age, 
sex, BMI, blood pressure, glucose levels and smoking. Capillary tortuosity in the subset of 
10 stable patients with eGFR of 36.7 ml/min/1.73 mm2 (1.40 ±0.13) was comparable with 
capillary tortuosity of the remaining patients with a stable allograft function with eGFR of 54.6 
±13 ml/min/1.73 mm2 (1.41 ±0.06). Capillary density showed no significant difference between 
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Table 1: Patients characteristics of acute rejection patients during AR, one (M1), six (M6) and twelve 
(M12) months after rejection compared with stable renal transplant recipients











Age (years) 53.2 ± 13  51.7 ± 10 51.8 ± 10  52.4 ± 10 52.7 ± 10
Sex, male N (%) 15 (60%) 9 (69%) 
Smoking, N (%) 3 (12%) 1 (8%) 1 (8%) 1 (8%) 0
Median time since transplantation 
(months) (IQR)
5 (1-19) 12 (3-22)
Primary kidney disease, N (%) 
 Glomerulonephritis
 Diabetes Mellitus
 Pyelonephritis or interstitial nephritis
 Focal segmental glomerulosclerosis
 Urologic






















































































BMI (kg/m2) 25.8 ± 4 24.3 ± 3 24.3 ± 3 23.8 ± 4 25.2 ± 4
Dialysis, N (%) 4 (16%) 0 0 0 0
Systolic BP (mmHg) 137 ± 20 142 ± 19 132 ± 10 132 ± 16 127 ± 19
Diastolic BP (mmHg) 82 ± 9 83 ± 13 77 ± 9 79 ± 12 72 ± 10
eGFR (ml/min/1,73 m2) 47.2 ± 13 38.1 ± 13# 35.4 ± 15# 40.2 ± 16# 36.0 ± 18#
Median proteinuria (g/24hr) (IQR) 0.2  (0.2-0.4) 0.4 (0.3-1.0)# 0.3 (0.2-0.7) 0.2 (0.2-0.3) 0.3 (0.1-0.3)
Glucose (mmol/L) 6.0 ± 2 8.3 ± 3# 5.7 ± 2* 6.3 ± 3 5.9 ± 1*
Hemoglobin (mmol/L) 7.9 ± 1 7.6 ± 1 7.3 ± 1 7.7 ± 1 7.7 ± 1
Hematocrit (L/L) 0.40 ± 0.06 0.38 ± 0.04 0.36 ± 0.05 0.39 ± 0.05 0.39 ± 0.05
























































Statines, N (%) 9 (36%) 5  (39%) 6  (46%) 7  (54%) 7  (64%)

























































 Sex, male N (%)













All data are mean ±SD, unless otherwise specified. #p<0.05 compared to stable patients. *P<0.05 
compared to AR. BMI, body mass index;BP, blood pressure ACE,angiotensin converting enzyme; eGFR, 










































Figure 1 .A. Sidestream darkfield images of the oral mucosa visualizing the microvascular capillaries of a representative patient in stable and AR 
group. Black arrows: capillary loops. B. Mean tortuosity index of microvascular capillaries in the stable (n=25) and AR (n=13) group. Data 































Figure 1 .A. Sidestream darkfield images of the oral mucosa visualizing the microvascular capillaries of a representative patient in stable and AR 
group. Black arrows: capillary loops. B. Mean tortuosity index of microvascular capillaries in the stable (n=25) and AR (n=13) group. Data 































Figure 1. A. Sidestream darkfield images of the oral mucosa visualizing the microvascular capillaries of 
a representative patient in stable and AR group. Black arrows: capillary loops. B. Mean tortuosity index of 
microvascular capill ries in the stable (n=25) and AR (n=13) group. Data shown are mean±SEM. *P<0.05 
compared to stable group.
During the follow-up period after AR, capillary tortuosity remained increased at 1 month 
(1.72 ±0.1, p<0.01), 6 (1.71 ±0.4, p<0.05) and 12 months (1.74 ±0.1, p<0.001) following AR 
compared to patients with a stable renal function (1.41 ±0.06) (Fig 2AB). 
Ang-2/Ang-1 ratio, VEGF-A and sTM levels are increased in AR patients 
To evaluate the effects of AR on the expression of angiogenic factors, we calculated the 
Ang-2/Ang-1 ratio and measured serum levels of VEGF-A and sTM. The Ang-2/Ang-1 ratio 
was significantly increased in AR group (0.09 ±0.02) compared with stable renal transplant 
recipients (0.05 ±0.01, p=0.01) (Fig 3A). In line with these observations, VEGF-A serum levels 
were increased in AR patients (567 ±188 pg/ml, p=0.02) compared to stable recipients (202 
±27 pg/ml) (Fig 3B). 
In addition, elevated sTM serum levels were detected in AR group (19667 ±1809 pg/ml) 
group compared with stable patients (9667±921 pg/ml, p< 0.0001) (Fig 3C). The differences 
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Figure 2. A. Sidestream dark field images of the oral mucosa visualizing the microvascular capillaries of a representative stable kidney 
transplant patient, one (M1), six (M6) and twelve (M12) months after rejection in the longitudinal rejection study. Black arrows: capillary loops. 
B. Longitudinal course of the mean tortuosity index of microvascular capillaries in the stable group (n=25) and at one (M1, n=13), six (M6, 
































M1 M12 Stable M6 
Figure 2. A. Sidestream dark field images of the oral mucosa visualizing the microvascular capillaries 
of a representative stable kidney transplant patient, one (M1), six (M6) and twelve (M12) months after 
rejection in the longitudinal rejection study. Black arrows: capillary loops.
B. Longitudinal course of the mean tortuosity index of microvascular capillaries in the stable group (n=25) 
and at one (M1, n=13), six (M6, n=13) and twelve (M12, n=11) months after rejection. Data shown are 
mean±SEM. * P<0.05 compared to stable group.
Figure 3: Ang-2/Ang-1 ratio (A), VEGF-A (B) and soluble thrombomodulin (C) serum levels 
(pg/ml) in stable (n=25) and AR (n=13) group. Data shown are mean±SEM. *P<0.05. 






























































Figure 3: Ang-2/Ang-1 ratio (A), VEGF-A (B) and soluble thrombomodulin (C) serum levels 
(pg/ml) in stable (n=25) and AR (n=13) gr up. Data shown are ean±SEM. *P<0.05. 






























































Figure 3: Ang-2/Ang-1 ratio (A), VEGF-A (B) and soluble thrombomodulin (C) serum levels










































Ang-2/Ang-1 ratio remained increased and VEGF-A and sTM serum levels decreased in 
the first year after acute rejection
During follow up, the Ang-2/Ang-1 ratio remained elevated at 1 month (0.07 ±0.02, p=0.35), 
6 months (0.06 ±0.02, p=0.44) and 12 months (0.07 ±0.02, p=0.36) after AR compared 
with stable renal transplant recipients (0.05 ±0.01) however, statistical significance was not 
reached (Fig 4A). Furthermore, VEGF-A serum levels remained significantly increased up 
to 1 month after rejection (465 ±109 pg/ml) compared with stable renal transplant recipients 
(202 ±27 pg/ml, p=0.03) and started to show a decrease at 6 (368 ±150 pg/ml, p=0.23) and 12 
months (257 ±95 pg/ml, p=0.42) compared with period during AR (Fig 4B). Mean sTM serum 
levels were significantly higher at 1 (20083 ±3468 pg/ml, p=0.02) and 6 months (14927 ±2330 
pg/ml, p=0.02) after rejection compared to stable patients. At 12 months after rejection, sTM 
serum levels showed a significant decrease (10875 ±1549 pg/ml, p<0.05) compared to during 
AR (19667 ±1809 pg/ml) (Fig 4C). The differences remained significant after correction for 
age, sex, BMI, blood pressure, glucose levels and smoking.
Figure 4: Longitudinal course of Ang-2/Ang-1 ratio (A), serum VEGF-A (B) and soluble 
thrombomodulin (pg/ml) (C) levels at one (M1, n=13), six (M6, n=13) and twelve (M12, 
n=11) months after r jection co r d with stable group. Data shown are me n±SEM. 
*P<0.05. 
A.       B.     








































































Figure 4: Longitudinal course of Ang-2/Ang-1 ratio (A), serum VEGF-A (B) and soluble 
thrombomodulin (pg/ml) (C) levels at one (M1, n=13), six (M6, n=13) and twelve (M12, 
n=11) months after rejection compared with stable group. Data shown are mean±SEM. 
*P<0.05. 
A.     B.     








































































Figure 4: Longitudinal course of Ang-2/Ang-1 ratio (A), serum VEGF-A (B) and soluble 
thrombomodulin (pg/ml) (C) levels at one (M , n=13), six (M6, n=13) and twelve (M12, 
n=11) months after rejection compared with stable group. Data shown are mean±SE . 
*P<0.05.
A.       B.     






































































Figure 4: Longitudinal course of Ang-2/Ang-1 ratio (A), serum VEGF-A (B) and soluble 
thrombomodulin (pg/ml) (C) levels at one (M , n=13), six (M6, n=13) and twelve (M12, 
n=11) months after rejection compared with stable group. Data shown are mean±SE . 
*P<0.05. 
A.       B.     







































































Figure 4: Longitudinal course of Ang-2/Ang-1 ratio (A), serum VEGF-A (B) and soluble thrombomodulin 
(pg/ml) (C) levels at one (M1, n=13), six (M6, n=13) and twelve (M12, n=11) months after rejection 
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Serum levels of VEGF-A and sTM correlate with capillary tortuosity, eGFR and 
proteinuria
Next, the correlation between Ang-2/Ang-1 ratio, VEGF-A, sTM serum levels and capillary 
tortuosity, time since transplantation, eGFR, glucose levels, calcineurin inhibitors use (CNI) 
and proteinuria was assessed. sTM levels correlated positively with capillary tortuosity (r=0.43, 
p<0.0010), proteinuria ( r=0.58, p<0.001) and glucose levels (r=0.44, p<0.0001). Moreover, 
there was a negative correlation with Ang-2/Ang-1 ratio, VEGF-A, sTM and eGFR (r= -0.43, 
p<0.001, r=-0.38, p=0.01, r=-0.48, p<0.001, respectively). 
Discussion
In the present study, we demonstrate that the systemic microvasculature, assessed by SDF 
imaging, is markedly disturbed in patients with AR compared with stable renal transplant 
recipients. This coincides with an increased Ang-2/Ang-1 ratio as well as increased VEGF-A 
and sTM serum levels in the circulation. Interestingly, capillary tortuosity remained increased 
up to 1 year after rejection in patients in the longitudinal study. The current findings suggest 
that AR alter the systemic microvasculature chronically, and that SDF imaging might be a 
useful tool to assess the degree of microvascular damage in these patients.
To date, there are only a few studies that have used SDF for assessment of microvascular 
alterations after solid organ transplantation. In our previous study, it was demonstrated that 
capillary tortuosity is reversed in the first year after SPK in DM patients, which was also 
associated with a normalization of the Ang-2/Ang-1 balance and sTM levels. Interestingly, 
in this study DM patients who received a solitary kidney transplantation did not demonstrate 
reversibility of increased capillary tortuosity (24). These findings support the hypothesis that 
with SPK, i.e. beta cell function and renal failure reversal and not renal function alone is 
required to restore systemic microvascular tortuosity (24). In the current study, an increased 
systemic microvascular tortuosity was observed in patients after AR using SDF imaging. 
Interestingly, in the longitudinal rejection study this increased capillary tortuosity remained 
for up to 1 year after the rejection episode, suggesting that rejection can induce a sustained 
injury of the endothelium. Graft biopsies performed in patients after treatment of allograft 
rejection episodes revealed persistence of infiltrates in the graft (5;26;27). Interestingly the 
presence of monocytes/ macrophages and CD3+T cell infiltrates was strongly associated with 
the induced expression of VEGF in rejecting human cardiac allografts and VEGF is likely a 
key intermediary between sustained cell-mediated immune inflammation and the associated 
angiogenesis reaction (5;6). Alternatively, loss of kidney function after rejection may be 
responsible for the observed sustained sysmic microvascular damage. Indeed, Edwards et 










































function deterioration (28). To differentiate between AR and loss of renal function as a cause 
for the sustained change in microvascular parameters we did a case-control analysis in 
subjects with stable renal function that was matched for the renal function after 1 year in the 
AR group. Capillary tortuosity of this subset of patients was similar to the other patients with a 
stable renal function, making loss of renal function as an explanation less likely.
An interesting observation in our study is that the observed increased microvascular tortuosity 
coincided with a disturbed Ang-2/Ang-1 ratio and with increased levels of sTM and VEGF-A. 
This is in line with previous studies that have demonstrated a positive correlation between 
microvascular destabilization and such markers of endothelial dysfunction (14-16;18;24). Ang-
1 is a competitive ligand for the same Tie-2 receptor as for Ang-2, with competing, antagonistic 
effects on angiogenesis and microvascular remodeling (10;14). It has been reported that Ang-
2 displays VEGF dependent modulation of the microvascular structure, suggesting that these 
factors may act in concert to induce the observed microvascular damage (29). A disturbed 
Ang-2/Ang-1 balance and increased sTM levels, have been reported in patients with chronic 
kidney disease, with normalization after renal transplantation (14;16). Similarly, sTM levels 
have been reported to be higher during rejection after liver transplantation (23). Moreover, 
during chronic cardiac allograft rejection, Ang-1 expression was decreased, while Ang-2 
was upregulated in the microvascular ECs of rejecting cardiac allografts (30). In our study 
a disturbed Ang-2/Ang-1 balance in AR patients was observed compared with stable renal 
transplant recipients and remained increased up to 1 year following rejection.
Several studies have reported on the pivotal role of VEGF-A in the development of endothelial 
dysfunction in acute and chronic rejection (4;31). High serum and urine levels of VEGF-A were 
found in patients with cardiac and renal allograft rejection, which return to baseline levels after 
successful treatment of the rejection (22;32). Increased serum VEGF-A levels were also found 
in our study in patients with AR, which remained significantly increased up to 1 month after 
rejection and had almost normalized at 1 year following rejection. 
In conclusion, the current study demonstrates systemic microvascular damage in AR patients. 
Simultanous increase of angiogenic growth factors and capillary tortuosity suggests that 
these factors might participate in the pathogenesis of microvascular damage during rejection. 
Since EC activation results in impaired survival of allografts, therapies aimed at maintaining 
microvascular integrity may have beneficial effects on long-term graft survival after rejection 
episodes. Monitoring of the microcirculation by SDF imaging may be a novel non-invasive 
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Endothelial injury and repair are most important concepts for our understanding of renal 
disease and allograft injury. The concept that injury to the endothelium may precede renal 
fibrosis strongly suggests that interventions to maintain vascular integrity are of major 
importance for renal function. Understanding the mechanisms of microvascular dysfunction 
in renal disease and after transplantation might be helpful to determine future targets for 
therapeutic interventions. 
Renal I/R injury is an important clinical problem and an inevitable consequence of organ 
transplantation, and a major determinant of patient and graft survival. So far, many 
contributors to I/R injury are incompletely understood. It has become increasingly recognized 
that microvascular EC damage and aberrant capillary repair are one of the earliest events 
following I/R injury, that precede and drive the profibrotic changes of the kidney parenchyma. 
In this context, potential causes of vascular damage are disturbances in EC-pericyte 
interactions, regulated by angiogenic growth factors (including the angiopoietins) involved 
in the maintenance of vascular integrity. In Chapter 2, we studied the effect of renal I/R on 
dynamics of angiopoietin expression and its association with microvascular remodeling, 
pericytes and fibrosis development up to 9 weeks after renal I/R injury in a rat model. We 
demonstrate loss of peritubuar capillary ECs at early timepoints after renal I/R injury, which 
coincided with a dysbalance in Ang-2/Ang-1, proliferation of pericytes and development of 
renal interstitial fibrosis. Importantly, our study shows reversal of the Ang-2/Ang-1 balance 
to baseline at 9 weeks after renal I/R, which was accompanied by restoration of ECs and 
pericytes. These findings support the hypothesis that angiopoietins and pericytes play an 
important role in renal microvascular remodeling. 
Although these experimental data suggest a functional role of angiopoietins in microvascular 
ECs damage in renal I/R injury, their involvement in human renal I/R injury had not been 
investigated yet and was the aim of our subsequent study. We hypothesized that the 
inflammatory cascade of human clinical I/R injury is initiated by endothelial activation and 
consequent Ang-2 release. In chapter 3, this hypothesis was studied in clinical kidney 
transplantation (both LD and DD) using an unique method of arteriovenous measurements 
over the reperfused kidney. Paired arterial and renal venous blood samples were collected 
at consecutive time-points during early reperfusion. In this study, Ang-2 release from both 
LD and DD kidneys shortly after reperfusion was observed, indicating injury to ECs, which 
could release Ang-2 from Weibel–Palade bodies upon activation. This was accompanied by 
a loss of ECs, reflected by decrease in CD34 and vWF protein expression, and diminished 
Ang-1 protein and mRNA expression. Our findings suggests that angiopoietins may play an 










































In chapter 4, we continued our studies on local capillary damage in kidneys during early stage 
of DM. Microvascular abnormalities in the kidneys are common histopathologic findings in 
DN. In human DN, morphological changes in capillaries, such as elongation and an increase 
in the number of glomerular capillaries, are demonstrated. Furthermore, alterations in the 
expression of VEGF-A and angiopoietins have been implicated in the progression of DN. Using 
an established streptozotocin-induced model of diabetes and atherogenesis, we investigated 
whether the early stages of DM combined with atherogenesis are associated with systemic 
microvascular disease. In addition, we assessed the earliest events in DM induced renal 
damage, focusing on microvascular alterations and angiopoietins in pigs with a follow-up period 
up to 15 months after induction of DM. We show that early atherogenic DM leads to systemic 
microvascular abnormalities, reflected by increased capillary tortuosity as assessed by SDF 
imaging. Furthermore, development of glomerular lesions representative of early stages of DN 
and a dysbalance of Ang-2/Ang-1 expression in the kidneys of diabetic atherogenic pigs in the 
early stage were observed, which coincided with increased urinary albumin/creatinine ratio. 
The dysbalance of Ang-2/Ang-1 was correlated with increased capillary tortuosity, suggesting 
a relationship between increased systemic microvascular tortuosity and altered expression of 
renal Ang-2/Ang-1 balance, in favor of the proinflammatory marker Ang-2. Collectively, these 
observations suggest that systemic microvascular damage and Ang-2/Ang-1 dysbalance may 
represent initiating events of renal injury in early DM combined with atherogenesis. 
In the following studies we assessed systemic microvascular damage in DN patients and 
patients with CKD (non-diabetic). In chapter 5, the effects of SPK on microvascular damage in 
DM type 1 patients, with and without DN, were assessed in a cross-sectional and longitudinal 
study using SDF imaging. Furthermore, systemic capillary tortuosity was correlated with 
markers for endothelial dysfunction. Consistent with previous reports, this study shows 
increased capillary tortuosity using SDF imaging in DM type 1 patients compared with healthy 
controls. This was accompanied by a dysbalance in Ang-2/Ang-1 ratio and increased levels of 
sTM. Interestingly, reversal of capillary tortuosity and normalization of the Ang-2/Ang-1 ratio 
was found after SPK, but not after KTx alone suggesting that both beta cell function and renal 
failure reversal, and not renal function alone is required to restore systemic microvascular 
damage early after transplantation. Furthermore, increased microvascular tortuosity correlated 
with increased Ang-2/Ang-1 ratio. In our longitudinal study both reversibility of microvascular 
damage and a decrease in sTM and Ang-2/Ang-1 balance occurred in the first year after SPK. 
Angiopoietins might play a role alongside other angiogenic pathways in the pathophysiology 
of microvascular derangements observed in DM patients. Assessment of capillary tortuosity, 
as marker for microvascular disease using the noninvasive SDF imaging and measurements 
of serum levels of angiopoietins, could be useful tools to estimate the degree of microvascular 
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In chapter 6 SDF analysis and measurements of endothelial dysfunction markers were 
performed in non-diabetic CKD patients and compared with healthy controls. Our first 
observation in this study is that CKD patients have a markedly disturbed microvasculature 
with increased tortuosity and enhanced levels of Ang-2 and sTM compared to healthy controls. 
Thus besides increased capillary tortuosity in DN patients, as shown in chapter 5, non-diabetic 
CKD patients also have systemic microvascular damage. Moreover, in the longitudinally 
study the effects of KTx were investigated on the observed microvascular derangements. 
Interestingly, KTx results in restoration of tortuosity and normalization in Ang-2 and sTM levels 
within 6 months after transplantation. Thus, normalization of renal function in non-diabetic 
CKD patients is able to improve microvascular damage evident in these patients. 
Finally, microvascular alterations were studied in renal recipients during and after allograft 
rejection, as described in chapter 7. It is known that repetitive insults of AR target ECs and 
lead to capillary destabilization, however, whether AR after KTx is associated with sustained 
systemic microvascular damage had not been studied so far. We found a markedly disturbed 
systemic microvasculature, assessed by SDF imaging, in patients with AR compared with 
stable renal transplant recipients. In line, increased Ang-2/Ang-1 ratio as well as increased 
VEGF-A and sTM serum levels were observed in the circulation. Surprisingly, capillary 
tortuosity remained increased up to 1 year after rejection in patients in the longitudinal study. 
Since EC activation results in impaired survival of allografts, therapies aimed at maintaining 
microvascular integrity may have beneficial effects on long-term graft survival after rejection 
episodes. Monitoring of the microcirculation by SDF imaging may be a novel non-invasive 
approach for the detection of early microvascular damage during allograft rejection. 
In conclusion, the results of this thesis demonstrate an important role for endothelial injury 
and repair in renal disease and after transplantation. Both renal I/R and DM induced systemic 
capillary damage reflected by increased capillary tortuosity by SDF imaging and a dysbalance 
in angiopoietins. In addition, patients with renal disease and allograft rejection after renal 
transplantation also had systemic microvascular derangements. Transplantation was effective 
in reversing the systemic microvascular alterations. Since angiopoietins are considered 
important microvascular regulators, future research including studies with a therapeutic 
intervention would be required to prove a causal relationship between the functions of 
angiopoietins and pericytes and its role in EC stabilization and repair. Modulation of the 
Ang-2/Ang-1 balance may have therapeutic potential for microvascular stabilization in renal 
disease. Complementary use of SDF imaging to measure microvascular tortuosity and the 
assessment of endothelial dysfunction markers may be useful diagnostic tool for monitoring 



























































































In de ontwikkeling van nierziekten en afstotingsreactie na niertransplantatie, spelen endotheel 
schade en herstel en de ontwikkeling van nierfibrose (bindweefselvorming) een belangrijke 
rol. Endotheel cellen (EC) vormen de binnenste laag van onze bloedvaten in de nieren. 
Het concept dat het begin van nierfibrose zou kunnen ontstaan door beschadiging aan EC, 
suggereert dat interventies om vasculaire integriteit in stand te houden essentieel zijn voor 
het behoud van nierfunctie. Door beter te begrijpen welke mechanismen betrokken zijn bij EC 
schade tijdens nierziekten en na niertransplantatie, is het wellicht mogelijk om hierop in te 
grijpen en therapeutische interventies te ontwikkelen. In dit proefschrift is onderzocht welke 
factoren van belang zijn in het proces van EC schade en herstel in chronische nierfalen (CKD), 
diabetes mellitus (DM) type 1, Ischemie/Reperfusie schade (I/R schade) en na transplantatie.
I/R schade van de nier ontstaat na transplantatie en is een belangrijke voorspeller voor 
nierfalen na een niertransplantatie. Tot dusver is niet geheel bekend welke mechanismen 
bijdragen aan I/R schade. Steeds meer studies wijzen in de richting van EC schade en een 
gestoord capillair herstel als vroege mechanismen die betrokken zijn bij I/R schade. De 
microvasculaire EC schade die optreedt is geassocieerd met profibrotische veranderingen 
van het nierweefsel. Het begin van deze microvasculaire schade zou kunnen ontstaan 
doordat EC niet meer op normale wijze signaleren naar pericyten (de steuncellen van de 
bloedvaten). Deze interactie tussen pericyten en EC wordt gereguleerd door verschillende 
angiogene factoren, waaronder angiopoietine-1 (beschermend/anti-inflammatoir) en 
angiopoietine-2 (pro-inflammatoir). In hoofdstuk 2, werd gebruik gemaakt van een rat model 
waar I/R schade van de nieren geïnduceerd werd en 9 weken daarna vervolgd is. In deze 
periode werd op verschillende tijdspunten het effect van nier I/R schade op veranderingen 
in angiopoietines expressie bestudeerd. Daarnaast werd de associatie met microvasculaire 
remodelling, pericyten expressie en ontwikkeling van nierfibrose bestudeerd. Uit deze studie 
bleek dat verlies van peritubulaire capillaire EC vroeg na I/R schade in de nier gepaard ging 
met een gestoorde Ang-2/Ang-1 balans, toename in pericyten en ontwikkeling van interstitiële 
fibrose. Negen weken na inductie van I/R schade trad er een verbetering op in de Ang-2/Ang-
1 balans welk gepaard ging met herstel in aantal EC en pericyten. Deze data ondersteunen 
de hypothese dat angiopoietines en pericyten een belangrijke rol spelen in de microvasculaire 
EC schade en in het herstel van de nierschade. 
Hoewel deze experimentele bevindingen een functionele rol suggereren van angiopoietines 
in EC schade in de nieren, is er weinig bekend of de rol van angiopietines bij humane I/R 
schade in de nieren. Onze hypothese was dat de inflammatoire cascade in humane nier 










































afgifte. In hoofdstuk 3, werd deze hypothese bestudeerd in klinische niertransplantatie 
(zowel levende als overleden donoren), door gebruik te maken van arterioveneuze metingen 
over de gereperfundeerde nier. Gepaarde arteriële en veneuze bloedsamples uit de nieren 
werden verzameld opeenvolgende tijdstippen gedurende de vroege fase van reperfusie. Deze 
studie liet zien dat nieren van zowel levende als overleden donoren Ang-2 afgeven. Dit ging 
gepaard met verlies van ECs in de nieren, wat bleek uit daling in CD34 en vWF expressie en 
verminderde angiopoietine-1 (Ang-1) eiwit en mRNA expressie. Onze bevindingen suggereren 
dat angiopoietines en pericyten een belangrijke rol spelen in microvasculaire remodeling 
tijdens I/R schade in de nier. 
In hoofdstuk 4, werd onze studie naar lokale vasculaire EC schade voortgezet in vroege DM. 
Microvasculaire afwijkingen in de nieren zijn veel voorkomende histopathologische bevindingen 
bij diabetische nephropathie (DN). In humane DN worden morfologische veranderingen 
in capillairen gevonden, zoals elongatie en toename in aantal glomerulaire capillairen. 
Veranderingen in angiogene factoren zoals VEGF-A en angiopoietines zouden betrokken 
zijn bij de progressie van DN. Door gebruik te maken van een streptozotocine geïnduceerd 
diabetes model in varkens met een atherogeen dieet, is onderzocht of het vroege stadium 
van DM geassocieerd is met systemische microvasculaire schade. Daarnaast is onderzocht 
welke vroege factoren betrokken zijn bij de ontwikkeling van diabetische nefropathie. Hiervoor 
werd een varkensmodel gebruikt met een follow-up periode van 15 maanden na inductie van 
DM. Deze studie liet zien dat vroege atherogene DM leidt tot systemische microvasculaire 
afwijkingen, weerspiegeld door toegenomen capillaire kronkeligheid gemeten met de niet-
invasieve sidestream darkfield techniek (SDF). Daarnaast werden er glomerulaire afwijkingen 
gevonden passend bij vroege DN en een dysbalans in angiopoietines in de nieren van 
diabetische atherogene varkens. Dit ging gepaard met een verhoogde urine albumine/
creatinine ratio. De dysbalans in angiopoietines was geassocieerd met toegenomen capillaire 
kronkeligheid. Dit suggereert een relatie tussen toegenomen systemische miscrovasculaire 
kronkeligheid en veranderde expressie van angiopoietines in de nieren. Samenvattend wijzen 
deze bevingen erop dat systemische microvasculaire schade en angiopoietine dysbalans de 
eerste gebeurtenissen zijn in het initiëren van nierschade in de vroege fase van DN.
In de vorige hoofdstukken lag de focus vooral op microvasculaire schade in de nieren na 
I/R schade en DM type 1. Om te onderzoeken of deze beschadigingen aan het endotheel 
zich ook systemisch manifesteren hebben wij de microcirculatie in beeld gebracht met SDF 











































In hoofdstuk 5, werden de effecten van gecombineerde nier-pancreas transplantatie op 
microvasculaire schade in DM type 1 patiënten, met en zonder DN, bestudeerd in cross-
sectionele en longitudinale studies. Daarnaast werd systemische capillaire kronkeligheid 
gecorreleerd met markers voor endotheelschade in het bloed, inclusief soluble 
thrombomoduline (sTM) en Ang-2/Ang-1. Vergelijkbaar met andere studies, liett deze studie 
toegenomen capillaire kronkeligheid zien in DM type 1 patiënten ten opzichte van gezonde 
controles. Dit ging gepaard met Ang-2/Ang-1 dysbalans en een toename in sTM. Een 
interessante bevinding van deze studie is dat er een verbetering werd gezien van capillaire 
kronkeligheid en normalisatie van Ang-2/Ang-1 balans na nier-pancreas transplantatie, 
maar niet na niertransplantatie alleen. Dit suggereert dat zowel β-cel functie als herstel 
van nierfunctie noodzakelijk zijn om systemische microvasculaire schade te verbeteren na 
transplantatie. Tevens werd er een correlatie gevonden tussen microvasculaire kronkeligheid 
en toegenomen Ang-2/Ang-1 ratio. In de longitudinale studie werden reversibiliteit van zowel 
microvasculaire schade als afname in sTM en Ang-2/Ang-1 dysbalans waargenomen binnen 
het eerste jaar na nier-pancreas transplantatie. Beoordeling van de mate van capillaire 
kronkeligheid, als marker voor microvasculaire schade, door gebruik te maken van de SDF 
techniek en angiopoietine waardes in het serum, zouden belangrijke hulpmiddelen kunnen 
zijn om de mate van microvasculaire verstoringen in DM patiënten in te schatten voor en na 
nier-pancreas transplantatie. 
Naast onze bevindingen in nier-pancreas transplantatie patiënten, werden in hoofdstuk 6 
de resultaten van SDF metingen en endotheel dysfunctie marker bepalingen vergeleken 
in niet-diabetische CKD patiënten en gezonde controles. Daarnaast werd het effect van 
niertransplantatie bestudeerd. Onze eerste bevinding was dat niet diabetische CKD patiënten 
een gestoorde systemische microvasculatuur habben met toegenomen kronkeligheid en 
verhoogde Ang-2 en sTM waardes in het serum in vergelijking met gezonde vrijwilligers. Dus 
naast toegenomen capillaire kronkeligheid in DN patiënten, zoals besproken in hoofdstuk 
5, lieten niet-diabetische CKD patiënten ook systemische microvasculaire schade zien. 
De groep CKD patiënten werd vervolgens gedurende 12 maanden na niertransplantatie 
vervolgd om het effect van transplantatie op microvasculaire veranderen te onderzoeken. 
Interessant is dat niertransplantatie leidt tot verbetering van microvasculaire kronkeligheid en 
normalisatie in Ang-2 en sTM binnen 6 maanden na transplantatie. Dus, herstel van uremie in 
niet-diabetische CKD patiënten leidt in deze patiënten tot verbetering van de microvasculaire 
schade.
Tot slot werden in hoofdstuk 7 microvasculaire veranderingen bestudeerd in niertransplantatie 
patiënten na acute rejectie (AR). Het is bekend dat herhaalde episodes van AR de EC 










































niertransplantatie geassocieerd is met systemische microvasculaire schade is nog niet eerder 
onderzocht. Uit onze studie bleek dat AR tot gestoorde systemische microvasculaire schade 
leidt met toegenomen capillairen kronkeligheid, in vergelijking met stabiele niertransplantatie 
patiënten. De capillaire kronkeligheid bleef aanhouden tot 1 jaar na AR. Daarnaast was er een 
stijging in circulerende Ang-2/Ang-1 ratio, VEGF-A en sTM. Deze angiogene factoren, zouden 
een rol kunnen spelen in de pathogenese van microvasculaire schade tijdens inflammatoire 
processen en acute rejectie in de nieren. Sinds EC activatie/schade de kans op overleving 
van het transplantaat beïnvloedt, zouden therapeutische interventies gericht op behoud van 
microvasculaire integriteit een gunstig effect kunnen hebben op de lange termijn transplantaat 
overleving na AR. Monitoring van de microcirculatie middels SDF techniek zou een nieuwe 
niet-invasieve methode kunnen zijn om in een vroeg stadium microvasculaire schade te 
detecteren tijdens AR. 
Concluderend lieten de resultaten van dit proefschrift zien dat EC schade en herstel een 
belangrijke rol spelen in nierziekten en na transplantatie. Zowel nier I/R schade als DM 
induceerden systemische microvasculaire schade wat blijkt uit in toegenomen capillaire 
kronkeligheid, gemeten met SDF techniek, en een dysbalans in angiopoietines. Tevens 
vertoonden patiënten met nierziekten en rejectie na niertransplantatie systemische 
microvasculaire afwijkingen. Transplantatie liet herstel zien van systemische microvasculaire 
verstoringen in diabetische en niet-diabetische CKD patiënten. De resultaten in dit proefschrift 
suggereren dat angiopoietines belangrijke factoren zijn in het reguleren van microvasculaire 
homeostase. Toekomstig onderzoek gericht op therapeutische interventies is noodzakelijk 
om een oorzakelijk verband aan te tonen tussen de rol van angiopoietines en pericyten in EC 
stabilisatie en herstel. Agentia om de Ang-2/Ang-1 balans te moduleren zouden een gunstig 
effect kunnen hebben als therapeutisch middel voor microvasculaire stabilisatie in nierziekten. 
Het gebruik van SDF techniek en markers voor endotheel dysfunctie zouden als diagnostisch 
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